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Assessing the Contribution Antiretroviral Therapy to Neuronal Damage and Death
as a Mediator of Cognitive Decline in HIV-Associated Neurocognitive Disorders
Abstract
The advent of combination antiretroviral therapy (ART) in 1996 revolutionized the treatment of HIV/AIDS
and significantly decreased the incidence of HIV-associated neurocognitive disorders (HAND), a
spectrum of HIV-related CNS dysfunctions ranging from mild cognitive deficits to severe dementia.
Although the long-term prognosis for ART-treated, HIV-positive individuals continues to improve, the lifeexpectancy for this population remains 10-30 years less than that of uninfected individuals. Additionally,
the clinical and pathologic presentation of HAND has evolved from a subacute, subcortical encephalitic
condition, to a prolonged, cortical, neurodegenerative disease with pathological features that resemble
those found in Alzheimer Disease (AD). The specific mechanisms driving these pathological changes
remain unknown, although emerging evidence suggests that antiretroviral neurotoxicity may be a
significant contributing factor. Here, we examined mechanisms by which antiretroviral drugs induce
stress in neurons leading to changes in amyloid precursor protein (APP) processing. Utilizing in vitro
models of acute ART exposure, we observed that HIV protease inhibitor (PI)-class ART drugs robustly
active the unfolded protein response in primary neurons leading to translational de-repression of beta-site
cleaving enzyme 1 (BACE1) by phosphorylated eIF2alpha; and augmented amyloidogenic cleave of APP.
These results were corroborated in ART-treated, SIV-infected macaques were we saw increased
hippocampal expression of BACE1 AND IN HAND patients where we also found similar increases in
BACE1 expression in CA1 and CA3 hippocampal regions accompanied by accumulation of intraneuronal
oligomeric Abeta;. Finally, we demonstrate that inhibition of neuronal BACE1 activity in vitro protects cells
from hydrogen peroxide and antiretroviral drug-mediated toxicity. From this body of work, we conclude
that PI-class antiretroviral drugs play a prominent role in stress activation of CNS neurons leading to
aberrant changes in APP processing and potentially contributing to neuronal damage and death in HAND.
Lastly, we have identified BACE1 as an important adjunctive therapeutic target in the treatment of chronic
cognitive decline in ART-medicated, HIV-positive individuals.
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ABSTRACT
ASSESSING THE CONTRIBUTION OF ANTIRETROVIRAL THERAPY TO NEURONAL
DAMAGE AND DEATH AS A MEDIATOR OF COGNITIVE DECLINE IN HIV-ASSOCIATED
NEUROCOGNITIVE DISORDERS

Patrick Joseph Gannon
Kelly L. Jordan-Sciutto

The advent of combination antiretroviral therapy (ART) in 1996 revolutionized the treatment of
HIV/AIDS and significantly decreased the incidence of HIV-associated neurocognitive disorders
(HAND), a spectrum of HIV-related CNS dysfunctions ranging from mild cognitive deficits to
severe dementia.

Although the long-term prognosis for ART-treated, HIV-positive individuals

continues to improve, the life-expectancy for this population remains 10-30 years less than that of
uninfected individuals. Additionally, the clinical and pathologic presentation of HAND has evolved
from a subacute, subcortical encephalitic condition, to a prolonged, cortical, neurodegenerative
disease with pathological features that resemble those found in Alzheimer Disease (AD). The
specific mechanisms driving these pathological changes remain unknown, although emerging
evidence suggests that antiretroviral neurotoxicity may be a significant contributing factor. Here,
we examined mechanisms by which antiretroviral drugs induce stress in neurons leading to
changes in amyloid precursor protein (APP) processing. Utilizing in vitro models of acute ART
exposure, we observed that HIV protease inhibitor (PI)-class ART drugs robustly active the
unfolded protein response in primary neurons leading to translational de-repression of beta-site
cleaving enzyme 1 (BACE1) by phosphorylated eIF2α and augmented amyloidogenic cleave of
APP. These results were corroborated in ART-treated, SIV-infected macaques were we saw
increased hippocampal expression of BACE1 AND IN HAND patients where we also found
similar increases in BACE1 expression in CA1 and CA3 hippocampal regions accompanied by
accumulation of intraneuronal oligomeric Aβ. Finally, we demonstrate that inhibition of neuronal
BACE1 activity in vitro protects cells from hydrogen peroxide and antiretroviral drug-mediated
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toxicity. From this body of work, we conclude that PI-class antiretroviral drugs play a prominent
role in stress activation of CNS neurons leading to aberrant changes in APP processing and
potentially contributing to neuronal damage and death in HAND.

Lastly, we have identified

BACE1 as an important adjunctive therapeutic target in the treatment of chronic cognitive decline
in ART-medicated, HIV-positive individuals.
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CHAPTER 1
INTRODUCTION
1.1: HIV AND THE NEUROPATHOGENESIS OF HAND
Since its first clinical diagnosis in 1981, acquired immunodeficiency syndrome (AIDS) has
become a global pandemic responsible for over 22 million deaths worldwide with an estimated
sixteen thousand new human immunodeficiency virus (HIV) infections occurring daily (1). HIV,
+

discovered in 1983 to be the causative agent of AIDS, is a retrovirus that primarily targets CD4 T
cells and cells of the monocyte/macrophage lineage that express the CD4 receptor and one of
the two required co-receptors, CXCR4 or CCR5. If untreated, HIV infection ends in the selective
+

loss of the CD4 T cell population, leading to severe immunodeficiency and eventually death (2).
In addition to destruction of the immune system, HIV infection can also lead to a spectrum of
central

nervous

system

(CNS)

complications,

known

collectively

as

HIV-associated

neurocognitive disorders (HAND), in approximately 50% of infected individuals. According to the
diagnostic criteria established for the assessment of neurocognitive impairment in HIV-infected
individuals, the neurological deficits in HAND are divided into three diagnostic groups.

This

classification is based on the neuropsychological evaluation of multiple cognitive domains,
including simple motor skills or sensory perceptual ability, complex perceptual motor skills,
attention and working memory, learning and memory recall, verbal and language skills,
abstraction and executive function.

First, asymptomatic neurocognitive impairment (ANI) is

defined as acquired impairment in at least two cognitive domains without a decline in activities of
daily living (ADL), while mild to moderate neurocognitive impairment that affects ADL is termed
minor neurocognitive disorder (MND). Finally, moderate to severe impairment in two or more
domains with marked impact on ADL is defined as HIV-associated dementia (HAD).
Additionally, behavioral and emotional problems such as depression, psychosis, and
anxiety are commonly observed in HAND patients. Since the multi-drug regimens that form the
basis of antiretroviral therapy (ART) have become the mainstay for HIV treatment, the clinical
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presentation and the course of HAND have become more unpredictable. The severity of deficits
appears to fluctuate over time during the course of infection: some patients may experience
continuing decline in cognitive abilities, while others show improvement of more severe
neurocognitive impairments and exhibit only minor deficits for the remainder of the disease.
While clinical studies clearly establish that suppression of viral replication below the level of
detection is paramount to a more favorable outcome, the clinical course of HAND, once
diagnosed, cannot be predicted successfully in most patients. Furthermore, while the prevalence
of severe HAD has decreased in the post-ART era, the prevalence of ANI and MND, and HAND
in general, has increased significantly due in part to the longer lifespan of HIV-infected individuals
(3). Pathological studies have revealed that brains of ART-naïve HAND patients exhibit classic
hallmarks of neuroinflammation including microglial nodules, multinucleated giant cells
astrogliosis, and myelin pallor (1).

However, in the post-ART era, these hallmarks are not

frequently found in post-mortem HAND brain tissue, although syanptodendritic damage still
persists (4-9). Similarly, while extensive neuronal death in the CNS of HAND patients has been
mitigated in the post-ART era, there remains evidence for ongoing neuronal damage in the form
of dendritic pruning, decreased synaptic density and loss of interneurons (10).
In the healthy brain, the blood brain barrier (BBB) and the blood-cerebrospinal fluid
barriers are the first lines of defense against invading pathogens; however, HIV can circumvent
these barriers and enter the CNS within 1-2 weeks after systemic infection. The mechanism(s) of
HIV neuroinvasion remain a matter of speculation, however there is evidence that HIV can enter
via transcytosis across endothelial cells or within infected monocytes (11, 12). The latter model
was first proposed by Haase and colleagues who used visna virus to model HIV infection and
proposed that HIV, and other lentiviruses, enter the CNS as passengers in infected monocytes
(13-15). According to this “Trojan Horse” model, supported by a multitude of in vitro and in vivo
studies, the infected monocytes traverse the BBB and differentiate into macrophages, thus
constituting the viral reservoirs in the CNS (15-18). Direct contact of the infected cells with
neighboring, resident immune cells of the CNS, including perivascular macrophages, astrocytes,
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and microglia, leads to their subsequent infection and activation.

This population of infected

immune cells then releases a variety of neurotoxic molecules, including proinflammatory
cytokines, chemokines, reactive oxygen species (ROS), quinolinic and arachidonic acid,
glutamate, and nitric oxide, leading to activation of uninfected immune cells and eventual
neuronal damage and dysfunction observed in HAND.
Importantly, neurons themselves are not a source of productive infection in the CNS, as
they lack the CD4 receptor, rather HIV replication occurs primarily in monocyte-derived
perivascular macrophages and microglia (18).

However, given the extensive evidence of

neuronal damage in HAND, other mechanisms have been implicated in HIV-mediated
neurodegeneration. The first hypothesis, known as the indirect or bystander effect hypothesis,
maintains that neuronal damage is mediated largely by the immune response mounted by
infected and uninfected non-neuronal cells against HIV infection, as described previously.
Chronic neuroinflammation then leads to an excitotoxic environment within the CNS, chronic
activation of neuronal N-methyl-D-aspartate (NMDA) receptors and a toxic accumulation of
intraneuronal Ca

2+

2+

leading to free radical production, oxidative stress, and activation of Ca -

dependent death proteases, such as calpains and caspases.

Alternatively, the direct injury

hypothesis holds that HIV viral proteins, such as gp120, Tat, and Vpr, released from infected
monocytes and microglia, interact directly with neurons through a variety of mechanisms,
including interaction with chemokine receptors, leading to neuronal damage and apoptosis.
Despite several lines of in vitro data supporting this hypothesis, in vivo studies suggest that
markers of neuroinflammation continue to persist in post-ART HAND despite suppression of HIV
replication in the CSF to levels below the limit of detection. These findings suggest that indirect
mechanisms of neuronal toxicity may be the major contributors to the underlying neuropathology
of HAND in the post-ART era.
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1.2: ANTIRETROVIRAL THERAPY: MECHANISMS OF ACTION
Initial quantitative studies of in vivo HIV-1 dynamics and virion clearance rates using novel
antiretroviral drugs yielded several critical findings: 1) viremia is sustained by continuous rounds
of replication, infection, and rapid cell turnover, 2) mutations in the HIV-1 genome likely occur at
every position multiple times per day accounting for the failure of previously-used monotherapy,
3) when new cycles of infection are halted by antiretroviral drugs, plasma virus levels fall by as
much as 99% within weeks after treatment, and 4) effective treatment of HIV must employ the
use of multiple, potent antiretroviral drugs to force the viral genome to mutate at several distinct
positions simultaneously (19, 20). From these landmark studies came the advent of combinatorial
highly active antiretroviral therapy (HAART), now simply termed ART, which is the mainstay
treatment for HIV, leading to suppression of viral replication to below the limits of detection,
reconstitution of the immune system, and increased long-term survival rates in HIV-positive
individuals (21).
The United States Panel on Antiretroviral Guidelines for Adults and Adolescents currently
3

recommends the initiation of ART when CD4 cell counts are below 350 /mm peripheral blood or
in those with AIDS-defining illnesses irrespective of CD4 levels (22, 23). Initial ART regimens
typically include the use of two nucleoside reverse transcriptase inhibitors (NRTI) combined with
either a non-nucleoside reverse transcriptase inhibitor (nNRTI), HIV protease inhibitor (PI), or
integrase inhibitor.

The 24 FDA-approved antiretroviral drugs currently available fall into six

broad categories based on which step of the HIV viral replication cycle they inhibit: entry, reverse
transcription, integration, transcription, virus assembly and production, and protease processing
(24).

The first step in HIV replication involves viral entry into helper T lymphocytes and

monocytes via engagement of the viral envelope glycoprotein, gp120, with the CD4 receptor
followed by binding to either the CXCR4 or CCR5 co-receptors (25). These interactions induce a
conformational change in the HIV envelope, leading to gp41-mediated fusion with the host cell
membrane (26). This process, which lasts approximately 1 hour, is targeted by entry inhibitors,
divided further into attachment inhibitors, chemokine receptor antagonists, and fusion inhibitors.

4

Currently, two entry inhibitors, maraviroc and enfuvirtide, are approved for use in humans,
however, antibody-based drugs directed at gp120 and CD4 are in development and show
promising clinical results (24, 27).
Viral entry and fusion is followed by uncoating of the viral core and intracellular injection
of the single-stranded RNA genome along with various viral enzymes, including reverse
transcriptase (RT), which generates double-stranded, complimentary proviral DNA from viral RNA
over a period of 10 hours (24, 28). RT was the first HIV-1 enzyme targeted for antiviral treatment
with the advent of zidovudine (AZT) in 1987, which comprised HIV monotherapy until combination
ART in 1996 (29-31). HIV-1 RT has since become a major area of drug development, which
includes nucleoside and non-nucleoside reverse transcriptase inhibitors that encompass 12 FDAapproved drugs, accounting for half of all approved antiretroviral drugs. NRTIs are administered
as prodrugs that must be phosphorylated in three steps by cellular thymidine kinases to become
actively antiviral in vivo (32-35). Following activation, NRTIs serve as structural analogs of native
deoxynucleotides needed for reverse transcription, but lack the 3’-hydroxyl group on the
deoxyribosyl moiety which prevents formation of a 5’-3’ phosphodiester bond between
incorporated NRTIs and incoming native nucleosides (23, 36). The net result is early chain
termination of the growing viral DNA chain. nNRTIs also prevent production of proviral DNA from
viral RNA but do so by binding to an allosteric, hydrophobic site proximal to the active site,
thereby changing its conformation and inhibiting its catalytic activity (37-39).

Unlike NRTIs,

nNRTIs do not require phosphorylation to become active in vivo and they do not inhibit the RT
activity of other lentiviruses. One advantage of nNRTIs compared to NRTIs is their ability to
evade pyrophosphorolysis as a viral resistance mechanism, which selectively removes NRTIs
from the 3’ end of the nascent chain (24, 38). However, viral resistance to nNRTIs has emerged
in the form of amino acid substitutions in the allosteric binding site that prevents nNRTIs from
binding (38, 40, 41).
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Reverse transcription and generation of proviral DNA leads to assembly of the preintegration complex which is transported into the nucleus of the host cell and integrated in the
host genome, a process that is catalyzed by the integrase enzyme and occurs within roughly 20
hours of initial cellular infection (42). Integration occurs in three sequential steps: assembly of the
viral DNA, removal of 2-3 nucleotides from one or both 3’ ends of the viral DNA, and finally strand
transfer in which viral DNA is ligated to the host genome (43). Integrase inhibitors represent the
newest class of antiretrovirals, with two FDA-approved drugs, raltegravir and dolutegravir, that
specifically inhibit strand transfer by preventing binding of the pre-integration complex to the host
DNA (44). These drugs have proven to be very efficacious in preventing viral replication in
randomized clinical trials, and in some cases outperformed more widely-used drugs, such as
efavirenz (45).
Integration is a necessary precursor to transcription of viral genes leading to the
production and assembly of mature infectious HIV-1 particles. HIV transcription is unique in that
it requires binding of a regulatory protein, Tat, to the HIV RNA element (TAR) for transcript
elongation, making it a promising therapeutic target (24, 46). However, efforts to design small
molecule inhibitors against this process have proved to be inefficacious in clinical trials. Similarly,
while HIV assembly and maturation has become an area of increasing interest for drug discovery,
inhibitors, such as betulinic acid, have not shown evidence of sufficient in vivo antiviral activity to
be considered viable for use in humans (47).
The final step in the 24 hour intracellular HIV-1 replication cycle is proteolytic cleavage of
the viral gag and gag-pol polyprotein precursors by the HIV-1 aspartyl protease enzyme at the
inner surface of the host cell plasma membrane leading to generation of mature virions (37, 48).
Targeting the last essential enzyme in the viral replication cycle, HIV protease inhibitors (PIs)
constitute some of the most potent antiretroviral agents developed to date. The 10 approved PIs
all share similar peptidomimetic structural features and bind to the active site of the HIV protease
inhibiting its ability to cleave viral polyprotein precursors (49).
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Given the large size and

lipophilicity of PIs, co-administration of a boosting agent, ritonavir, is typically recommended to
enhance bioavailability via reduction of CYP450-mediated inactivation in the liver during first-pass
metabolism (50, 51).
Despite the remarkable achievement of ART in transforming HIV-1 disease into a
manageable, chronic disorder, numerous issues remain including treatment failure, poor
adherence to life-long therapy due to drug toxicity and pill burden, and sub-optimal
pharmacokinetics of ART in many patients (52). Fixed-dose combination antiretrovirals, such as
Kaletra (lopinavir/ritonavir) have been developed to improve regimen adherence and reduce pill
burden for patients, while efforts to enhance the pharmacokinetic profile of ART drugs include the
use of nanoformulated ART (NanoART).

Recently, Gendelman and colleagues developed a

long-acting, folic-acid coated, NanoART formulation that improved targeting of ART to HIVinfected macrophages while increasing plasma and tissue drug concentrations by five-fold up to
two weeks after a single dose in mice (53, 54). More importantly, these NanoART formulations
were also shown to improve biodistribution of ART to viral reservoirs in the CNS, leading to
speculation that nano-targeting of ART could alleviate the growing problem of HAND persistence
in the post-ART era (55-57). However, the toxic side effects of many ART drugs has led to
questions regarding the role of antiretrovirals in the persistence of HAND among the aging HIVpositive population in the developing world.
1.3: HIV AND AGING IN THE POST-ART ERA
The widespread use of ART has drastically decreased the incidence of AIDS-related
complications and improved the long-term prognosis of HIV-positive individuals. As of 2011, 30%
of the HIV-positive population in the United States was over the age of 50, and by 2015 it is
estimated that more than 50% will be over the age of 50 (58, 59). Despite this remarkable
development, the life expectancy for ART-treated, HIV-positive individuals remains 10-30 years
less than that of uninfected individuals (60). Given the rapid global expansion of this population,
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it has become increasingly important to understand the risk factors that lie at the intersection of
HIV, ART, and aging.
Older HIV-positive patients, including those treated with ART, are at increased risk for
systemic diseases including atherosclerosis, liver and kidney failure, cancer, and osteoporosis
(60, 61). The aging brain may also be more vulnerable to the effects of HIV as older adults
display an increased susceptibility to HAND, and emerging evidence suggests an increased
prevalence of neurodegenerative diseases, including Alzheimer and Parkinson, in this patient
population (62, 63). It remains unclear if the increased prevalence of HAND is a result of HIV and
related comorbidities, including hypertension, insulin resistance, and lipodystrophy, or other
confounding factors such as immunosenescence and ART toxicities, all of which are likely to
impact CNS disease progression in older HIV-positive individuals (64, 65).
Antiretroviral therapy effectively limits HIV disease progression, maintains patients in a
state of partial immune competence, and arrests subjects in a pre-symptomatic state (66).
However, despite the ability of ART to reduce plasma HIV RNA to undetectable levels, HIVpositive individuals remain at higher risk for opportunistic infections and premature death (3, 67).
Thus, ART may reduce, but does not appear to eliminate, premature and/or accelerated aging in
HIV-infected individuals.

This may be attributed to many factors including drug toxicity and

slower immune recovery following ART initiation in older patients, compared to younger adults
(68). Furthermore, advanced age has been linked to decreased production of T cells, B cells,
and cytokines, as well as to chronic immune activation, the latter of which may be linked to the
breakdown of gut-associated lymphoid tissue (GALT) and to the elevated levels of systemic
lipopolysaccharide (LPS) (69, 70).
Older patients also display a dampened recovery of CD4 cells following treatment with
ART, which may increase their risk for systemic diseases ranging from heart disease to cancer
(70).

Thus, it is not surprising that advanced age at seroconversion and/or onset of ART

treatment is considered a major risk factor for severe HIV disease (71, 72).
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Gotez et. al.

performed a retrospective study on HIV-positive patients receiving ART treatment at the
Veteran’s Administration Greater Los Angeles Medical Center between 1996 and 1999, and
found that for every 10 years of additional age at the onset of ART treatment, the rate of CD4 cell
replenishment decreased by 35 cells per microliter of blood (73). Despite the obvious benefits of
beginning ART treatment in asymptomatic HIV-positive individuals, there remain significant
concerns for initiating drug therapy sooner than necessary and how this may negatively impact
drug toxicity, long-term patient outcome, and the evolution drug resistant strains of HIV (72, 74).
Based on the updated recommendations for treatment initiation, all HIV-infected individuals will
be put on an ART regimen upon diagnosis, and the impact of this approach on older patients will
be revealing.
Lower CD4 count, in addition to advanced age, also places older patients at a nearly
four-fold higher risk for liver-related mortality compared to younger patients (75). This risk is
exacerbated by other factors commonly afflicting ART-treated, HIV-positive individuals including
diabetes, alcohol abuse, as well as antiretroviral and cholesterol drug toxicity (75). Among all
non-AIDS-related complications, liver disease is the primary cause of death in HIV-positive
patients (75). In addition, older HIV-positive individuals are at increased risk for frailty, bone loss,
and non-AIDS related cancers (76, 77). It remains unclear if HIV itself places older individuals at
higher risk for heart disease compared to older, HIV-negative individuals, though specific classes
of antiretrovirals, especially protease inhibitors, have been linked to atherosclerosis (69, 78, 79).
The CNS is particularly susceptible to the synergistic neurodegenerative effects of HIV
and aging. Several studies have demonstrated that, compared to younger (age 20 to 39 years)
cohorts, older HIV-positive individuals (age >50 years) display decreased neurocognitive
functioning in several areas including memory, psychomotor speed, and executive functions (59,
80, 81). The persistence of HAND in individuals with an undetectable viral load and CD4 cell
counts greater than 200/µL is not well understood and may be a result of aging-associated
processes rendering the cells of the CNS more vulnerable.
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Several recent neuroimaging studies have begun to address the structural, physiological,
and functional changes in the CNS in the context of HIV and aging. Six MRI investigations that
assessed the structural changes in the brains of older HIV-positive individuals between 1998 and
2012 found evidence of premature or accelerated aging characterized by significant brain atrophy
in the basal ganglia, cerebellum, and frontal and temporal brain regions, when compared to
seronegative controls (64). However, several diffusion tensor imaging (DTI) studies found only
normal, age-dependent changes in mean diffusion and fractional anisotropy, which reflects the
directionality of water diffusion in the brain, and is greater along organized white matter tracts, but
decreased in pathologically damages, disorganized tracts (64, 82-84).
Other studies have employed proton magnetic resonance spectroscopy (MRS) to assess
changes in brain metabolite levels that are indicative of neuronal damage and death or glial
activation. Ernst and Chang demonstrated a five-fold acceleration of aging effects in a relatively
young (mean age 36 years) ART-naïve, HIV-positive cohort, as compared to HIV-negative
controls, as reflected by increased levels of glial activation markers, myoinositol (MI), and choline
compounds (CHO) and a decrease in the neuronal marker, N-acetylaspartate (NAA) (85). A
recent multicenter MRS study of slightly older (ages 30-70), ART-treated HIV-positive individuals
demonstrated elevated MI and CHO in all brain regions of patients with asymptomatic or mild
neurocognitive impairment, but decreased levels of MI in those with dementia, which the authors
interpreted as premature microglial senescence (64, 86). In addition, this study found an agedependent decrease in NAA in frontal white matter, but only in patients with HAD (87). Thus,
while ART-naïve, HIV-positive patients show evidence of increased, age-dependent glial
activation and neuronal damage leading to accelerated aging, ART-treated individuals show only
signs of premature aging.
As discussed previously, the clinical and pathological hallmarks of post-ART HAND differ
from those in the pre-ART era. While HAND presented as a subcortical dementia afflicting the
basal ganglia and white matter, many post-ART studies suggest the focus of the inflammation
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has shifted primarily to the hippocampus, even in effectively treated patients (88-90).
Furthermore, there is emerging evidence that pathologic similarities exist between HAND and
some common neurodegenerative disorders such as Alzheimer disease, which is characterized
by the presence of extracellular beta amyloid (Aβ) plaque deposits and intracellular neurofibrillary
tangles composed of hyperphosphorylated Tau (61, 66, 91, 92). In vitro work involving the viral
protein Tat has demonstrated the ability of this viral protein to inhibit the activity of the Aβdegrading enzyme, Neprilysin, and bind to the receptor for advanced glycation end products
(RAGE), all of which may promote Aβ accumulation in the CNS. Indeed, some individuals with
HAND display CSF levels of Aβ42 comparable to those observed in AD patients (61, 93, 94).
Among the studies underlining the similarities between HAND and AD, Esiri et. al. were the first to
report a predisposition to plaque formation in the brains of pre-ART, HIV-positive individuals (95).
Such pathological changes have since been observed in HIV-positive patients despite successful
virologic control with ART, suggesting that antiretrovirals either cannot achieve therapeutic
concentrations within the brain parenchyma, allowing for ongoing viral replication and
neuroinflammation, or may have toxic effects that could facilitate neurodegeneration (96, 97). To
address the latter concern, several reports investigated differences in either phospho-Tau or Aβ
in ART-naïve vs. ART-treated individuals.

Two groups independently reported elevated Aβ

deposition/accumulation in the hippocampus of ART-treated individuals compared to pre-ART
patients, while Bell and colleagues reported only increased hyperphosphorylated Tau, but no Aβ
deposition in the hippocampus and entorhinal cortex of HIV-positive individuals (61, 90, 92, 98).
To date, no group has reported concomitant phospho-Tau accumulation and Aβ plaque
deposition in the same brain samples from HIV-positive cohorts. Although differences in patient
age and the antibodies used to detect Aβ may account for the varied outcomes of these reports,
11

studies utilizing the amyloid-binding, carbon 11-labeled Pittsburgh compound B ( C-PiB) and
PET imaging found that irrespective of neurocognitive impairment, HIV-positive individuals
showed no increase in
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C-PiB levels, highlighting a potential key difference between Aβ

metabolism in HAND vs. AD despite some overlapping pathological features (91, 99).
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Importantly, the aforementioned studies highlight the potentially underappreciated
concern of antiretroviral-associated neurotoxicity and its effect on neuropsychological outcomes
in long-term ART-treated patients.

ART drugs have been linked to wide-ranging, peripheral

metabolic and neural disturbances that could themselves influence the progression of HAND and
foretell potential mechanisms of toxicity in the CNS (78, 100-111). Specifically, PIs have been
associated with ER stress and the development of premature atherosclerosis as well as
metabolic syndrome, characterized by lipohypertrophy, hypercholesterolemia, and insulin
resistance (78, 112-114). Yet, the most serious limitation of ART drugs, specifically NRTIs, is
mitochondrial dysfunction and oxidative stress, manifested clinically as peripheral neuropathy and
myopathy (100, 115). NRTI toxicity is specific to myocytes and peripheral neurons due to the
presence of thymidine kinase isoforms in these cell types capable of phosphorylating the
prodrugs to their active form. Following phosphorylation, NRTIs are sequestered by DNA
polymerase γ and are either incorporated into mitochondrial DNA (mtDNA), causing permanent
damage, or terminate the growing DNA chain, depleting mtDNA-encoded enzymes necessary for
the electron transport chain (ETC).

Decreased mtDNA results in the loss of mitochondrial

membrane potential, decreased oxidative phosphorylation, increased reliance on glycolysis for
ATP production, and lactic acidosis. While direct CNS effects of ART are poorly understood,
Schweinsburg et. al. demonstrated an association between NRTIs and decreased levels of frontal
white matter NAA, which they attributed to NRTI-mediated mitochondrial dysfunction and
depletion of cellular respiration (102). Recently, a cross-sectional analysis of 540 HIV-infected
individuals in Amsterdam found that cumulative use of high dose ritonavir (> 400 mg/ 24 hours)
was associated with an increased risk factor for age-associated non-communicable comorbidities,
potentially due to the known effects of ritonavir on endothelial dysfunction and induction of
premature cellular senescence (116).
Confounding the issue of direct CNS toxicity of antiretroviral medications is the variability
in BBB permeability amongst different drug classes as determined by various physicochemical
properties such as plasma protein binding, lipophilicity, molecular size, and interaction with drug
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transporters in the BBB, such as P-glycoprotein (P-gp) and multidrug resistance associated
proteins. Based on these properties, a scoring system, called the CNS penetrance effectiveness
(CPE) score, was developed to estimate the efficacy with which various ART drugs would reach
therapeutic concentrations in the brain (117). ART drugs with poorer CNS-penetrating properties,
such as nelfinavir and saquinavir, are given a score of 0, while those with intermediate
penetrance are given a score of 0.5, and others with high penetrance, such as AZT, receive a
score of 1. However, the accuracy of this scoring system has recently been called into question
based on a number of experimental and clinical studies that refute these assumptions.

For

example, based on the CPE scoring system many PIs, which are targets of P-gp transporters,
have high molecular weights ( >500 Daltons) and are highly protein bound (up to 99%) in blood,
are estimated to achieve sub-therapeutic concentrations in the brain based on CSF levels
measured in humans (118, 119). Yet, a recent pharmacokinetic analysis of ART administration in
3

guinea pigs showed significantly higher uptake of [ H] ritonavir into brain parenchyma compared
to CSF, suggesting that clinical estimates of CNS penetrance for some antiretrovirals may be
lower than actual drug concentrations in the brain (50, 120, 121).
Although it is widely held that ART regimens with higher CNS penetrance generally
confer improved neuropsychological outcomes in HIV-positive individuals, numerous clinical
studies have suggested these regimens may negatively impact cognition. In a prospective study,
Marra et. al. found a significant association between highly CNS-penetrant ART regimens and
worse neurocognitive and motor performance 24 and 52 weeks after beginning or changing
therapy, despite decreased CSF HIV RNA in a small HIV-positive cohort (122). In addition,
Robertson et. al. reported an improvement in neuropsychological outcomes in a cohort of patients
with interrupted drug treatment (123). Studies using SCID mice, which display neuropathological
hallmarks similar to those associated with HIV, showed reduced viral load and astrogliosis
following administration of ART, but no improvement in cognitive dysfunction (124). Altogether,
these studies reinforce an emerging hypothesis that chronic use of antiretroviral drugs may be
contributing to the rising prevalence of HAND in the aging HIV-positive population.
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In contrast, numerous clinical studies have demonstrated beneficial effects on
neurocognitive functioning by ART regimens with high CPE scores (125, 126). A cross-sectional
study of 2636 adults from the AIDS Clinical Trials Group Longitudinal Linked Randomized Trials
(ALLRT) cohort on effective ART for at least 6 weeks showed better neurocognitive performance
in individuals receiving ART medications with higher CPE scores, although in some cases,
participants required more than 3 antiretrovirals to treat HIV in the CNS. (127). Letendre et. al.
demonstrated improvements in cognition over a 15-week period in patients beginning ART with
higher CPE scores versus those beginning ART with lower CPE scores (128). Another recent
investigation utilized MRS imaging to investigate the effect of multiple ART regimens with various
CPE scores on changes in brain NAA metabolite levels. Over 48 weeks, HIV-positive, ART-naïve
individuals receiving regimens with the highest CPE scores displayed the greatest increases in
NAA levels and showed the most improvement in a battery of neuropsychological tests (129).
These studies suggest that ART medications with higher CNS penetrance may have a
neuroprotective effect, at least initially, in successfully treated HIV-positive adults. Importantly,
these studies assess the effects of ART only after initiation of therapy, but given the wellcharacterized toxicities of ART medications in the periphery and the potential impact of related
co-morbidities on brain pathology, the long-term synergistic effects of aging and ART warrant a
careful longitudinal examination of the safety profile of these drugs in the CNS.
1.4: THE UNFOLDED PROTEIN RESPONSE AND TRANSLATIONAL PROTEIN CONTROL
The unanticipated persistence and evolution of HAND in the post-ART era has led to a concerted
effort to understand the underlying molecular pathways affected in chronic HIV-1 disease in the
CNS.

As discussed previously, there is extensive evidence for chronic neuroinflammation,

oxidative stress, and accumulation of neurodegenerative proteins in brains of ART-medicated,
HIV-positive individuals. Common among these various conditions is their ability to induce ER
stress and activate the unfolded protein response (UPR), a ubiquitous cellular response
mechanism conserved from yeast to humans (130). While the UPR has long been implicated in
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many neurodegenerative diseases, such as Parkinson and Alzheimer disease, Lindl et. al. were
the first to show evidence of ER stress activation in HAND, as evidenced by increased CNS
expression of the ER-resident molecular chaperone, BiP, ATF-6β, and phosphorylated eIF2α (peIF2α) (131-138). These findings suggest that chronic UPR activation, which has been linked to
long-term memory loss and neurodegeneration, may play an important role in the pathogenesis of
HAND (139, 140).
In eukaryotes the UPR is comprised of three major pathways, each under the control of
an upstream effector protein, PKR-like endoplasmic reticulum kinase (PERK), activating
transcription factor 6 (ATF6), and inositol-requiring enzyme 1α (IRE1α), located in the ER
membrane (141, 142). In the absence of ER stress, each of the effector proteins is kept inactive
via interaction at its luminal domain with the molecular chaperone, BiP/GRP78 (Immunoglobulin
heavy-chain binding protein/glucose-regulated protein 78), which serves as the main regulator of
the UPR (143). Accumulation of misfolded proteins and exposed hydrophobic residues in the ER
disrupts the interaction between BiP and PERK, ATF6, and IRE1α, permitting their subsequent
activation (144). The most evolutionarily conserved pathway of the UPR, IRE1α is a 100 kDa
type I transmembrane protein that homo-oligomerizes after dissociation from BiP and activates
both its kinase and endoribonuclease activity via autophosphorylation of its C-terminal kinase
domain (145). IRE1α regulates the expression of numerous molecular chaperones and protein
degradation genes via use of its endoribonuclease activity, which is utilized to non-conventionally
splice a 26-nucleotide intron from XBP1-mRNA (146-148). The resulting 376 amino acid spliced
XBP1 acts as a potent transcription factor that enhances expression of many genes including
IPK

P58

, which inhibits PERK activity (149). If transient UPR activation is unable to restore cellular

homeostasis, sustained IRE1α activation leads to autophagy and later apoptosis through its
regulation of B-cell lymphoma 2 (Bcl2) expression and activity (142, 150).
ATF6 activation is unique among the three branches of the UPR in that it does not
involve dimerization and autophosphorylation, but rather translocation to the Golgi and sequential
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regulated intramembrane proteolysis in two steps by serine protease site-1 protease (S1P), which
cleaves at the luminal domain, followed by N-terminal cleavage by metalloprotease site-2
protease (S2P) (141, 147).

The resulting 50 kDa cleaved ATF6 product constitutes the

transcriptional domain, which translocates to the nucleus and activates transcription of a cohort of
genes with ATF/cAMP and ER stress response elements (ERSE) in their promoters (151). These
genes include molecular chaperones, such as BiP, transcription factors, and ER-associated
degradation (ERAD) machinery (142).

The ATF6 transcriptional profile is ultimately a

cytoprotective, pro-survival program designed to aid cells in adapting to sub-toxic accumulation of
misfolded proteins.
Under mild stress conditions, PERK, a serine-threonine kinase, is the first initiator protein
to be activated in the UPR, although following sustained ER stress PERK can initiate pro-death
signaling, similar to IRE1α. Following dissociation from BiP, PERK dimerizes and activates its
kinase domain via autophosphorylation. This phosphorylation event results in a subsequent,
PERK-mediated phosphorylation of the eukaryotic translation initiation factor 2 (eIF2) at Ser51 of
the α subunit and global repression of cap-dependent protein translation (152, 153). eIF2 is
composed of three subunits, α, β, and γ, and when bound to GTP and Met-tRNA, comprises the
ternary complex that binds to the 40S ribosomal subunit to form part of the 43S pre-initiation
complex (154, 155). After binding to the eIF4F cap recognition complex at the 5’ end of mRNA,
the pre-initiation complex scans the 5’ leader sequence for an AUG start codon. Once an AUG is
recognized within a favorable sequence for translation initiation, GTP is hydrolyzed releasing eIF2
from the pre-initiation complex allowing the 60S ribosomal subunit to bind the mRNA and begin
the elongation phase of translation (156).

Phosphorylation of eIF2α inhibits this process by

blocking the dissociation of eIF2 from eIF2B, a guanine nucleotide exchange factor that is needed
for the exchange of GDP for GTP on the γ subunit of eIF2 (157). This converts eIF2 from a
substrate into a competitive inhibitor of eIF2B, slowing the exchange rate of GDP for GTP and
limiting the availability of competent ternary complex to form the pre-initiation complex (158).
Repression of global protein synthesis ultimately reduces influx of new mRNAs into the ER,
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allowing folding enzymes and molecular chaperones to reduce the burden of misfolded proteins
and prevent cellular toxicity.
Importantly, eIF2α is phosphorylated by numerous kinases that respond to a wide variety
of stress factors, highlighting its importance in cellular adaptation and protein translational control
(Figure 1). The first eIF2α kinase identified was heme-regulated inhibitor of translation (HRI)
kinase, which serves the critical function of balancing the amount of globin production with the
amount of heme available by inhibiting protein translation in reticulocytes in response to low
heme levels (159-162). HRI binds heme at its N-terminus which triggers the formation of stable
HRI dimers (162). When heme levels are low, HRI dimers undergo autophosphorylation, similar
to PERK, activating its kinase domain and leading to eIF2α phosphorylation and inhibition of
global protein synthesis (160). HRI knockout mice display hyper-sensitivity to heme deficiency
but no other physiological abnormalities (163-165). HRI is not thought to play a significant role in
neuronal p-eIF2α levels given that it is primarily expressed in erythroid cells and has no known
roles in other cell types.
Double-stranded RNA-dependent protein kinase (PKR) is a cytosolic, constitutivelyexpressed, mammalian kinase that was discovered after the initial observation that extracts from
vaccina virus-infected cells treated with interferon showed enhanced sensitivity to translational
inhibition after addition to a cell-free system of exogenous mRNAs or synthetic double-stranded
RNA (dsRNA) (166-168). Follow-up studies revealed that activation of PKR kinase is stimulated
through binding of dsRNA at its N-terminal double-stranded RNA-binding domains (DSRBs),
leading to dimerization and autophosphorylation of its kinase domain

(167).

Downstream

phosphorylation of eIF2α limits translation of viral mRNAs while enhancing the expression of
antiviral proteins (159, 169, 170). PKR can also be activated by a variety of dsRNA-independent
stress conditions including type 1 interferons, oxidative stress, and ER stress via interaction with
the PKR Activator (PACT) (171). PACT is phosphorylated under various stress conditions and
utilizes one of its three DSRBs to interact with and activate PKR (172). Overexpression of PACT
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sensitizes cells to viral infection and other stresses while knockdown of PACT mitigates stressinduced PKR activation and promotes clonal cell growth. Following activation by PACT, PKR
phosphorylates eIF2α and a variety of other targets, including signal transducers and activators of
transcription (STAT), interferon regulatory factor 1 (IRF-1), Jun-N terminal protein kinase (JNK)
and p53, which may mediate some of the observed tumor suppressor activity of PKR (167, 173,
174).

Overexpression of PKR leads to potent activation of apoptosis, likely as a protective

response against the spread of viral infection. However, despite the ability of PKR to regulate cell
survival and death, PKR knockout mice develop normally and display no phenotypic
abnormalities (175).

Several studies have suggested that PKR may play a key role in AD

pathogenesis based on observations that phospho-PKR is upregulated in the AD brain and
correlates with increased levels of the beta-site APP cleaving enzyme 1 (BACE1) (176-178).
General control non-derepressible 2 (GCN2) was originally identified in yeast as a gene
that senses and responds to amino acid deprivation, although in mammals it appears to be
sensitive to other stressors including viral infection and UV irradiation (179, 180).

GCN2 is

activated when uncharged tRNAs bind to its histidyl-tRNA synthetase (HisRS)-related domain
inducing dimerization and autophosphorylation to activate its kinase domain (172).

GCN2-

mediated phosphorylation of eIF2α results in translational upregulation of activating transcription
factor 4 (ATF4), which stimulates the transcription of numerous genes involved in the amino acid
biosynthetic pathway (181, 182). GCN2 can sense infection by RNA viruses, such as Sindbis
virus and Semliki Forest virus, by binding to viral RNA at its HisRS-related domain and inhibiting
translation via eIF2α phosphorylation (159, 183). One recent study also demonstrated that GCN2
inhibits replication of HIV in vitro and in vivo and is directly cleaved by the HIV-1 protease (184).
Given its prominent expression in the brain and interaction with HIV, GCN2 may provide a
mechanistic link between HIV infection in the CNS and UPR activation observed in HAND.
PERK was the final eIF2α kinase to be identified although it is the most physiologically
important for control of protein translation in mammals. In addition to alleviating ER stress, PERK
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plays a critical role in limiting oxidative stress via activation of nuclear factor (erythroid-derived 2)like 2 (Nrf2), a transcription factor that regulates the expression of a battery of genes involved in
the antioxidant response, including detoxifying enzymes such as glutathione S-transferase A2
(GSTA2) and NADPH quinone oxidoreductase (NQO1) (185). Normally, Nrf2 is kept inactive in
the cytoplasm via interaction with and constitutive targeting for degradation by Kelch-like ECHassociated protein 1 (KEAP1) (186). Following phosphorylation by PERK, Nrf2 dissociates from
KEAP1, migrates to the nucleus and activates transcription of genes with an antioxidant response
element (ARE) in the promoter (187). The importance of this link between ER stress and Nrf2
activation is highlighted by the fact that cells lacking Nrf2 are hyper-sensitive to compounds that
activate ER and oxidative stress (188).

PERK also plays an important physiological role in

secretory cell types, such as pancreatic β-cells, which are frequently under a large biosynthetic
load in response to varying demands for insulin production. Missense mutations in the PERK
gene have been linked to Wolcott-Rallison syndrome in humans, which is characterized by
permanent neonatal diabetes, growth retardation, pancreatic and skeletal system deficits, and in
some cases mental retardation (189, 190). Similar phenotypic abnormalities have also been
observed in PERK -/- mice. Forebrain-specific ablation of PERK in mice results in impairments in
cognitive and information processing, suggesting that PERK plays a key role in cognition in the
adult brain. However, aberrant PERK signaling is also implicated in neurodegenerative disorders,
such as AD, where it is known to be upregulated early in disease and may contribute to increased
amyloidogenic processing of APP via upregulation of BACE1 (133, 191-201). Similarly, genetic
and pharmacologic disruption of PERK activity in the CNS has been shown to have protective
effects in mice inoculated with prions and in an AD mouse model (197, 202). Altogether, these
studies suggest that eIF2α phosphorylation by HRI, PKR, GCN2, and PERK is a critical cellular
and physiological mechanism of protein translational control that protects cells against a wide
variety of stressors, but can lead to pathogenic conditions when activated in a chronic,
uncontrolled fashion, as in AD and other neurodegenerative diseases.
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Importantly, eIF2-mediated repression of protein translation is not universal; a subset of
genes involved in redox homeostasis, protein refolding and cell survival, such as ATF4, are
translationally upregulated in response to ER stress.

These mRNAs escape translational

repression through a variety of mechanisms including the presence of internal ribosome entry
sites (IRESs) within the 5’ untranslated region (UTR). Originally discovered in piconavirus RNAs,
IRESs are cis-acting elements found in the 5’ UTR of many viruses and up to 3-5% of eukaryotic
mRNAs (203). IRESs directly recruit the small ribosomal subunit in a cap-independent manner to
internal codons with the help of trans-acting cellular proteins known as IRES trans-acting factors
(ITAFs) which can confer tissue-specific regulation of protein translation (204, 205). Although the
regulation and function of cellular IRESs remains unclear, it appears that many genes with IRESs
encode for proteins involved in cell differentiation, growth, and apoptosis (206). Although IRESdependent translation also requires active ternary complex for initiation, some evidence suggests
that eIF2 phosphorylation augments IRES-mediated translation of some genes, including
vascular endothelial growth factor (VEGF), but not others (BiP) (206). Currently, the specific role
of p-eIF2α in cap-independent translation remains unknown.
A second method of evading translational repression, known as leaky ribosome scanning
(LRS), occurs when one or more upstream open reading frames (uORFs) in the 5’ UTR of an
mRNA are bypassed by the 40S ribosomal subunit allowing for translation to begin at a distal
AUG sequence.

Typically, LRS occurs when a particular upstream AUG is located in a

suboptimal nucleotide context to initiate translation. AUG initiators that differ drastically from the
optimal context 5’-CCRCCAUGG-3’ for initiation are likely to allow for stronger LRS, compared to
those that differ only slightly (207). The use of alternative codons due to weak LRS is emerging
as a common mechanism by which cells can derive several protein isoforms from a single mature
transcript, as has been characterized for histone H4 and C/EBP mRNA (207-209).
The most well characterized mechanism of cap-dependent escape from translational
repression, and the most relevant for ER stress-regulated genes, such as ATF4, is the utilization
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of small (~30 codons) uORFs in the 5’ UTR of gene transcripts (172, 181).

When eIF2α

phosphorylation is low and eIF2-GTP levels are high, scanning ribosomes will translate the first
uORF it encounters assuming the AUG is in an optimal context for initiation. If a transcript
contains uORFs upstream of the authentic start codon, as with ATF4, most of the ribosomes will
initiate translation at the proximal uORFs, which decreases the likelihood that scanning
ribosomes will re-initiate in time to begin translation at the authentic AUG start codon, resulting in
suppressed protein translation. However, when p-eIF2α levels are high and eIF2-GTP is limiting,
scanning ribosomes will still initiate translation at the first uORF, but are more likely to scan
through subsequent uORFs and re-initiate at the authentic start codon due to decreased
availability of the pre-initiation complex. Thus, decreased availability of the ternary complex/preinitiation complex simultaneously reduces the translation rate of most cellular mRNAs that contain
one start codon, while increasing the efficiency of translation in mRNAs with multiple uORFs.
This mechanism was first characterized in the yeast homologue of ATF4, GCN4, which contains
four uORFs and has subsequently been established for a variety of genes involved in stress
response, survival, and apoptosis (152, 172, 206, 210-212).

It is estimated that 35-49% of

human gene transcripts contain uORFs, indicating that protein translational control via p-eIF2α is
likely a widespread mechanism of regulation involved in many cellular functions and may be a
rich area of investigation for therapeutic intervention in the pathophysiology of human disease
(213).
Many genes encoding for growth factors, transcription factors, and proto-oncogenes also
utilize long, GC-rich 5’ UTRs to regulate protein translation levels through formation of extensive
secondary structures, which inhibit the helicase activity of eIF4A and promote dissociation of
ribosomes from the mRNA prior to initiating translation at the first start codon (214). Secondary
structures in GC-rich 5’ UTRs, typically hairpins, are the result of complementary base-pairing
and strong hydrogen bond formation between guanosines and cytosines.

The position and

stability of the secondary structures determines how effectively they inhibit translation of a
transcript. For example, a hairpin with a free energy of -30 kcal/mol located near the 5’ cap is
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sufficient to prevent binding of the pre-initiation complex, while hairpins located further down the
5’ UTR require free energies of at least -50 kcal/mol to inhibit translation (214-216).

The

endogenous mechanism(s) by which cells overcome translational block by secondary structure is
unclear, however, overexpression of eIF4A and eIF4B can partially overcome the free energy
requirements needed for unwinding (214, 217).

Notably, many transcripts utilize secondary

structure in conjunction with uORFs, IRESs, or trans-acting factors, such as RNA binding proteins
to further suppress protein translation. One of the most well characterized examples of this is
found in the mRNA of transforming growth factor-beta 1 (TGF-β1), which controls cell growth and
proliferation and is stimulated by growth factors and cytokine signaling (218). The 5’ UTR OF
TGF-β1, which is 867 nucleotides in length, forms stable stem loops which utilize the RNAbinding protein, Y-box protein-1 (YB-1), to cooperatively facilitate formation of duplex structures
that significantly downregulate translation of TGF-β1 under normal conditions in renal proximal
tubular cells (214, 218-220). In the presence of platelet-derived growth factor, YB-1 dissociates
from the 5’ UTR and the translational block is overcome (218). In summary, eukaryotic cells have
evolved eloquent mechanisms to regulate protein translation of critical gene transcripts allowing
for rapid cellular adaption to ever-changing inter- and intracellular conditions.
1.5: REGULATION AND FUNCTION OF BACE1 IN NEURONS
Alzheimer disease (AD) is a debilitating neurodegenerative condition characterized by
progressive memory loss and impaired cognition over a period of 15-20 years. AD remains the
leading cause of dementia in the elderly, affecting over 5.4 million people in the United States and
an estimated 26.6 million people worldwide (221).

Although patients with AD often follow a

stereotypic pattern of short-term memory loss followed by impairment in other cognitive domains,
such as language and reasoning, a definitive diagnosis of AD can be made only after postmortem analysis of brain tissue in patients suffering from dementia. The pathological hallmarks
of AD include intraneuronal neurofibrillary tangles (NFTs), composed of hyperphosphorylated
Tau, and extracellular senile plaques composed primarily of 38 to 42 amino acid-length Aβ
peptides.

Although most AD is sporadic, approximately 5% of cases result from genetic
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mutations that invariably affect production of Aβ, supporting the idea that Aβ accumulation and
deposition is a critical early event in AD pathogenesis.

This theory, known as the amyloid

cascade hypothesis, posits that Aβ dysregulation precedes and contributes to NFT formation and
the ensuing loss of synapses and neurons that underlie dementia (222). Despite overwhelming
genetic and pathophysiological evidence that Aβ accumulation is critical in AD development, the
number of NTFs, and not senile plaques, correlates with the degree of dementia in patients.
These observations suggest that senile plaques themselves are not toxic, but rather an attempt to
sequester and segregate toxic Aβ oligomers and aggregates that induce neuronal death. Under
pathological conditions, Aβ monomers can undergo rapid aggregation to form oligomeric species
that slowly transition into the large, insoluble fibrils that comprise senile plaques (223, 224). A
growing body of work suggests that Aβ oligomers are the toxic intermediates responsible for
neuronal death in AD, while the fibrils found in plaques are relatively inert (225).
Aβ is produced constitutively from the sequential endoproteolysis of the amyloid
precursor protein (APP), a ubiquitously expressed type I transmembrane protein of unknown
function found at highest levels in the CNS. During amyloidogenic processing, APP localized in
endosomes or the trans-golgi network (TGN) is first cleaved at the N-terminus by β-secretase
yielding a large, secreted fragment, sAPPβ, and a small, membrane-bound C-terminal fragment,
C99, that contains the Aβ domain.

C99 is then cleaved by a second protease complex, γ-

secretase, which is comprised of four transmembrane proteins: presenilin 1/2 (active site), Aph-1,
PEN-2, and nicastrin. The γ-secretase cleavage, which also occurs in the TGN or endosome
compartments, releases the APP intracellular domain (AICD) fragment and Aβ peptides of either
40 or 42 amino acids in length, which are exocytosed out of the cell. While Aβ42 peptides
constitute only a small fraction of the total Aβ produced, they are known to be more highly
amyloidogenic and are more likely to contribute to fibril formation in the CNS. Alternatively, APP
can be cleaved by α-secretase (primarily by ADAM10, a matrix metalloprotease) at the plasma
membrane yielding sAPPα and C83 fragments and, after sequential cleavage by γ-secretase, a
non-toxic p3 peptide plus AICD. Importantly, α-secretase cleavage of APP occurs within the Aβ
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domain, preventing the production of any Aβ peptides and thus constituting the nonamyloidogenic pathway of APP metabolism. Although Aβ is produced during normal cellular
conditions, its physiological function remains elusive. Additionally, it is unclear when normal
production of Aβ becomes pathogenic, although familial AD (FAD) mutations that lead to earlyonset AD typically result in enhanced processing of APP through the amyloidogenic pathway,
indicating that cleavage of APP is normally skewed heavily towards α-secretase and disruption of
this homeostatic balance can lead to pathology. Other FAD mutations linked to γ-secretase shift
the ratio of Aβ40:Aβ42 production towards increased Aβ42, triggering enhanced fibrillogenesis
and plaque deposition (226). Importantly, overexpression of APP, even in the absence of FAD
mutations that alter APP processing, is sufficient to cause amyloid pathology, which is best
exemplified in trisomy 21, wherein patients harbor three copies of the APP gene and develop
early onset memory loss accompanied by senile plaque and NFT formation in the CNS (227,
228).
Following the characterization of APP processing in the early 1990s, intensive efforts
were directed towards identifying the enzyme responsible for β-secretase activity in neurons.
Extensive biochemical analysis revealed that β-secretase was insensitive to pepstatin, closely
associated with membranes, highly expressed in neurons, and most enzymatically active in acidic
compartments of the secretory pathway (221, 229). Initially, cathepsin D, a major endosomal/
lysosomal aspartyl protease upregulated in AD and located in senile plaques, was thought to be
responsible for β- or γ-site cleavage of APP (230-232). However, follow up studies in cathepsin
D knockout mice indicated this protease had no role in amyloidogenic or non-amyloidogenic APP
processing and was responsible only for lysosomal degradation of Aβ (233, 234). In 1999, a
novel, 501 amino acid transmembrane aspartyl protease, BACE1, was identified by five
independent groups as the major β-secretase enzyme (235-239).

BACE1 was found to be

expressed in most cell types and tissues throughout the body with the highest levels in the brain
and pancreas. Within the CNS, BACE1 protein and mRNA are expressed at high levels in
neurons and at much lower levels in astrocytes. Importantly, BACE1 protein and activity are
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elevated in transgenic mouse models of AD and in brains of familial and sporadic AD patients
compared to age-matched controls (240-242). Furthermore, immunohistochemical analysis by
Vassar and colleagues showed BACE1 elevation occurs in swollen dystrophic neurites near
amyloid plaques and co-localizes with APP, implicating BACE1 as a causal agent in AD
pathogenesis (243).
Further characterization of BACE1 revealed that it is synthesized in the ER as a 60 kDa
zymogen that undergoes rapid maturation to the active 70 kDa form following N-terminal
cleavage by furin and N-linked glycosylation at four asparagine residues in the ER and Golgi.
Mature BACE1 cycles between compartments of the secretory pathway, similar to APP, and
displays peak enzymatic activity in endosomes at pH 4.5, from where it can be ubiquitinated and
sent to the proteasome or transported to the lysosome for degradation. In addition to APP,
BACE1 has been shown to cleave a variety of other targets, including neuregulin 1 (NRG1) type
III, which plays an important role in myelination of the peripheral nervous system (PNS). Although
BACE1 knockout mice were initially thought to be physiologically normal, it is now evident that
these animals display hypomyelination in the PNS, similar to that observed in NRG1 type III
knockouts, indicating that a key physiological role of BACE1 may be regulation and/or
maintenance of myelination via cleavage of NRG1. Within the CNS, BACE1 is concentrated
within pre-synaptic terminals and is believed to play a role in maintenance of synaptic function.
Consistent with this idea, BACE1 -/- mice display a variety of complex neurological and
behavioral abnormalities including memory deficits, axon guidance defects, hyperactivity, reduced
serotonin and dopamine levels in the hippocampus, and spontaneous seizures.

These

phenotypes are not recapitulated in APP or APP-like protein null mice, suggesting they are
related to other established BACE1 substrates, such as NRG1 and Nav1 β2, or novel functions of
BACE1 within the CNS.
BACE1 expression peaks in early postnatal brain indicating it may also play a role in
growth and differentiation (244). Given the multitude of processes mediated by BACE1, it is thus
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unsurprising that BACE1 expression is tightly controlled at the transcriptional and translational
levels. The human BACE1 gene spans 30 kb and contains a complex promoter with binding sites
for a host of transcription factors including Sp1, HIF-1α, and nuclear factor-κB (NF-κB), which
suppresses BACE1 under normal cellular conditions but increases the transcription of BACE1 in
the presence of stressors, such as Aβ peptides, indicating BACE1 may play a role in stress
response or homeostasis signaling (245, 246).

The BACE1 promoter is also differentially

regulated by oxidative stress and inflammatory mediators, such as interferon gamma (INFγ)
which activates Janus Kinase 2 (JAK2) and extracellular signal related MAP kinase 1/2 (ERK 1/2)
leading to STAT1 phosphorylation and subsequent upregulation of BACE1 expression (247).
Yet, despite the presence of inflammation and oxidative stress in AD, upregulation of BACE1
appears to be mediated primarily at the post-transcriptional level given that protein levels are
consistently elevated in the CNS without corresponding changes in mRNA (241, 248-252).
BACE1 translation is known to be strictly regulated on multiple levels, consistent with the
presence of a long, highly conserved leader sequence (246). In particular, the BACE1 5’ UTR is
446 nucleotides long, with 3 uORFs, two of which contain uAUGs that reside in optimal contexts
for translational initiation, and has a GC content of 77%, which contributes to the formation of
stable secondary structures (253).

Translation of BACE1 occurs through a cap-dependent

mechanism with no detectable IRES activity, indicating that uORFs and secondary structure are
the primary mechanisms of BACE1 translational regulation (253, 254).

Although there is

disagreement in the literature, several mutagenesis analyses revealed that uAUG #2 has the
strongest inhibitory effect on translation initiation while the other two uAUGs are largely bypassed
via leaky ribosome scanning or ribosome shunting and do not contribute significantly to
translational block (253-256). In contrast, a report by Lammich et. al. concluded that the uORFs
in BACE1 contribute minimally to translational repression and that tightly folded secondary
structures in the UTR with a predicted free energy of -215.3 kcal/mol were sufficient to inhibit
translation (253). Additionally, there is evidence that the BACE1 5’ leader sequence undergoes
alternative splicing that can reduce the number of uAUGs and improve translational efficiency

26

(257). In short, BACE1 is subject to complex translational controls that result in very low protein
expression under normal conditions. However, recent evidence indicates that translational block
of BACE1 is overcome during various stress conditions that activate mediators of the unfolded
protein response. A report by O’Connor et. al. in 2008 was the first to describe that energy
deprivation in neurons results in chronic activation of PERK, phosphorylation of eIF2α, and
translational de-repression of BACE1 leading to enhanced amyloidogenesis in vivo (191). Others
have shown that oxidative stress leads to translational upregulation of BACE1 through PKRmediated phosphorylation of eIF2α (176, 178). Altogether, these observations strongly reinforce
an emerging hypothesis that BACE1 may act as a stress response protein in the CNS. Potential
mechanisms by which BACE1 activity could be protective to neurons remains an area of active
investigation. A recent report demonstrated that BACE1 is upregulated in zebrafish in response
to low oxygen levels via transcriptional upregulation by HIF-1, similar to what is seen in
mammals, suggesting that activation of BACE1 is an evolutionarily conserved mechanism (258).
Furthermore, BACE1 processing of APP to generate Aβ appears to be an activity dependent
process in hippocampal neurons whereby Aβ protects cells from hyperactivity and excitotoxicity
(259). Therefore, it is reasonable to assume that BACE1 upregulation serves a neuroprotective
function during acute stress conditions in the brain. However, chronic inflammation, hypoxia,
oxidative stress, and ER stress, which are hallmarks of many neurodegenerative disorders, might
lead to unchecked, maladaptive BACE1 activation and over-production of Aβ.

This would

explain, in part, why amyloid pathology is often found in neurodegenerative disorders other than
AD. Thus, BACE1 has emerged as a key therapeutic target that lies at the crossroads between
cellular stress, stress response signaling, and Aβ production in AD and a growing list of other
chronic, neurodegenerative diseases.
1.6: RATIONALE AND HYPOTHESIS
HAND has evolved into a complex, neurodegenerative condition that has persisted
despite the use of successful antiretroviral therapy. Initial studies of the underlying mechanisms
contributing to dementia in patients with HIV suggest that inflammation and excitotoxicity are key
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mediators of neuronal damage and death. However, adjunctive therapies with anti-inflammatory
and anti-excitotoxic properties have proved to be unsuccessful in the treatment of HAND.
Additionally, the use of ART regimens with high CNS penetrance has yielded mixed
neuropsychological results in patients with HIV, suggesting that ART is either unable to mitigate
neuronal damage in HAND or contributes to the neurodegenerative process. We hypothesized
that the persistence and evolution of HAND is a direct result of antiretroviral neurotoxicity in the
CNS, leading to chronic ER stress, translational upregulation of BACE1, and aberrant
amyloidogenic processing of APP. First, we provide an extensive review the contributing factors
to HAND pathogenesis, including inflammation, aging, drugs of abuse, and antiretroviral
neurotoxicity (Chapter 2). Next, we used in vitro models to demonstrate for the first time that ART
drugs, and PIs in particular, potently activate the neuronal unfolded protein response leading to
PERK-dependent phosphorylation of eIF2α and translational upregulation of BACE1 (Chapter 3).
Importantly, enhanced BACE1 expression was accompanied by increased Aβ42 production in
ART-treated cells, which was dose-dependently blocked with a cell-permeable beta-secretase
inhibitor. These findings were corroborated by our in vivo findings that SIV-infected, ART-treated
macaques and ART-treated, HIV-positive patients display increased expression of UPR markers,
BACE1, and Aβ oligomers compared to age-matched controls (humans only) (Chapter 3).
We also sought to determine the role of BACE1 in neuronal survival under conditions of
oxidative and ER stress (Chapter 4). In contradiction to the idea that BACE1 plays a protective in
acute cellular adaptation to stress, we found that inhibition of BACE1 protected neurons against
damage and death in the presence of hydrogen peroxide or ritonavir in vitro. Furthermore, using
a pharmacological approach, we found that PKR may be critical for ART-mediated
phosphorylation of eIF2α and BACE1 upregulation.
Altogether, this body of work implicates HIV protease inhibitor class ART drugs in the
persistence and evolution of HAND pathology via chronic induction of ER stress in neurons. We
have characterized a specific mechanism by which PIs induce translational upregulation of
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BACE1 leading to enhanced amyloidogenic cleavage of APP and corroborated these findings
with post-mortem analysis in human patients.

We have also identified BACE1 as a key

therapeutic target in HAND, that appears to be mediate some of the neurotoxic effect of
antiretroviral drugs and, more broadly, oxidative stressors, such as hydrogen peroxide.
Ultimately, this work contributes to our understanding of HAND pathogenesis and the basic
biological functions of BACE1 in neurons, which will enhance our ability to treat and prevent
neurodegenerative disease.
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Figure 1. Phosphorylation of eIF2α by four kinases integrates cellular stress responses. A
wide variety of stress conditions result in phosphorylation of the eukaryotic translation initiation
factor 2α (eIF2α) which is mediated by four distinct kinases, PERK, PKR, GCN2, and HRI that
display cell- and tissue-specific expression levels. Phosphorylated eIF2α results in decreased
translation of most mRNAs, which reduces the influx of new proteins into the ER to alleviate ER
stress. Paradoxically, a subset of mRNAs that contain upstream open reading frames (uORFs) in
the 5’ UTR, which are normally repressed, are translationally upregulated leading to increased
expression of transcription factors, such as ATF4, that active gene transcription of molecular
chaperones involved in protein re-folding . Alternatively, chronic induction of phospho-eIF2α can
lead to expression of CHOP which activates apoptotic cell death.
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2.1: ABSTRACT
Purpose: This review discusses current concepts of HIV-associated neurocognitive disorders
(HAND) in the era of anti-retroviral therapy (ART). As the HIV epidemic enters its fourth decade
(the second decade of ART), research must address evolving factors in HAND pathogenesis.
These include persistent systemic and central nervous system (CNS) inflammation, aging in the
HIV infected brain, HIV subtype (clade) distribution, concomitant use of drugs of abuse, and
potential neurotoxicity of ART drugs.
Recent findings: Although the severest form of HAND, HIV-associated dementia (HAD) is now
rare due to ART, the persistence of milder, functionally important HAND forms persist in up to half
of HIV-infected individuals. HAND prevalence may be higher in areas of Africa where different
HIV subtypes predominate, and ART regimens that are more effective in suppressing CNS HIV
replication can improve neurological outcomes. HAND is correlated with persistent systemic and
CNS inflammation, and enhanced neuronal injury due to stimulant abuse (cocaine and
methamphetamine), aging, and possibly ART drugs themselves.
Summary: Prevention and treatment of HAND requires strategies aimed at suppressing CNS HIV
replication and effects of systemic and CNS inflammation in aging and substance-abusing HIV
populations. Use of improved CNS-penetrating ART must be accompanied by evaluation of
potential ART neurotoxicity.
Key words: HIV, cognitive dysfunction, inflammation, antiretroviral therapy, HIV- associated
neurocognitive disorders
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2.2: INTRODUCTION
The term HIV-associated Neurocognitive Disorders, or HAND, represents a group of syndromes
of varying degrees of impairment of cognition and associated functioning in HIV infected
individuals [1,2]. Its clinical severity ranges from asymptomatic neuropsychological impairment
(ANI) through Minor Cognitive Motor Disorder (MCMD) and HIV-associated dementia (HAD),
grouped collectively as HAND. The neuropathogenesis of HAND is generally considered to be
initiated and driven by HIV invasion and replication within the brain parenchyma, largely through
productive infection of brain perivascular macrophages and endogenous microglia, and perhaps
to some degree by restricted infection of astrocytes [3,4].

Associated with this infection is

neuroinflammation and immune activation of resident glia (macrophages, microglia, astrocytes),
which is associated with neuronal injury (both reversible and irreversible).

Although the

widespread utilization of anti-retroviral therapy (ART) has dramatically decreased the prevalence
of the severest form of HAND, HAD, the overall prevalence of HAND and associated morbidity
remain high (~50%) [5-8**].

The persistence of this high risk for HAND in individuals

experiencing effective control of systemic HIV viral load is incompletely explained, and suggested
factors include effects of aging on brain vulnerability, persistence of HIV replication in brain
macrophages, evolution of highly neurovirulent CNS HIV strains, and even long-term CNS toxicity
of ART [8**,9**]. This review will discuss several of these key factors implicated in modulating
HAND pathogenesis:

inflammation, HIV-1 subtype (clade), drugs of abuse, aging, and

antiretroviral drug effects. Other important factors, including co-morbidity effects of Hepatitis C,
host genetic susceptibility, viral gene adaptations, and others are discussed elsewhere
[4,10*,11*].

2.3: ROLE FOR INFLAMMATION IN NEUROPATHOGENESIS OF HIV-ASSOCIATED
NEUROCOGNITIVE DISORDERS
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Inflammation is associated with HIV replication, both in the periphery and within the CNS where
macrophage activation has been correlated with HAND [12,13].

In the last few years the

inflammatory response in the systemic circulation has been recognized as a key driver of HIV
pathogenesis, both in the periphery and in the CNS [14**-26]. In the CNS there is considerable
evidence that this inflammatory response drives the development of HAND or worsens it, possibly
independently of viral replication [4,27*-29].

Evidence for persistent inflammation in the CNS in the ART-experienced patients. The era of ART
is associated with changes in the neuropathology of HIV infection, which reflects the partial
efficacy of ART drugs in suppressing, albeit incompletely, CNS virus replication and associated
inflammation [30-32]. Before the introduction of ART, robust neuroinflammation was frequently
observed in brain autopsies from HIV-infected patients and the severity of inflammation generally
increased throughout clinical disease progression from the early asymptomatic stage to AIDS to
severe HAND [33-36]. Although inflammation is less severe since ART inception, it nonetheless
persists within the macrophage/microglial populations, which represent the primary reservoir for
HIV in the brain [37-38]. Perivascular monocyte-derived macrophages (MDM) and microglia are
the primary CD4+cells in the CNS and the major sources of productive HIV infection in the brain
[39-42] and clinical disease severity correlates more strongly with the amount of monocyte
infiltration and MDM/microglia activation than with the quantity of infected cells or viral load
[12,13]. This suggests that MDM/microglia play a predominant role in the neuroinflammation and
neurodegeneration seen in HAND.

Immune activation of MDM/microglia is demonstrated by

expression of CD14 (LPS receptor), CD16, CD68, and MHC class II in vivo [34,43-45].
Furthermore, cerebrospinal fluid markers of immune activation and inflammation are commonly
detected in individuals with HAND. These markers include CCL2 [46,47]

[48-

51], quinolinic acid [52-55], arachidonic acid metabolites [56,57], oxidative stress markers [58,59],
and platelet activating factor [60].
Although ART has limited the severity of pathological changes characteristic of HAND, it has not
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eliminated them. These persistent pathological findings in ART-experienced individuals include
neuronal loss with apoptosis, astrocytosis, myelin pallor, and at least some activated microglia
and perivascular macrophages, although the neuropathological hallmarks of HIVE, multinucleated
giant cells and microglial nodules, are typically absent [37]. Persistent CNS immune activation
has also been documented in pediatric AIDS patients, as evidenced by detection of sCD14 and
an elevated CSF IgG index despite prolonged (>4 years) ART use and undetectable serum viral
loads [61]. Thus, despite some ART effectiveness in limiting the infiltration of infected cells
(monocytes/macrophages) into the CNS, neuroinflammation still persists. Nonetheless, the
primary sites of neuroinflammation are different; the characteristic involvement of the basal
ganglia in pre-ART specimens is less commonly seen in post-ART specimens, which display
inflammation in the hippocampus and in adjacent parts of the entorhinal and temporal cortices
[32,38,62].

Overall these studies confirm the notion that neuroinflammation continues to be

associated with HIV CNS infection in ART-experienced individuals [63].
Chronic systemic inflammation and microbial translocation in the gut as a driving force for CNS
inflammation and HAND. Chronic systemic inflammation has been tightly linked to morbidity and
mortality in HIV infected patients receiving ART, which suggests that adjunctive anti-inflammatory
drug therapy is needed to improve outcomes [14**-26]. Studies have correlated systemic
inflammation (elevated plasma sCD14, LPS), CNS inflammation and HAND [64] and persistence
of CSF immune activation (sCD14, elevated IgG index) despite ART use and undetectable serum
viral loads [61]. A strong association between the early and persistent damage caused to gutassociated lymphoid tissue (GALT) by HIV infection (SIV infection in macaques), increased
microbial translocation resulting in systemic immune/monocyte activation, and disease
progression has been established [21,22*,24-26,65].

An association between this systemic

immune activation and HAND has also been established, and a causal relationship between
increased systemic monocyte activation, increased transendothelial migration of activated
monocytes into the brain, and neurocognitive decline secondary to neurodegeneration has been
proposed [64]. Furthermore, the persistence of HAND (~50% prevalence) despite prolonged
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ART use is associated with not only neuropathologic but also neuroradiologic evidence of
persistent CNS inflammation [7,61,66*-68]. Persistent systemic and CNS inflammation in ARTtreated individuals are thus clear targets for adjunctive therapies against disease progression.

2.4: ASSOCIATION OF HIV-1 CLADES/SUBTYPES AND RISK OF HIV-ASSOCIATED
NEUROCOGNITIVE DISORDERS
Until recently, HAND has been studied nearly exclusively in developed countries (United States
and Europe), where a single HIV clade, or genotypically-defined subtype predominates (HIV
clade B).

The distribution of HIV-1 clades varies worldwide, and differences in phenotypic

characteristics including induction of immune responses, viral fitness, drug resistance, coreceptor utilization, antibody neutralization sensitivity, and neuruovirulence among HIV clades
have been described [69-76]. Several recent publications have suggested that HAND prevalence
varies among populations based upon clade predominance, thus representing an independent
risk factor for HAND [77,78]. The majority of clinical studies have been performed in cohorts
infected with clade B, and the neuropathogenesis of HAND has, until recently, been exclusively
described in these populations. Furthermore, HIV clades can be further modified through genetic
recombination events, which could alter their pathogenic potential.

Early studies in Uganda

(where clades A and D predominate), have shown that prevalence of some HAND features is
comparable to that observed in the United States during the pre-ART era, and that advanced age
and low CD4+ T cell count are major risk factors [81*]. Other investigators observed a greater
prevalence of HAND in anti-retroviral-naïve HIV+ individuals in Uganda who are infected with
clade D strains in comparison with individuals infected with clade A strains (89% vs. 24%) [79*].
Notably, the use of ART can significantly improve neurocognitive function in these individuals
within a few months [80].

More studies have focused on clade C, as it is the most common HIV clade and it accounts for
approximately 50% of HIV infections worldwide, Clade C is linked to growing epidemics in sub-
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Saharan Africa and parts of Asia, including China and India [81*]. Some studies have associated
infection with clade C with a low risk for HAND (in Ethiopia) while others (performed by AustraliaPacific NeuroAIDS consortium in many countries in the Pacific Rim) associate it with a higher
risk.

Studies in India, where clade C accounts for 95% of HIV infections, have produced

conflicting results. In southern India, approximately 60.5% of ART-naïve HIV+ individuals in one
study (n=119) were found to have neuropsychological test impairments without clinically
identifiable neurological symptoms (consistent with asymptomatic HAND, ANI), while another
study indicated a higher than expected prevalence of clinically symptomatic HAND. A study of
HIV+ (clade C) individuals in China, showed that the prevalence, pattern and severity of some
HAND deficits were comparable to those reported for (clade B) in western countries. Finally, a
recent study of clade C-infected ART-experienced (average 2 years on ART) individuals in
Botswana,

demonstrated

a

prevalence

of

neurocognitive

impairment

detected

by

neuropsychological testing and a modified International HIV Dementia Scale (IHDS) of greater
than 33%, which exceeds the expected prevalence of HAD, even in the pre-ART era [82*]. Thus,
several studies in distinct clade C cohorts worldwide suggest a potentially high risk for moderate
to severe HAND complications with clade C infection. Notably, despite possible different risks for
HAND among these different HIV clades, beneficial effects of ART have been demonstrated
worldwide (reviewed in [83*]).

2.5:

ASSOCIATION OF DRUGS OF

ABUSSE AND RISK FOR HIV-ASSOCIATED

NEUROCOGNITIVE DISODERS
Although the strict definition of HAND requires the exclusion of other co-morbid conditions
(besides HIV infection) as the cause of neurocognitive dysfunction, the contribution of drugs of
abuse as a major co-morbidity risk for neurocognitive dysfunction in HIV+ individuals is a major
concern worldwide [84-87*]. Among the major drugs of abuse contributing to HIV pathogenesis
are opiates (morphine), and stimulants (cocaine, methamphetamine/METH).

In developed

countries, approximately 30% of HIV+ individuals are intravenous drug abusers, and the risk for

54

HAND is clearly greater among these individuals [87*]. The neuroinflammation associated with
HAND appears to be exacerbated by drugs of abuse, as demonstrated by brain autopsy studies
revealing a higher prevalence of HIV encephalitis (microglia activation, presence of
multinucleated giant cells, and blood brain barrier disruption) in drug-abusing HIV+ individuals in
comparison with non-abusing HIV+ controls [88-90]. These findings suggest that drug abuse,
exerts an additive (if not synergistic) effect with HIV within the CNS. However, the inherently
heterogeneous nature of drug abusing patient populations confounds the specific effects of drugs
of abuse on neuronal function and survival in vivo.

Both in vitro and in vivo studies, however, clearly implicate drugs of abuse in exacerbating
neuronal injury induced by HIV (or the primate homolog, SIV/simian immunodeficiency virus),
although conflicting evidence for certain drugs of abuse has been presented [91-97]. Enhanced
HIV replication in MDM and T lymphocytes through opioid exposure has been demonstrated [98100] as has enhancement of MDM-associated inflammation and oxidative stress [101]. Opiates
(methadone) also activate HIV replication in latently infected macrophages in vitro [102].

In

nonhuman primate models of simian immunodeficiency (SIV) infection (the primate homologue of
HIV infection), carefully controlled studies show that chronic morphine administration markedly
increases viral loads in the plasma and cerebrospinal fluid (CSF) [103]. Interestingly, activation of
mu opioid receptors, which are expressed in neurons, MDM, and T lymphocytes, can increase
the expression of some of the chemokine receptors (CCR3, CCR5, and CXCR4) that serve as
HIV co-receptors for HIV in susceptible cells (MDM, T lymphocytes) [104,105]. Furthermore,
activation of Kappa opioid receptors (MDM, T lymphocytes) can decrease CCR5 expression, and
thus decrease cell susceptibility to HIV infection [106,107]. Nonetheless, a role for opiates in
exacerbating neurodegeneration in HAND remains controversial [85*,108].

A role for stimulants such as cocaine and methamphetamine in exacerbating the risk for HAND is
more strongly established by in vivo and in vitro studies [109]. Enhancement of HIV replication in
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MDM by stimulants (cocaine, methamphetamine) has been consistently demonstrated in vitro,
and the expected consequence of enhanced HIV replication in MDM is enhanced
neurodegeneration through enhanced production of neurotoxic factors from infected and
activated macrophages within the CNS [3,84].

Cocaine can also increase HIV replication in

monocytes, and even astrocytes in vitro [110,111]. The later observation could be significant, as
restricted infection of astrocytes in vivo has been demonstrated in several studies, suggested that
this could be a second HIV reservoir (in addition to the primary HIV reservoir,
macrophages/microglia) [112-114].

In addition, cocaine can facilitate HIV infection by

upregulating DC-SIGN, another HIV co-receptor, in dendritic cells, through dysregulation of
mitogen-activated protein kinases [115]. Methamphetamine can increase macrophage HIV
infection in association with increased expression of CXCR4 and CCR5, and perhaps by
downregulation of extracellular-regulated kinase (ERK) and the upregulation of p38 mitogenactivated protein kinase [116]. Methamphetamine can also enhance HIV replication in monocytederived dendritic cells [116].

Alterations in blood-brain-barrier (BBB) integrity by cocaine and methamphetamine are another
proposed mechanism for enhancing neurodegeneration through enhanced monocyte entry and
disruption of cellular homeostasis.

In vitro, cocaine can enhance monocyte transendothelial

migration, induce the expression of adhesion molecules on endothelial cells, and disrupt
intercellular junctions [117-119]. Methamphetamine and the HIV envelope protein, gp120, can
modulate

tight

junction

expression

in

brain

endothelial

cells,

leading

to

decreased

transendothelial resistance across the blood–brain barrier and enhanced transendothelial
migration of monocytes [120]. Morphine alone, on the other hand, does not appear to alter the
integrity of the blood–brain barrier, although in combination with the HIV transactivator protein,
Tat, it can alter tight junction expression in brain endothelial cells in vitro. Interestingly, although
morphine by itself is not toxic to striatal neurons in culture, it can significantly potentiate Tat
toxicity in striatal neurons [121]. Thus, these studies of effects HIV-derived proteins and cocaine

56

and methamphetamine that demonstrate alterations in endothelial cell function and/or disruption
the blood–brain barrier suggest potential additive effects of HIV infection, cocaine and
methamphetamine in vivo.

Evidence for in vivo neuropathologic effects of cocaine and methamphetamine in HIV+ individuals
is also accumulating [85*]. Disruption of the blood–brain barrier in such individuals has been
demonstrated in neuropathologic studies, and this disruption correlates with early inflammatory
changes in the CSF, particularly with increased monocyte chemoattractant protein-1 (MCP1/CCL2) levels [122]. However, whether BBB integrity is even further compromised in individuals
abusing cocaine or methamphetamine is unknown.

Autopsy studies of adult methamphetamine

abusers have demonstrated neuronal loss within the substantia nigra and structural and
metabolic changes within the brain have been detected in children after prenatal exposure
[123,124]. Injury to dopaminergic pathways and the basal ganglia also occurs in HIV+ individuals
in the presence and absence of abuse of cocaine, which can result in profound clinical symptoms
of basal ganglia dysfunction [125].

Thus, drugs of abuse, particularly cocaine and

methamphetamine are strongly associated with enhanced brain injury in HIV+ individuals, which
is expressed as enhanced risk for HAND and other neurologic complications.

2.6: AGING AND HIV-ASSOCIATED NEUROCOGNITIVE DISODERS
The long-term prognosis for ART-treated HIV+ individuals continues to improve as the incidence
of many AIDS-related complications declines, and by 2015 more than 50% of the HIV+ population
in the United States will be over 50 years of age [14**]. Nonetheless, life expectancy for treated
HIV+ individuals remains 10 to 30 years less than uninfected individuals [14**]. ART-treated
patients are at increased risk for systemic and CNS diseases associated with aging: renal failure,
osteoporosis, cancer, cardiovascular disease, and cognitive decline, which can be associated
with Alzheimer’s disease (AD) and Parkinson’s disease (PD)-like pathology [14*,126*].

This

suggests that the aging brain might be more vulnerable to neuronal injury associated with HIV
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infection, although co-morbidity factors in aging patients complicate establishing a causal
relationship between age and HAND risk.

Several published neuroimaging and neurobehavioral studies have suggested an increased risk
for cognitive impairment with increased age in HIV+ individuals [66*,127,128], although an
additional study has suggested that the effects of HIV infection and aging in the brain might act
independently [129].

Ernst and Chang [127] used brain proton magnetic resonance

spectroscopy (MRS) to demonstrate that the combined effects of HIV+ serostatus resulted in a
greater than five-fold acceleration of aging effects (rather than additive effects) in the basal
ganglia, in a cohort of 46 HIV+ subjects in comparison with HIV negative controls. Cherner et al
[128] showed that an HIV+ subject cohort with an age greater than 50 years and detectable CSF
viral loads had a two-fold higher prevalence of neuropsychological impairment in comparison with
a younger cohort (less than 35 years of age) showing undetectable viral loads. Notably, this
relationship was not found in those individuals younger than 50 years of age. These studies
suggest that older adults are at higher risk for neurocognitive dysfunction because of age-related
brain vulnerability;

however, whether this dysfunction reflects accelerated neuropathological

processes associated more specifically with HAND or processes more specifically associated
with other familiar neurodegenerative diseases, or neither, remains to be determined.

Some recent studies have begun to address the underlying neuropathology of age-related
neurocognitive dysfunction in HIV+ subjects. AD and PD-like pathological changes observed in
ART-treated patients [130*,131] include elevated levels of hyperphosphorylated Tau (p-Tau) in
the hippocampus and beta-amyloid (Aβ) deposition, both intra and extracellular, in the frontal
cortex and hippocampus [132-135]. Recent evidence has also shown increased levels of alphasynuclein in the substantia nigra and increased risk for PD in aging HIV+ patients on ART [131].
Although accumulation of neurodegenerative-related proteins might be accounted for by the
increased lifespan associated with ART, possible toxic effects of ART in the CNS are now being
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considered as a contributing factor in HAND [11*,136*]. One study demonstrated that pre-ART
subjects who lived up 15 years with HIV infection did not express excessive levels of
hyperphosphorylated Tau or beta-amyloid, nor were they associated with HAND [38]. Other
studies have demonstrated increased levels of amyloid precursor protein in damaged axons in
brain specimens from ART-naive patients without evidence for elevated p-Tau expression or
neuritic plaque formation [137,138].

Thus, studies utilizing neuropsychological performance

testing, neuroimaging, and neuropathological analyses strongly support a strong correlation
between accelerated neurocognitive decline driven by HIV infection in aging individuals, even
those with what is considered ‘effective’ suppression of systemic HIV replication. These studies
further emphasize the need for developing new strategies, involving current ART and possibly
adjunctive therapies, for protecting the brain against injury in the aging HIV+ population.

2.7: POSSIBLE ROLE FOR ANTIRETROVIRAL THERAPY DRUGS IN HIV-ASSOCIATED
NEUROCOGNITIVE DISORDERS
The persistent high prevalence of less severe forms of HAND, including ANI and MCMD, after
widespread implementation of ART was not anticipated, and several causes have been
suggested, including effects of aging and associated co-morbidity factors on the brain [9*,39,66*].
Antiretroviral drugs, particularly nucleoside reverse transcriptase inhibitors (NRTIs) are highly
neurotoxic, and ART drug-induced neuropathy is a major complication of HIV treatment [10*]. In
addition, some clinical studies have also suggested a role for direct and/or indirect neurotoxic
effects of ART drugs in the CNS [139-141]. In addition to direct neurotoxicity, ART has been
linked to multiple risk factors for neurodegenerative disease, such as insulin resistance,
lipodystrophy, atherosclerosis, coronary artery disease, and immune reconstitution syndrome
[142-149]. These studies suggest possible direct and indirect effects of ART drugs in the CNS
that could be linked to impaired neurocognitive performance.
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However, other studies have demonstrated beneficial effects on neurocognitive functioning by
ART regimens ranked according to their predicted effectiveness (termed CNS penetrationeffectiveness ranking, CPE) in suppressing HIV replication within the CNS [8*, 150*-152]. Better
neurocognitive performance was observed over a 15 week period in adult individuals beginning
ART with regimens of higher CPE [151] and improved survival rates over 6+ years of follow up of
pediatric HIV encephalopathy patients receiving higher CNS-penetrating regimens were also
observed [153**,154**]. A cross sectional study of 2636 adults (ALLRT cohort) on effective ART
(less than 50 HIV RNA copies/ml) also demonstrated better neurocognitive performance in those
receiving higher CPE ART [150*].

Another recent study utilized MRS brain imaging and

neurocognitive testing to demonstrate partial reversal of neuronal injury in patients and greater
improvements in neurocognitive functioning in other patients receiving different ART regimens
over a 48 week period, which might relate to CNS drug penetrance [155*].

These studies

suggest a neuroprotective effect of ART based upon use of higher CPE regimens, and ongoing
prospective clinical studies are further addressing this critical issue [8**,9**,154**].

2.8: CONCLUSION
HAND pathogenesis is driven by HIV replication and the factors associated with amplifying the
inflammatory milieu within the CNS.

Systemic immune activation, migration of activated

monocytes, drugs of abuse, and secondary effects of aging all contribute to neuronal injury
associated with HAND, which persists despite effective systemic control of HIV replication by
current ART. Accordingly, drugs that suppress systemic immune activation and associated
inflammation, both systemically and within the CNS compartment, could represent effective
adjunctive neuroprotectants [4, 27*-29]. Investigating drugs in current clinical use that target
these cellular pathways could rapidly facilitate testing and implementation of feasible adjunctive
neuroprotective strategies against HAND.
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“Antiretroviral drugs promote amyloidogenesis via translational upregulation of BACE1”
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3.1: ABSTRACT
The clinical and pathologic presentation of HIV-associated neurocognitive disorders (HAND) has
changed in the post-antiretroviral (ARV) era, evolving from a subacute, subcortical dementia to a
cortical, neurodegenerative disease.

Mounting evidence implicates ARVs as potential

contributing factors to the persistence and evolution of HAND. Based on their ability to induce ER
stress in a wide variety of cell types, we hypothesized that ARVs also cause ER stress in the
CNS, resulting in chronic dysregulation of the unfolded protein response (UPR) and altered
amyloid precursor protein (APP) processing. Here, we utilized in vitro and in vivo models to show
that HIV protease inhibitor (PIs) class ARVs induce neuronal ER stress leading to PKR-like ER
kinase (PERK)-dependent phosphorylation of the eukaryotic translation initiation factor 2α
(eIF2α), and enhanced translation of β-site APP cleaving enzyme-1 (BACE1). Additionally, we
demonstrate PI-mediated Aβ production, indicative of amyloidogenic APP processing, in primary
rodent neuroglial cultures and Chinese Hamster Ovary (CHO) cells expressing human APP.
These effects were abrogated by genetic excision of PERK or overexpression of a kinase-dead
PERK mutant. Finally, ARVs administered to SIV-infected macaques resulted in elevated levels
of APP in the CNS. Altogether, these findings implicate PIs as potential mediators of
neurodegeneration in HAND.
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3.2: INTRODUCTION
The advent of antiretroviral (ARV) therapy as the mainstay for HIV treatment has significantly
reduced the prevalence of HIV-associated dementia (HAD), a severe motor/cognitive disorder
afflicting AIDS patients (1-3), from ~20-30% to 1-2% (1).

However, the prevalence of HIV-

associated neurocognitive disorders (HAND), a spectrum of HIV-related CNS dysfunctions
ranging from mild cognitive deficits to HAD, has remained high despite this dramatic reduction in
HAD prevalence (1, 4-7).

In addition, HIV-associated neuropathology has evolved from a

subcortical encephalitis to a prolonged, cortical, neurodegenerative disease (8).

Recently,

several groups have reported beta-amyloid (Aβ) immunoreactivity, both intra and extracellular in
the frontal cortex and hippocampus of ARV-medicated subjects, while others have observed only
accumulation of hyperphosphorylated Tau (8-14).

While increased longevity of HIV-infected

populations is suggested to contribute to these changes in HAND neuropathology, other risk
factors, such as peripheral toxicities of ARVs and potential central effects linked to enhanced
amyloidogenesis and aging, remain largely underexplored.
Among the six classes of ARVs currently prescribed, nucleoside reserve transcriptase
inhibitors (NRTIs) and HIV protease inhibitors (PIs) are the oldest and continue to provide the
backbone for treatment regimens.

NRTIs inhibit the viral reverse transcriptase enzyme,

preventing the generation of proviral DNA from viral RNA (15).

In addition, PIs are

peptidomimetics that bind to the active site of the HIV aspartyl protease and prevent cleavage of
gag-pol precursor polyproteins, blocking viral maturation (16). As a result of combination ARV
therapy, HIV-infected individuals have experienced a 50% reduction in death rates and incidence
of HAD (16).

Despite their numerous benefits, ARVs have been linked to wide-ranging,

peripheral metabolic and neural disturbances that could themselves influence the progression of
HAND. Specifically, NRTIs have been linked to mitochondrial dysfunction, manifested clinically
as peripheral neuropathy and myopathy. (17-19). On the other hand, PIs have been associated
with

dyslipidemia,

hypercholesterolemia,

and

metabolic

lipodystrophy, atherosclerosis, and insulin resistance (20-27).
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syndrome,

characterized

by

We have shown that ARVs administered to healthy adult rats and SIV-infected macaques
lead to extensive synaptodendritic damage in the CNS. Furthermore, treatment of rat cortical
neurons with ARVs led to accumulation of ROS and eventual synaptic damage and neuronal
death (28).

These data support a growing body of evidence that ARVs have significant

neurotoxic effects in the CNS, as they do in the peripheral nervous system (PNS), and may
influence the long-term neurocognitive outcome of patients. Importantly, NRTIs and PIs have
each been shown to induce numerous cellular stressors, including ER and oxidative stress, both
of which are commonly found in HAND and other neurodegenerative diseases, such as
Alzheimer disease (AD) (29, 30). Recently, it has become clear that diverse cellular stressors
converge on a ubiquitous intracellular response mechanism termed the unfolded protein
response (UPR) or ER stress response (31, 32). In eukaryotes, the UPR entails three sensor
proteins, pancreatic ER kinase (PERK), activating transcription factor 6 (ATF6), and inositolrequiring enzyme 1α (IRE1), located in the ER membrane, which are kept inactive through
complex formation with the ER-resident chaperone, Binding Protein (BiP)/GRP78 (33-35).
Accumulation of misfolded proteins in the ER disrupts interaction between BiP and the lumenal
domain of one or more of the three UPR sensors, permitting their consequent activation (33).
Downstream effects of UPR induction include global protein synthesis attenuation via eIF2α
phosphorylation, upregulation of genes containing the ER Stress Response Element (ERSE), and
ER-mediated protein degradation (35).
While transient UPR activation serves a protective function, the chronic nature of cellular
stress and stress response activation in the CNS during HIV infection may ultimately overwhelm
the capacity of the ER resulting in aberrant UPR activation and eventual cell death (30, 36). We
and others have demonstrated a potential role for ER stress and the UPR in the pathogenesis of
HAND as well as other neurodegenerative diseases (30, 37-40).

The examination of post-

mortem brain tissue from ARV-treated, HIV-positive patients and AD patients shows increased
expression of BiP, p-eIF2α, ATF6, and other markers of the UPR primarily in neuronal cells (30,
35, 41). Interestingly, in vivo studies utilizing glucose deprivation or tunicamycin to induce UPR
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activation in CNS neurons have demonstrated consequent increases in APP and A deposition
(42-44). Vassar and colleagues subsequently showed that impaired brain energy metabolism,
induced by glycolysis inhibition, leads to chronic activation of the PERK arm of the UPR, allowing
for sustained phosphorylation of eIF2α and upregulation of -secretase (BACE1) (44). Extensive
studies have shown that phosphorylation of eIF2α globally inhibits protein translation while
upregulating the translation of a subset of mRNA species that contain multiple upstream open
reading frames (uORF) in the 5’-UTR, one of which is BACE1 (44).

BACE1 is an aspartyl

protease critical for generation of Aβ from APP and is upregulated in brains of patients suffering
from AD (45, 46). Increased BACE1 expression and activity in the brain have been correlated
with plaque number and cognition status, and has been implicated as a biomarker of mild
cognitive impairment (MCI) and AD (46). Altogether, these studies suggest that UPR-mediated
upregulation of BACE1 may function as an early event in AD pathogenesis.
In the present study, we sought to determine the mechanisms by which ARVs induce
damage and death in primary CNS neurons and whether BACE1 expression and function could
contribute. Here, we report that PIs induce ER stress in primary neurons leading to PERKdependent translational upregulation of the APP-cleaving enzyme, BACE1.

Additionally, we

found that PIs enhance production of Aβ in neurons and CHO cells stably expressing human
APP. Moreover, these findings were corroborated with in vivo findings that chronic ARV drug
treatment results in CNS damage and increased expression of APP. These findings suggest that
PIs may be altering APP processing, and thus contributing to the changing neuropathology and
the persistence of cognitive decline among ARV-treated, HIV-infected individuals.

3.3: EXPERIMENTAL METHODS
Chemicals and Reagents. The following antibodies used in this study were purchased from the
indicated vendors: BACE1 (5606S); phospho-eIF2α (9721S); Total eIF2α (9722); Lamin A/C
(2032S); Presinilin-1 (5643) [Cell Signaling Technology], BiP/Grp78 (610978) [BD Transduction
Laboratories], APP (6E10) [Covance], Synaptophysin (ab8049); ADAM10 (ab1997); MAP2 (5392)
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[Abcam], GAPDH (sc-32233) [Santa Cruz], Actin (A2066) [Sigma].

The mouse monoclonal

antibody against BACE1 (3d5) was a generous gift from Dr. Robert Vassar (Feinberg School of
Medicine, Northwestern University, Chicago, IL). The antibody against Aβ-oligomers (Nab61)
was kindly provided by Dr. Virginia Lee (The Perelman School of Medicine, University of
Pennsylvania, Philadelphia, PA). The antibody against ATF4 was generously provided by Dr.
Ron Wek (School of Medicine, Indiana University, Indianapolis, IN).

The rabbit monoclonal

antibody against PERK was a generous gift from Dr. Alan Diehl (The Abramson Family Cancer
Research Institute, University of Pennsylvania, Philadelphia, PA).

The following chemical

reagents used in the study were purchased from the indicated vendors: 4’,6-diamidino-2phenylindole (DAPI); Citifluor, Ltd. (London, UK): citifluor AF1; Dulbecco’s Modified Eagle’s
Medium (DMEM); Neurobasal media and B27 supplement [Invitrogen], Protein assay dye (5000005), Polyvinylidene fluoride (PVDF) membrane; Prestained broad range molecular weight
ladder [BioRad], Neuromag Transfection Reagent (NAN14000) [Nanotherics], Fast Green FCF;
Protease inhibitor cocktail, 4-hydroxytamoxifen (H7904); Anisomycin (A9789); Actinomycin D
(A1410) [Sigma].

Antiretroviral reagents (AIDS Research and Reference Reagent Program,

Division of AIDS, NIAID, NIH). Poly-L-Lysine (Peptide International). Tyramide Amplification
System (New England Biolabs).

Normal Antibody Diluent (Scytek Labs).

All horse radish

peroxidase (HRP)-conjugated secondary antibodies were obtained from Thermo Scientific and all
dye-conjugated secondary antibodies were obtained from Jackson ImmunoResearch Labs.
Immunofluorescence. Paraffin-embedded tissue sections from the hippocampus of control and
HIV(+) human autopsy cases obtained from the NNTC and paraffin-embedded tissue sections
from

hippocampus

of

pigtailed

macaques

(Macaca

nemestrina)

were

prepared

for

immunofluorescent staining with minor modifications of previously described protocols (30, 47).
The age, neurocognitive status, sex, and postmortem interval of each human specimen was
provided by the NNTC (Table 1). Glass slides containing paraffin-embedded tissue sections (10
o

μM) were heated overnight to 55 C, deparaffinized in histoclear and rehydrated in 100%, 95%,
90%, and 70% ethanol washes. Tissue was then incubated in 3% H 202 in methanol to inactive
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endogenous peroxidase activity. Antigen unmasking was performed with target retrieval solution
o

at 95 C for 1 h. Sections were then blocked with 10% normal goat serum and incubated with
o

various primary antibodies overnight at 4 C. Tyramide amplification was used to detect BACE1
and DNA was visualized with DAPI staining. Slides were washed with PBS plus 0.1% Tween-20
(PBS-T) and mounted in Citifluor AF1 and analyzed by laser confocal microscopy at 600x on a
BioRad Radiance 2100 equipped with Argon, Green He/Ne, Red Diode, and Blue Diode lasers
(BioRad, Hercules, CA).

Post-acquisition analysis was performed using Metamorph 6.0

(Universal Imaging, Downingtown, PA). Total intensity for MAP2 and APP were determined by
the measurement of integrated pixel intensity per z-stack image, where integrated pixel intensity
is defined as total pixel intensity per image times the area of pixels with positive MAP2 or APP
signal. Averages are expressed as mean ± SEM. All data was analyzed by Prism 5.0 software
(Graphpad Software, San Diego, CA).
SIV/pigtail macaque model of HIV CNS disease. Pigtailed macaques (Macaca nemestrina) were
inoculated with SIV/DeltaB670 and SIV/17E-Fr, as described previously (48).

12 days after

infection, animals were divided into placebo and ARV-treated groups until necropsy (range, day
161-175).

ARV treatment was composed of the NRTI tenofovir (Gilead) at 30 mg/kg

subcutaneously given once daily, saquinavir (Roche) and atazanavir (Bristol-Myers Squibb) at
205 and 270 mg/kg, respectively, given twice daily via oral administration, and an integrase
inhibitor, L-870812 (Merck) (49) at 10 mg/kg orally twice daily (50). Tenofovir dosing was based
on previous studies (51) while saquinavir and atazanavir dosing was based on pharmacokinetic
analysis carried out in pigtail macaques to reflect similar area under the curve parameters as
those detected in human treated with atazanavir and saquinavir (50).

L-870812 integrase

inhibitor dosing was based on previous work conducted in rhesus macaques (49).
Preparation of Primary Cortical Neuroglial Cultures. Primary rat or mouse cortical neuroglial
cultures were isolated from brains of embryonic day 16 Sprague Dawley rat pups or embryonic
day 16.5-17.5 floxed PERK mice, with modifications of previously described protocols (52).
Briefly, to generate neuroglial cultures, cortical cell suspensions were isolated from rat or mouse
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pups and plated in poly-L-lysine coated tissue culture dishes and maintained in neurobasal media
o

supplemented with B27 at 37 C with 5% CO2, as described previously (53, 54). Unless otherwise
indicated, all experiments were performed at 21 days in vitro (DIV) on cultures containing
approximately 90% neurons and 10% astrocytes/glia. Pure neuronal cultures were prepared by
treating neuroglial cultures with 10μM Ara-C 48 hours after plating and were maintained in
o

neurobasal media with B27 at 37 C with 5% CO2.
Human primary cortical neurons were obtained from the Comprehensive NeuroAIDS Center
(CNAC), Temple University, Philadelphia, PA. Cultures were prepared from fetal brain tissue
(gestational age, 16-18 weeks) performed in full compliance with National Institutes of Health and
Temple University ethical guidelines as described previously (55).

Neurobasal medium
o

supplemented with B27 was half-changed every 4 days and cultures were maintained at 37 C
with 5% CO2 for 21 DIV.
Previously characterized Floxed PERK (Perk

loxP/loxP

) mice (56) were crossed with tamoxifen-

inducible cre (Cre-ERT2) heterozygous mice and the resulting PERK
kindly provided by Dr. Alan Diehl.

loxP/loxP

; Cre-ERT2 mice were

PERK deletion was achieved by treating 10 DIV mouse

neuroglial cultures with various concentrations of 4-hydroxytamoxifen (4-OHT).

Antiretroviral

drug treatments were performed 4 days following 4-OHT treatment to allow for maximal PERK
-/-

excision. 16 h following antiretroviral drug treatment, PERK neuroglial cultures were harvested
for Immunoblotting or genotyping using routine methods.
Drug Treatments. 21 DIV rat cortical neurons or human fetal neurons were treated with various
log-fold concentrations of either AZT, prepared in sterile water at 25 mM stock, saquinavir, or
ritonavir, both prepared in DMSO at 25 mM stock concentrations. All antiretroviral drugs were
added to neuroglial cultures 16 h prior to harvest. Anisomycin and Actinomycin D were prepared
in DMSO at 50 mM and 5 mM stock concentrations, respectively. 21 DIV rat cortical neurons
were pre-treated with either 10 μM or 50 μM Anisomycin or 5 μM Actinomycin D for 12 hours then
treated with 10 μM ritonavir 16 h prior to harvest.
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Immunoblotting. Flash-frozen whole-brain tissue samples from HIV (-) control (n=4), HIV (+)
neurocognitively normal (n=8), and HIV (+) HAND (n=6) human autopsy cases were obtained
from the tissue banks of the National NeuroAIDS Tissue Consortium (NNTC).

Tissue was

prepared for western blotting as described previously (30). 30 μg protein for each sample was
loaded into each lane of 10% Bis-Tris gels and transferred to PVDF membranes followed by
blocking with TBS-T with 5% bovine serum albumin (BSA) for 30 min at room temperature.
o

Membranes were probed with various primary antibodies overnight at 4 C.
Whole-cell extracts of mouse brain tissue samples were prepared by homogenization in ice-cold
tissue extraction buffer (50 mM Tris pH 7.5, 0.5M NaCl, 1% NP-40, 1% SDS, 2 mM EDTA, 2 mM
EGTA, 5 mM NaF, 0.4 mM Na3VO4, 1 mM dithiothreitol (DTT) and 1:100 protease inhibitor
o

cocktail). Extracts were then centrifuged at 12,000 g at 4 C for 20 min.
Whole cell extracts of primary rat cortical cultures were prepared with ice-cold whole-cell lysis
buffer containing 50 mM Tris pH 7.5, 120 mM NaCl, 0.5% NP-40, 0.4 mM Na3VO4, 100 mM, and
o

1:100 protease inhibitor cocktail. Lysates were centrifuged at 14,000 g at 4 C for 10 min. Protein
concentrations were determined using the Bradford method and equal amounts of protein (15-20
μg) were loaded into each well of 4-12% Bis-Tris Gradient gels or 3-8% Tris-Acetate gradient gels
(for confirmation of PERK overexpression) followed by transfer at 25 V at room temperature for 1
h to PVDF membranes. Membranes were subsequently blocked in TBS-T and 5% BSA for at
least 30 min at room temperature.

Membranes were then incubated in primary antibodies

o

overnight at 4 C, washed with TBS-T, and incubated with appropriate HRP-conjugated secondary
antibodies for 30 min. at room temperature. Membranes were developed using SuperSignal
West Dura extended duration substrate and densitometric analysis was performed using the NIH
ImageJ software program (Image J v1.44, NIH). Equal loading and transfer was confirmed by
fast green staining of membranes.

Band densities of interest were normalized to indicated

loading controls or fast green stains of membranes. Immunoblots shown are representative of at
least three independent biological replicates.
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RNA Isolation and Quantitative RT-PCR. Total RNA was isolated from primary rat neuroglial
cultures using the RNeasy Mini Kit (Qiagen, Valencia, CA). To assess the expression of spliced
XBP-1 and BACE1 genes, 1 μg total RNA from each sample was subjected to the SuperScript II
First-Strand Synthesis system (Invitrogen).

Approximately 100 ng cDNA was amplified via

quantitative RT-PCR using Custom TaqMan® Gene Expression Assays purchased from Applied
Biosystems. Relative expression of mRNA levels from each sample were quantified using the
comparative CT method and data was normalized to unspliced XBP-1 and TBP for spliced XBP-1
and BACE1 genes, respectively.

All samples were run in triplicate and experiments were

repeated in at least three biological replicates.
Human/Rat Aβ ELISAs. Cell media from 21 DIV primary rat neuroglial cultures and CHO cells
stably expressing Human wild-type APP were diluted 25-fold and subjected to a human/rat Aβ42or Aβ40-specific sandwich ELISA (Wako Chemicals, Richmond, VA) according to manufacturer’s
protocols. For CHO cell experiments, cultures were pre-treated with 10 nM, 100 nM, or 1 μM
Beta-Secretase IV (Calbiochem, Billerica, MA) for 12 h followed by treatment with 10 μM ritonavir
or DMSO vehicle for 16 h at which time media was collected. For rat neuroglial cultures, cells
were treated with combinations of antiretroviral drugs followed by media collection at 4 and 16 h.
Human sAPP ELISAs. Cell culture media from CHO cells stably expressing human wild-type or
APP were pre-treated with 10 nM, 100 nM, or 1 μM Beta-Secretase IV (Calbiochem, Billerica,
MA) for 12 h followed by treatment with 10 μM ritonavir or DMSO vehicle for 16 h at which time
media was collected. Conditioned media was then diluted 25-fold and subjected to a human
sAPPα or sAPPβ ELISA (IBL International, Toronto, ON) according to manufacturer’s
recommendations.
Pulse-Chase and Immunoprecipitation. Primary rat neuroglial cultures were grown in 60 mM
plates for 21 DIV in neurobasal media supplemented with B27. Cultures were pulse-labeled with
2 mL methionine/cysteine-free DMEM containing 0.4 mCi

35

S-labeled methionine and cysteine for

30 minutes. Cultures were washed twice with sterile DPBS and chased with neurobasal media
supplemented plus B27 with or without 10 μM ritonavir. At 0, 6, 12, 18, and 24 hr after labeling,

90

cultures were harvested with ice-cold lysis buffer (50 mM Tris pH 7.5, 120 mM NaCl, 0.5% NP-40,
0.4 mM Na3VO4, 100 mM, and 1:100 protease inhibitor cocktail).

Lysates were

immunoprecipitated with Dynabeads Protein A [Novex] and 2 μg anti-BACE1 [Cell Signaling].
Immunoprecipitates were run on a 4-12% Bis-Tris gradient gel for separation and transferred onto
PVDF membranes for approximately 7 hr.

Membranes were dried and exposed via

autoradiography.
Subcellular Fractionation. To evaluate ATF4 nuclear translocation in the context of antiretroviral
drug toxicity, 21 DIV rat neuroglial cultures were treated with 10 μM ritonavir, or DMSO vehicle,
for 16 h and fractionated. To prepare nuclear extracts, cultures were washed twice in ice-cold
PBS and lysed for 10 min in 10 mM HEPES (pH 7.9), 10 mM KCL, 10 mM EDTA, 1 mM DTT,
AND 0.4% Nonidet P-40 supplemented with protease inhibitor cocktail. Extracts were centrifuged
o

o

at 4 C for 3 min at 15,000 x g and the supernatant (cytoplasmic fraction) stored at -80 C. The
resulting nuclear pellet was resuspended in 20 mM HEPES (pH 7.9), 400 mM NaCl, 1mM EDTA,
o

10% glycerol, and 1 mM DTT with protease inhibitor cocktail then incubated at 4 C, with shaking,
for 2 h. The nuclear fraction (supernatant) was then generated by centrifuging the extracts at
o

15,000 x g for 5 min at 4 C. Protein concentrations were then determined using the Bradford
method and lysates run on 4-12% Bis-Tris gradient gels. Membranes containing nuclear fractions
were probed with rabbit anti-ATF4 (generous gift from Dr. Ron Wek, Indiana University).
Nanomagnetic Transfection. For transfection of primary rat neurons, pure neuronal cultures were
generated by treating DIV 3 neuroglial cultures with 10 μM AraC. DIV 10 pure neuronal cultures
were transfected with plasmid DNA via magnetotransfection using the Magnefect-Nano II system
(Nanotherics Ltd., Stoke-On-Trent, UK).

Briefly, 0.5 μg, 1 μg, or 2 μg of plasmid DNA:

pcDNA3.1Zeo(+) + BACE1 5’ UTR and -5’ BACE1 UTR (a generous gift from Robert Vassar),
pLenti CMV/TO Puro destination vector (backbone), wild-type mouse PERK, or kinase-dead,
K618A PERK was complexed with 2.4 μl of Neuromag transfection reagent (Nanotherics Ltd.) for
15-20 min in serum-free neurobasal media. Complexes were added drop-wise to 24-well plates
of pure neuronal cultures containing 500,000 cells per well. Plates were incubated for 30 min at
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o

37 C with 5% CO2 over a magnet array oscillating at 3 Hz with 0.2 mm amplitude of
displacement. Following transfection, plates were immediately removed from the magnet array
and placed on a shelf in the incubator at the same temperature and CO 2 conditions. Plates were
harvested after 48-72 h for Immunoblotting or cell staining following routine methods.
Statistical Analysis. All data were analyzed by Prism 5.0 software (GraphPad Software, San
Diego, CA). All quantifications are expressed as mean ± SEM. Paired results were analyzed by
Mann-Whitney U test or unpaired student t test while data with multiple categories were analyzed
by one-way analysis of variance (ANOVA) plus Newman-Keuls or Dunnett post hoc test, as
indicated. Values of p < 0.05 were considered significant.
Study Approval. All animal studies were performed in accordance with protocols approved by the
Institutional Animal Care and Use Committees of the University of Pennsylvania and Johns
Hopkins University.

3.4: RESULTS
BACE1 and Aβ oligomer immunostaining are elevated in brains of HIV(+) individuals. Previous
studies have shown accumulation of neurodegenerative proteins in the brains of HAND patients.
To investigate the mechanisms underlying age-related pathologies that are increasingly observed
in HAND, we first assessed levels of Aβ oligomers (Aβ-oligo), the Aβ species suggested to be
responsible for CNS neurotoxicity in AD, in the hippocampus of HIV(+) HAND patients (see Table
1 for a summary of cases). We observed elevated levels of intraneuronal Aβ oligomers in HAND
patients compared to HIV(+) neurocognitively normal and uninfected, healthy controls (Figure 1A,
Table 1). Importantly, we found no evidence of senile or diffuse Aβ plaque deposition in the
hippocampus using the BC05 antibody, an Aβ42-specific antibody generated by Dr. Virginia Lee
(not shown). As oligomeric Aβ is derived from cleavage of APP by the β secretase enzyme 1, we
determined whether BACE1 expression was altered in the same cohort of samples. When we
stained for BACE1 in the CA1, CA3, and dentate gyrus regions of the hippocampus, we observed
significantly elevated BACE1 immunoreactivity in HAND patients compared to healthy controls,
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consistent with our finding of elevated Aβ oligomers, despite decreased microtubule-associated
protein 2 (MAP2) expression (Figure 1B). Interestingly, no significant changes in BACE1 were
observed in the dentate gyrus. To confirm our immunostaining findings, we assessed protein
levels of BACE1 and APP in whole brain lysates from the mid-frontal cortex of uninfected (HIV(-)),
HIV(+) neurocognitively normal (HIV(+) Normal) and HIV(+) HAND patients by immunoblotting.
As shown in Figure 1D, and quantified in Figure 1E, BACE1 was elevated both in HIV(+) Normal
and HAND patients compared to uninfected controls; however, no differences were observed
between HIV(+) Normal and HAND samples. As increased Aβ production may also result from
changes in total APP expression, we also immunoblotted these lysates for full-length APP. As
seen in Figure 1F, we found no significant differences in APP protein levels when groups were
compared according to infection or cognitive status. Of note, levels of full-length APP showed
more variation among different samples from the HIV(+) HAND group. The significance of this
variation remains unclear. Importantly, we found that BiP levels were elevated in HIV(+) Normal
brain samples, but not in HAND (Figure 1D), in agreement with our previous findings. However,
p-eIF2α was unchanged with HIV infection and regardless of neurocognitive status, compared to
healthy controls (Figure 1G).
Antiretroviral therapy induces axonal damage and ER stress in vivo. Several clinical studies have
reported an inverse relationship between ARV regimens with high CNS penetration-effectiveness
(CPE) scores and neurocognitive outcome (57-59). However, it has been difficult to separate out
CNS toxicity induced by HIV versus that of ARV drugs themselves. Previously, we have shown
that ARV drugs administered to SIV-infected pigtail macaques lead to decreased markers of
synaptodendritic integrity, including synaptophysin in the hippocampus and calmodulin kinase II
in the frontal cortex, compared to SIV-infected, placebo-treated or uninfected controls (28). In
this model of lentiviral-induced neurodegeneration, adult pigtail macaques are inoculated with two
strains of SIV, SIV/DeltaB670 and SIV/17E-Fr, as described previously (48).

12 days post-

inoculation animals receive either a placebo or ARV therapy (ART) that includes tenofovir (NRTI),
atazanavir (PI), saquinavir (PI), and L-870812a (integrase inhibitor). 90% of placebo-treated
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animals develop neurologic disease within 12 weeks post-inoculation (p.i.), as described
previously (48). However, animals that receive ART do not develop SIV encephalitis, nor do they
demonstrate neurological dysfunction (50).

Further, ART-treated animals display a rapid

reduction in plasma and CSF viral load and suppression of viral replication with conservation of
CD4+ T cell counts until elective euthanasia at day 160 p.i.

To expand upon our previous

findings, we utilized immunofluorescence and immunoblotting to retrospectively assess formalinfixed, paraffin-embedded hippocampal tissue from SIV-infected animals for APP expression,
which serves as a sensitive marker of neuronal damage and impaired axonal transport in the
SIV/macaque model of HIV CNS disease (60). Consistent with our previous report, we found
significantly elevated APP expression in the SIV(+)/ART group compared to both SIV(+)/placebo
and uninfected controls (Figure 2A and 2B). Interestingly, placebo-treated animals showed a
reduction in hippocampal APP expression compared to uninfected controls. These changes were
corroborated by immunoblotting of total APP (Figure 2C). To validate our SIV/pigtail macaque
model of HIV CNS disease we also immunoblotted for BiP, BACE1,and p-eIF2α (Figure 2C).
Similar to our observations in human tissue, we observed increased BiP expression with infection
(SIV(+)/placebo animals) compared to uninfected controls but no significant change in the
SIV(+)/ART group (Figure 2D).

Importantly, SIV(+) macaques treated with ART displayed a

significant increase in BACE1 compared to both SIV(+)/placebo and uninfected controls (Figure
2E). However, no significant changes in p-eIF2α were observed (Figure 2G).
Antiretroviral drugs activate the unfolded protein response and upregulate BACE1 expression.
We and others have shown that ARVs are toxic to primary neurons (28, 61, 62). Although it is
suggested that such toxicity is mediated by mitochondrial DNA damage and/or pro-oxidant
properties of these drugs, additional mechanisms may also contribute to ARV-mediated neuronal
damage and death. Given our previous observations of elevated UPR markers in the postmortem mid-frontal cortex of patients with HAND and the established role of PIs inducing ER
stress in a variety of cell types, we hypothesized that antiretroviral drugs may be activating the
UPR in neurons.

Therefore, we examined canonical UPR markers in primary rat neuroglial
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cultures in response to increasing concentrations of zidovudine (AZT), saquinavir (Saq), or
ritonavir (Rit) (Figure 3A). Drug dose ranges used in our in vitro studies were based on reported
plasma and CSF levels of ARVs (63, 64). At 16 h post-treatment with ritonavir or saquinavir,
neurons displayed a five-fold increase in BiP expression and more than four-fold increase in
phospho-eIF2α (p-eIF2α) (Figure 3B and 3C). 25 μM AZT treatment resulted in a three-fold
increase in BiP expression, but had no significant effect on p-eIF2α. As an added parameter to
ensure the presence of ARV-mediated UPR activation, we treated primary neurons with 10 μM
Rit, 1 μM Saq, 25 μM AZT, or 1 μM thapsigargin (positive control) for 16 h and assessed levels of
spliced XBP-1 (sXBP1) by TaqMan quantitative real-time PCR relative to unspliced XBP-1
(uXBP1) (Figure 3H). We observed nearly a two-fold increase in sXBP1 mRNA in Rit and Saqtreated cultures, but no change in AZT-treated neurons, compared to vehicle controls. To rule
out the possibility of species-specific effects, we also treated 21 days in vitro (DIV) human fetal
neurons with increasing doses of AZT, Saq, and Rit for 16 h and found similar trends in both BiP
and p-eIF2α expression in Saq and Rit-treated cultures compared to rat cortical neuroglial
cultures (Figure 3I).
Recent studies have shown that induction of ER stress in neurons can increase protein
expression of the APP-cleaving enzyme, BACE1 (44, 65). Therefore, we sought to determine
whether ARV-treated neuroglial cultures, which show robust activation of ER stress, display
changes in BACE1 expression. Immunoblotting analysis revealed that 16 h drug treatment with
AZT, Saq, or Rit resulted in 4 to 5-fold increases in BACE1 expression (Figure 3E). Similar
results were observed in human fetal neurons treated with ARVs (Figure 3I).
In addition to BACE1, APP may be cleaved by two additional secretases, γ-secretase
and α-secretase, the latter of which comprises the non-amyloidogenic cascade. To examine
whether ARV-mediated BACE1 upregulation is specific to BACE1, or a shared mechanism
among all APP secretases, we also immunoblotted for presenilin-1 (PS-1) (γ-secretase) and
ADAM metalloproteinase domain 10 (ADAM10) (α-secretase) (Figure 3A).

We found no

significant changes in the expression of either of these enzymes regardless of drug treatment or
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dosage (Figure 3F and 3G). Notably, SIV(+)/ART macaques displayed increased hippocampal
expression of PS-1 and ADAM10 compared to uninfected controls (Figure 2H and 2I). Previous
work has shown that ER stressors are capable of altering APP expression as well (38); therefore
we also immunoblotted for APP and observed a small, but significant increase in APP levels in 25
μM AZT and Rit-treated neuroglial cultures (Figure 3D). Taken together, these data indicate that
antiretroviral drugs, and PIs in particular, induce ER stress in neurons leading to enhanced APP
and BACE1 expression.
Ritonavir increases amyloidogenic APP processing in primary neurons.

Based on our

observation that ARVs induce BACE1 expression in neurons, we sought to determine whether
this translated into functional changes in enzymatic APP processing. To that end, we treated
Chinese Hamster Ovary (CHO) cells stably expressing human APP with 10 μM Rit, as a
representative PI, for 16 h and measured the relative amount of Aβ species in the culture media
using a commercially available human/rat Aβ 40- or Aβ42-specific sandwich ELISA. While ritonavir
had no effect on secreted Aβ40 levels, Aβ42 peptide was increased by nearly two-fold (Figure 4A).
Addition of a cell-permeable BACE1 inhibitor (BSI) blocked ritonavir-mediated elevations in Aβ42
in a dose-dependent manner. These findings contradict previous reports that changes in BACE1
activity affect the generation of all Aβ isoforms equally (66). To further understand how ritonavir
affects human APP processing, CHO cell conditioned media was subjected to sAPPβ and sAPPα
ELISAs (Figures 4B and 4C).

In contrast to the observed elevations in Aβ 42 peptide, no

significant changes in sAPPβ or sAPPα were detected in the culture media from ritonavir-treated
CHO cells. We also utilized the human/rat Aβ40- or Aβ42-specific sandwich ELISA to assess Aβ40
and Aβ42 release into the media of rat cortical neuroglial cultures treated with combinations of
ARV drugs (Figures 4D and 4E). At 4 h post-treatment, no changes were observed in secreted
Aβ40 or Aβ42 peptides. However, at 16 h post-treatment, all combinations of ARV drugs resulted
in 1.5 and 3 fold increases in Aβ40 and Aβ42 levels, respectively. In conjunction with our in vivo
findings of elevated Aβ oligomers in HAND patients and increased APP in SIV-infected, ARV-
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treated macaques, these findings suggest that ARVs promote amyloidogenic APP processing in
CNS neurons.
Ritonavir upregulates BACE1 expression in a translation-dependent manner.

Vassar and

colleagues first reported that chronic activation of ER stress results in translational upregulation of
BACE1.

To determine if antiretroviral drugs increase BACE1 expression by altering mRNA

levels, we first treated 21 DIV rat neuroglial cultures with Rit, Saq, Azt, or thapsigargin for 16 h
and harvested mRNA for quantitative real-time PCR (qRT-PCR). We observed no changes in
BACE1 mRNA in any of the ARV-treated cultures compared to controls; however, there was a
significant decrease in BACE1 mRNA in thapsigargin-treated neurons (Figure 5A). To confirm
that BACE1 regulation is occurring via a post-transcription mechanism, we pre-treated neurons
with a translation inhibitor, anisomycin, or a transcription inhibitor, actinomycin D for 12 hours
followed by 16 h treatment with ritonavir and harvested protein lysates for analysis by
immunoblotting for BACE1. Inhibition of transcription with 5 μM actinomycin D did not affect
upregulation of BACE1 protein levels by ritonavir; however translation inhibition by 10 or 50 μM
anisomycin abrogated Rit-mediated BACE1 protein upregulation (Figures 5B and 5C) indicating
that PIs are exerting their effects on neuronal BACE1 expression through a translational or posttranslational mechanism.
Activating transcription factor 4 (ATF4) is a canonical target of translational control by
phospho-eIF2α. Similar to BACE1, ATF4 mRNA contains multiple uORFs in the 5’ UTR, which
act to suppress translation under basal conditions, but undergo scan-through following
phosphorylation of eIF2α, leading to selective translational upregulation during conditions of ER
stress (44, 65, 67, 68). ATF4 subsequently translocates to the nucleus to upregulate expression
of genes involved in the ER stress response. Thus, we determined whether ATF4 was increased
in the nucleus of ritonavir-treated neurons following 16 h treatment. We observed nearly a fivefold increase in nuclear ATF4 in Rit- and thapsigargin-treated neuroglial cultures while
cytoplasmic levels remained unchanged (Figures 5D and 5E). Similarly, BACE1 expression was
increased greater than two-fold in the cytoplasm of Rit-treated cultures (Figures 5D and 5E).
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To confirm that translational control of BACE1 is occurring through its 5’ UTR, we
transfected rat cortical neurons with vectors containing full-length human BACE1 with (+5’ UTR)
or without (-5’ UTR) the 5’ UTR then treated cultures with DMSO or ritonavir for 16 h. Similar to
our wild-type rat cortical cultures, the neurons transfected with BACE1 +5’ UTR displayed nearly
a three-fold increase in BACE1 expression following treatment with ritonavir compared to vehicle
controls (Figure 5F). Deletion of the 5’ UTR resulted in a significant increase in overall BACE1
expression in transfected cells as described previously (44, 69), however overexpression of the 5’ UTR BACE1 construct prevented ritonavir-mediated upregulation of BACE1 in neurons (Figure
5F and 5G).
To rule out the involvement of a post-translational mechanism in BACE1 upregulation by
ritonavir, we performed a pulse-chase experiment using

35

S-metabolic radiolabeling to determine

the half-life of BACE1 in Rit-treated neurons compared to vehicle controls.

After confirming

immunoprecipitation of BACE1 from neurons (Figure 6A), we pulse-labeled 21 DIV neuroglial
cultures for 30 min and then chased with neurobasal media with or without 10 μM Rit for up to 24
h (Figure 6B). Compared to controls, we observed no apparent difference in BACE1 half-life in
Rit-treated neuroglial cultures over the course of 24 h (Figure 6C). In both treatment conditions,
we observed that BACE1 half-life was approximately 12 h, similar to what has been reported
previously (44, 70). Collectively, these data strongly suggest that ritonavir-mediated upregulation
of BACE1 in neurons occurs through a 5’ UTR-dependent translational mechanism.
PERK is necessary for ARV-mediated BACE1 upregulation in neurons. Several reports have
proposed a role for p-eIF2α in post-transcriptional regulation of BACE1 under conditions of
oxidative and ER stress (44, 65, 71). However, eIF2α can be phosphorylated by one of four
kinases (PERK, PKR, HRI, and GCN2) depending on the type of stress impinging on cells. Given
that PERK is the central kinase responsible for eIF2α phosphorylation under conditions of ER
stress, we assessed whether PERK was involved in the stress response signaling in neurons
treated with antiretroviral drugs. First, we determined the effect of blocking PERK signaling in
neurons through overexpression of a kinase-dead mutant of PERK (dnPERK).
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We

overexpressed wild-type (PERK) or kinase-dead (dnPERK) PERK in 14 DIV pure neuronal
cultures using magnetofection. 72 h after transfection, lysates were harvested for immunoblotting
and probed for markers of ER stress and BACE1 (Figure 7A).

In addition to successful

overexpression of both wild-type and kinase-dead PERK, we observed a significant decrease in
both p-eIF2α and BACE1 in neurons overexpressing dnPERK compared to cultures
overexpressing wild-type PERK (Figures 7B-7D). Consistent with our hypothesis, BACE1 and peIF2α levels in dnPERK-expressing cultures were not significantly different from neurons
transfected with the empty vector control (pLENTI).
Next, we sought to determine whether PERK signaling was necessary for ARV-mediated
BACE1 upregulation. To that end, we isolated PERK-excised neuroglial cultures from brains of
tamoxifen-inducible cre recombinase conditional PERK knockout embryonic mice. At DIV 10,
neuroglial cultures were treated with 100 nM or 1 μM 4-hydroxtamoxifen (4-OHT) to excise the
PERK gene (56). The estimated efficiency of PERK excision in neurons was approximately 50 to
60% after 96 h 4-OHT treatment (Figure 8A). Wild-type and PERK-excised neurons were treated
with 10 μM ritonavir (Rit) or 1 μM saquinavir (Saq) for 16 h. As shown in Figures 8B and 8C,
PERK-excised neuroglial cultures treated with Rit or Saq displayed reduced p-eIF2α, BACE1,
and APP compared to wild-type cultures treated with the same drugs. These findings indicate
that ARV-mediated BACE1 upregulation in neurons is dependent on ER stress response
signaling.

3.5: DISCUSSION
The unanticipated persistence of neurocognitive deficits in HIV-positive individuals has become a
growing public health concern as the average age of HIV-infected patients in the U.S. is expected
to be over the age of 50 by the year 2015 (72). Increasing clinical and experimental evidence
suggests that ARV drugs are toxic to CNS neurons, yet the potential mechanisms by which ARVs
may be contributing to HAND neuropathology remain elusive. Previously, we have reported that
ARVs induce ROS production in primary neurons leading to activation of the endogenous
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antioxidant response (28). Additionally, there is extensive evidence that ARVs induce ER stress
in a wide variety of peripheral cell types. Our findings provide a mechanistic link between ARVmediated ER stress in cortical neurons and our observations of increased BACE1 and Aβ
oligomers in post-mortem brain tissue of ARV-treated, HIV-positive individuals.
In the present study, we demonstrate for the first time the ability of ARV drugs, and PIs in
particular, to robustly activate the UPR in primary rat neuroglial cultures and human fetal neurons
as demonstrated by increased expression of BiP, p-eIF2α, and spliced XBP1. Additionally, we
observed increased levels of nuclear ATF4, indicating that ARV-mediated eIF2α phosphorylation
leads to functional changes in the translational profile of neurons. The specific mechanism by
which PIs and NRTIs activate ER stress in neurons remains unclear, but is likely to be
multifactorial. In other cell types, PIs have been shown to induce ER stress via proteasome
inhibition and depletion of ER calcium stores (21, 22, 73-75).

Interestingly, Zhang, et. al.,

reported that pharmacological inhibition of proteasome activity can activate PERK, the primary
kinase responsible for phosphorylating eIF2α under ER stress conditions (76). Further studies
will be necessary to determine if: 1) PIs can inhibit proteasome function in primary neuroglial
cultures, 2) proteasome inhibition precedes phosphorylation of eIF2α, and 3) rescue of
proteasome function abrogates phosphorylation of eIF2α and all purported downstream effects,
including translational upregulation of ATF4 and BACE1.
In agreement with our in vitro studies, BiP was elevated in HIV(+) Normal cases,
however, no significant difference was observed between HIV(+) HAND cases and uninfected
controls, indicating that severity of CNS impairment may be less important than early events
associated with HIV pathogenesis.

Unexpectedly, phospho-eIF2α was unchanged with HIV

infection in our cohort of patient samples, where it was previously reported to be elevated in HIVpositive cases (77). One potential reason for the conflicting results may be the variability of tissue
used to generate the whole-cell protein extracts from patient samples, and the relative
percentage of specific cell types, such as astrocytes and microglia, in the specimen used (77).
As the inflammation in ARV-medicated, HIV-infected brains is typically focused in the
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hippocampus and entorhinal cortex, there may be region-specific elevations in ER stress markers
correlating with these focal points of inflammation. Many clinical factors are also likely contribute
to the level of neuronal ER stress in HAND patients, including duration of HIV infection, comorbidities, latency between infection and onset of ARV medication, adherence to ARV
regimens, and the specific treatment regimen(s) prescribed during the course of infection.
Despite these complications, our data are consistent with UPR activation, BACE1 upregulation,
and Aβ oligomer generation as underlying contributors to pathology in HAND.
Our work also confirms a report by Vassar and colleagues that chronic activation of ER
stress in neurons is linked to translational BACE1 upregulation. AZT, saquinavir, and ritonavir all
increased expression levels of BACE1 in neuroglial cultures and human fetal neurons at 16 h
post-treatment, parallel to an increase in nuclear ATF4. This increase appears to be at least
partially mediated by PERK, although we cannot rule out the potential contribution of other eIF2α
kinases. Interestingly, PERK excision decreased expression of p-eIF2α and BACE1, but had no
effect on BiP or APP, indicating that the mechanism by which these markers are increased in
ARV-treated cultures is likely distinct from that of BACE1. While extensive evidence has shown
that BiP is increased transcriptionally following ER stress, the mechanism of APP upregulation
remains unclear, and may be unrelated to ER stress induction. Additionally, we report elevated
BACE1 expression in CA1 and CA3 hippocampal regions of HAND patients by IFA and confirmed
by immunoblotting of whole brain lysates. Notably, BACE1 was elevated in HIV-positive cases,
regardless of neurocognitive status, suggesting that BACE1 elevation may be an early event in
the pathogenesis of HAND; similar to what has been reported in AD (46). Importantly, neither γsecretase nor α-secretase, both of which cleave APP, showed any changes in expression
following ARV treatment. This distinction is likely a result of the different mRNA structure of these
enzymes. Unlike, γ-secretase and α-secretase, BACE1 mRNA contains three uORFs in its long,
GC-rich 5’-UTR, which act to suppress translation under normal cellular conditions (44, 68).
However, phosphorylation of eIF2α induces bypass, or scan-through, of the inhibitory uORFs
leading to more efficient translation of BACE1 mRNA. Indeed, placement of multiple uORFs in
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the 5’-leader sequence of mRNAs is an evolutionarily conserved mechanism among many
species to control translation of stress-related genes (67). However, it remains unclear what
protective role BACE1 might have, if any, in neurons undergoing ER stress.
One potentially detrimental consequence of elevated BACE1 expression is increased
amyloidogenic processing of APP to generate Aβ peptides. Giunta, et. al., first demonstrated the
ability of ARVs to increase Aβ production in N2a cells transfected with Swedish mutant APP (78).
Similarly, our ELISA results demonstrate that ritonavir, as a representative PI, induces increased
production of Aβ42 in rat neurons and CHO cells expressing human APP. Unexpectedly, no
changes in Aβ40 production were observed in CHO cells treated with ritonavir, although Aβ 40 was
increased in media of rat neuroglial cultures treated with all combinations of ARVs.

This

inconsistency may be a result of potential differences in APP processing in CHO cells versus
neurons, or an artifact resulting from overexpression of human APP, which itself may be
activating ER stress and the UPR.

Ultimately, these data suggest that ARVs alter APP

processing in CNS neurons, likely through upregulation of BACE1.
Contrary to these findings is a previous report by Ikezu and colleagues that PIs, including
ritonavir and saquinavir, modestly inhibit Aβ degradation in human monocyte-derived
macrophages, but decrease Aβ40 production and BACE1 activity in human cortical neurons (79).
Furthermore, they showed that oral administration of nelfinavir or lopinavir/ritonavir had no effect
on Aβ accumulation in an APP SCID mouse model. While these results are striking, several
caveats must be considered: 1) previous work indicates CRND8 transgenic animals begin to
show plaque deposition at approximately 9 weeks of age, yet the APP SCID mice generated by
Ikezu (BALB/cBy-Prkdc

scid

mice crossed with CRND8 mice) displayed no overt amyloid pathology

at 12 weeks of age. Therefore, the inclusion of age-matched, CRND8 transgenic controls is
necessary to ensure pathology in the APP SCID mice occurs in a similar, time-dependent
manner, 2) concentrations of PIs tested in human fetal neurons were 2.5 – 5 fold greater than the
highest concentrations of PIs tested in our experiments, 3) ARV concentrations tested on purified
BACE1 protein in vitro were up to 30-fold greater than concentrations employed in our studies,
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and 4) the effect of PIs on Aβ42 was not tested by Ikezu and colleagues, while we found that PIs
had the greatest effect on Aβ42 production. Notably, we found that concentrations of ARVs similar
to those employed by Ikezu were highly toxic to primary neurons even at time points less than 16
h. Thus, it is difficult to directly compare the results of our studies with those of Ikezu and
colleagues due to variations in drug concentrations and in vitro/in vivo model systems.

Clearly,

further investigation is needed in this area.
Previous studies investigating amyloid pathology in HIV-positive, ARV-medicated brain
tissue have yielded conflicting results.

Green et al., were the first to show increased APP

accumulation, primarily intraneuronal, and amyloid-associated pathology in ARV-treated, HIVpositive individuals compared to ARV-naïve controls (9). These findings were confirmed by Xu
and Ikezu who observed intraneuronal Aβ immunoreactivity and Aβ plaques in ARV-treated,
HIVE brains but only intraneuronal Aβ in ARV-untreated, HAD brains, with no evidence of
extracellular deposition (8). In contrast, Anthony et. al., found no evidence of increased Aβ
deposition or plaque accumulation in HIV-infected cases, but did observe increased hippocampal
hyperphosphorylated Tau, especially in ARV-medicated patients, compared to unmedicated
controls (10, 80, 81). To reconcile these differences and shed light on the clinical significance of
our in vitro findings, we stained aged-matched HIV-negative and HIV-positive post-mortem brain
tissue with Aβ42 C-terminal-specific (not shown) and Aβ oligomer-specific antibodies. We found
no evidence for Aβ plaque deposition in HIV-positive cases, but strikingly, we did observe
intraneuronal Aβ immunoreactivity, consistent with previous reports. More importantly, we show
for the first time, evidence for abundant intraneuronal Aβ oligomer formation in hippocampus of
ARV-treated patients. As Aβ oligomers are believed to be highly cytotoxic, and thus responsible
for neuronal damage and death in AD, this may be a contributing factor to early aging in HIVpositive individuals as well. However, future studies investigating ARV therapy as a specific
contributor to HIV pathogenesis are warranted.
One major caveat associated with human studies in HAND is the inability to separate out
pathological effects associated with HIV from those associated with confounding variables such
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as co-morbidities, drug abuse and antiretroviral toxicity. To address these concerns, we utilized
two animal models of chronic ARV drug treatment. We have previously shown that SIV-infected,
pigtailed macaques treated with an ARV cocktail show increased hippocampal synaptodendritic
damage compared to placebo-treated and uninfected controls. Here, we expand upon those
findings to report elevated neuronal APP in hippocampus of SIV(+)/ART macaques compared to
controls. Taken together, these observations strongly suggest that antiretrovirals in the presence
of virus may contribute to the neurodegenerative process associated with HAND. Although it
remains unclear why placebo-treated animals displayed decreased APP compared to uninfected
controls, several caveats must be considered when interpreting these results. First, the time to
euthanasia after the initial SIV infection is different between SIV(+)/placebo and SIV(+)/ART
groups, as these samples were obtained from animals used to address a distinct question
regarding use of ART.

Second, there was persistent viral DNA in the CNS of SIV(+)/ART

macaques, though it is uncertain if this DNA is replication competent (50). Lastly, there was no
SIV(-)/ART control group to account for the effects of the drugs by themselves in the absence of
virus. Future studies that include the use of SIV(-)/ART controls will be invaluable for separating
out the contribution of virus to CNS damage from that of ARVs. Importantly, concentrations of
ARV drugs used in the SIV/macaque studies have been demonstrated by Clements and
colleagues to closely reflect dose ranges measured in human plasma and CSF.
Although CNS effects of ARVs are still poorly understood, clinical studies have begun to
address the effect of drug regimens with high CNS penetration on populations of HIV-positive
individuals. While many studies have shown that ARVs are beneficial for improving cognition in
treated patients, others have found a significant association between ARV regimens with high
CPE scores and poorer neurocognitive performance (5, 57-59, 82-90). Confounding the issue of
ARV toxicity in the CNS is variation in blood brain barrier (BBB) permeability among different drug
classes, persistence of viral load in the brain, and the resulting difficulty to separate out neuronal
toxicity induced by HIV from that of antiretroviral drugs. While many ARV drugs are thought to
suffer from various physicochemical properties that impair their ability to penetrate an intact BBB,
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there is extensive evidence demonstrating increased entry of small molecules and serum proteins
into the CNS following HIV-mediated disruption of BBB endothelial cells and tight junctions (9198). Therefore, it is reasonable to consider that higher-than-anticipated concentrations of ARV
drugs

may

penetrate

the

compromised

BBB

of

HIV-infected

individuals.

Notably,

pharmacokinetic analysis of ARVs in guinea pigs revealed significantly higher uptake of
3

[ H]ritonavir into brain parenchyma compared to CSF, suggesting that clinical estimates of CNS
penetrance for PIs may be lower than actual drug concentrations in the brain (63). In addition to
uncertainties in ARV CNS penetration with currently prescribed regimens, current efforts to
enhance delivery of ARV drugs to the CNS via nanotherapeutics necessitate a careful
examination of the potential neurotoxic effects these drugs may exert in the brain.
While concentrations of ARVs utilized in this study are significantly higher than peak CNS
levels obtained in patients, the effects of ARV drugs on neurons we demonstrate here are likely to
occur in vivo over long-term exposures. In the present study, we sought to model these chronic,
low-dose effects of ARVs in a more acute time frame with higher doses of drug. Our results
indicate that nanomolar concentrations of HIV protease inhibitors robustly activate the UPR in
primary cortical neurons leading to PERK-dependent phosphorylation of eIF2α and translational
upregulation of BACE1. ARVs alone and in combination were also shown to increase production
of Aβ peptides in multiple cells types, which could be dose-dependently blocked by addition of a
cell-permeable BACE1 inhibitor. Lending further support to these findings were our observations
that ARV-medicated, HIV(+) patients display elevated levels of Aβ oligomers, BACE1, and BiP.
Taken together with our previous reports of elevated p-eIF2α and ATF6 in HAND tissue, these
data suggest a role for ER stress in CNS HIV pathogenesis.

These results bear striking

similarities to observations made in AD, PD, ALS and prion disease conditions in which markers
of ER stress, including phospho-PERK are elevated in multiple brain regions. While transient
eIF2α phosphorylation is protective to cells coping with ER stress, sustained suppression of
global protein synthesis in the CNS may ultimately lead to impaired LTP and synaptic failure.
However, promising therapeutics targeted at the UPR have already been reported.
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Several

studies have indicated that genetic and pharmacological suppression of PERK activity can
decrease brain p-eIF2α expression, improve synaptic plasticity and rescue memory deficits in an
AD mouse model and alleviate prion-mediated pathology and cognitive deficits in mice inoculated
with prion proteins (99, 100). Additionally, BACE1 inhibitors, which have already been tested
extensively in clinical trials, may have therapeutic benefits in patients suffering from HAND.
Future investigations will be necessary to determine the role of BACE1 in the ER stress
response.

Furthermore, we propose to investigate the potential effect of ARVs on BACE1

redistribution to the trans-golgi network and early endosomal compartments as a mechanism of
increased amyloidogenic APP processing, similar to what has been reported by Tan et. al (71).
These studies will enhance our understanding of BACE1’s role in cellular maintenance under
normal and stressed conditions in the CNS and provide insights into potential therapeutic targets
for neurodegenerative disease.
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Figure 1. BACE1 and Aβ oligomer immunostaining are elevated in the brain of HIV(+) cases.
Paraffin-embedded tissue sections from hippocampus of HIV(-) control, HIV(+) Normal and
HIV(+) HAND cases were prepared for immunofluorescent analysis and visualized by laser
confocal microscopy. A) Representative images are shown from hippocampal sections triple-
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labeled for Aβ oligomers (red), MAP2 (green), and nuclei (blue). Red and green colocalization
appears yellow. Aβ oligomers (red) are increased in MAP2-positive neurons in hippocampus of
HIV(+) cases compared to controls. B) CA1, CA3, and dentate gyrus hippocampal sections were
double-labeled for BACE1 (green) and MAP2 (red). Representative images are shown. Despite
a loss of MAP2 (red) in HIV(+) HAND cases compared to controls, BACE1 (green)
immunostaining was increased in CA1 and CA3 regions in HAND cases. C) Whole brain lysates
from the mid-frontal cortex of HIV(-) controls (n=4), HIV(+) neurocognitively normal (HIV(+)
Normal) (n=7), and HIV(+) HAND (n=6) cases were prepared for immunoblot and probed for BiP,
BACE1, APP, phospho- and total eIF2α. D-G) Densitometric analysis revealed no significant
changes in expression levels of phospho-eIF2α or APP in HIV(+) cases, however, BiP was
elevated in HIV(+) Normal cases and BACE1 was elevated in HIV(+) Normal and HIV(+) HAND
cases compared to controls (*p<0.05, ns: not significant, one-way ANOVA plus Newman-Keuls
post hoc testing).
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Figure 2.

Antiretroviral drugs administered to SIV(+) macaques induce CNS damage and

elevated BACE1.

Using double-label confocal microscopy, formalin-fixed, paraffin-embedded

hippocampal brain sections from pigtailed macaques were labeled by immunofluorescence for:
MAP2 (red) and APP (green). Pigtail macaques were either uninfected (n=6), SIV-infected and
treated with placebo (n=7), or SIV-infected and treated with combination antiretroviral therapy
(ART) (tenofovir, atazanavir, saquinavir, and L-870812a) (n=4). A) Representative images of
cases stained with APP and MAP2 are shown. B) Quantification indicates a significant increase
in intraneuronal APP in SIV(+) ART-treated macaques compared to uninfected and
SIV(+)/placebo-treated controls (**p<0.01, ***p<0.001, one-way ANOVA plus Newman-Keuls post
hoc testing). C) Fresh-frozen tissue sections from the hippocampus of pigtailed macaques were
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subjected to standard protein extraction and immunoblotting for expression of BiP, BACE1, APP,
p-eIF2α, total eIF2α, PS-1 CTF, and ADAM10. Fast green was used as a loading control. D-I)
Quantification

of

band

densities

from

immunoblots

shown

in

Figure

2C

(*p<0.05,

**p<0.01,***p<0.001, ns: not significant, one-way ANOVA plus Newman-Keuls post hoc testing).
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Figure 3. Antiretroviral drugs activate the unfolded protein response and upregulate BACE1
expression in primary neurons. A) 21 DIV rat neuroglial cultures were treated with indicated
concentrations of AZT, saquinavir, or ritonavir for 16 h, lysed, and immunoblotted for markers of
ER stress (BiP, phospho- and total eIF2α), APP, BACE1, ADAM10, and PS-1). Actin was used
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as a loading control for all targets except phospho-eIF2α which was normalized to total eIF2α.
Representative blots shown. B-G) Quantification of immunosignals were normalized to actin and
expressed as fold change relative to vehicle controls. BiP, p-eIF2α, APP, and BACE1 protein
levels were significantly elevated compared to controls. ADAM10, and PS-1 did not show any
significant changes (n=5, vehicle: 0.04% DMSO, *p<0.05, **p<0.01, one-way ANOVA with
Dunnett post hoc testing). H) Rat neurons were treated with 0.04% DMSO (Vehicle), 10 μM
Ritonavir, 1 μM Saquinavir, 25 μM AZT, or 1 μM thapsigargin for 16 h. Total mRNA was isolated
and expression levels of spliced XBP1 mRNA measured via TaqMan using the comparative Ct
method relative to unspliced XBP1 (uXBP1).

qRT-PCR assays were performed in triplicate.

Ritonavir and saquinavir induced significant increases in spliced XBP1 (n=4, *p<0.05, ***p<0.001,
one-way ANOVA with Dunnett post hoc testing). I) 21 DIV human fetal neurons were treated as
in (A) and lysates subjected to immunoblotting. Representative blot shown. Similar to (A), ARVs
appeared to induce increased protein expression of BiP, phospho-eIF2α, and BACE1, relative to
vehicle controls (n=3).
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Figure 4. ARV drugs increase amyloidogenic APP processing in primary neurons. CHO cells
stably expressing human APP were treated with 10 μM ritonavir for 16 h or pre-treated with
various doses of a cell-permeable beta secretase inhibitor (BSI) for 12 h then treated with
ritonavir for 16 h. After 16 h, culture media was collected and subjected to a human/rat Aβ42- or
Aβ40-specific sandwich ELISA (A) or a human sAPPα or sAPPβ ELISA (B, C). A) Ritonavir
treatment resulted in a two-fold increase in Aβ42 production that was dose-dependently blocked
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by addition of a beta secretase inhibitor, while Aβ40 levels were unaffected by addition of ritonavir
(n=6, ***p<0.001, ns: not significant, one-way ANOVA plus Newman-Keuls post hoc testing). B)
No statistically significant changes in sAPPβ or sAPPα were observed in ritonavir-treated
cultures, though sAPPβ was dose-dependently decreased by the presence of a beta secretase
inhibitor. D, E) Primary rat neuroglial cultures were treated with various combinations of ARV
drugs (10 μM ritonavir, 1 μM saquinavir, and 25 μM AZT) for 4 or 16 h. Culture media was then
subjected to a human/rat Aβ42- or Aβ40-specific sandwich ELISA as in (A). At 16 h, both Aβ 42 and
Aβ40 levels were increased in most treatment conditions. AZT appeared to blunt PI-mediated
enhancement of amyloidogenic APP processing in combination treatment (n=3, *p<0.05,
**p<0.01, one-way ANOVA plus Dunnett post hoc testing).
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Figure 5. Ritonavir upregulates neuronal BACE1 expression via translation-dependent control.
A) Rat neurons were exposed to the indicated treatments for 16 h. mRNA was isolated for RTPCR and cDNA subjected to real-time PCR. Levels of BACE1 mRNA were determined using the
ΔΔCt method relative to TBP. qRT-PCR assays were performed in triplicate. No significant
changes in BACE1 mRNA were observed in ARV drug-treated cultures (n=4, **p<0.01, one-way
ANOVA plus Dunnett post hoc). B) Rat neurons were treated with ritonavir alone or pre-treated
with anisomycin or actinomycin D for 12 h then treated with ritonavir. Fast green was used as a
loading control.

C)

Compared to ritonavir-only treated neurons, anisomycin pre-treatment

resulted in decreased BACE1 expression.

Actinomycin D had no significant effect (n=4,

**p<0.01, ns: not significant, one-way ANOVA plus Newman-Keuls post hoc). D) Rat neurons
were treated with the indicated drugs for 16 h, separated into cytoplasmic and nuclear fractions,
and analyzed by immunoblotting. E) Densitometric analysis revealed a significant increase in
ATF4 and BACE1 (n=4, **p<0.01, one-way ANOVA plus Dunnett post hoc). F) 14 DIV rat cortical
cultures were transfected via magnetotransfection with pcDNA3.1Zeo(+) vector containing the
entire human BACE1 coding region including the BACE1 5’ UTR but missing the 3’ UTR (+5’
UTR) or pcDNA3.1Zeo(+) vector containing the human BACE1 coding region including the 3’
UTR but missing the 5’ UTR (-5’ UTR). 48 hours following transfection, cultures were treated with
0.04% DMSO or 10 µM ritonavir for 16h, lysed, and immunoblotted for BACE1. Representaive
blots shown. G) Quantification of BACE1 immunosignal was normalized to actin (n=3, *p<0.05,
ns: not significant, one-way ANOVA plus Newman-Keuls post hoc testing).

117

Figure 6. Ritonavir does not affect BACE1 protein stability in primary neurons. A) Primary rat
neurons were pulse-labeled for 30 min with
chased with neurobasal media + B27.

35

S-methionine/cysteine-containing DMEM and

Radiolabeled BACE1 was immunoprecipitated with

Dynabeads Protein A and 2 μg anti-BACE1 12h post-labeling to confirm enrichment. B) Neurons
were pulse-labeled as in (A) and chased with neurobasal media +/- 10 μM ritonavir for 24 h.
BACE1 was immunoprecipitated as in (A), and visualized via autoradiography. Note that
immature BACE1 runs at ~60 kDa while mature, fully glycosylated BACE1 runs at ~70 kDa.
Representative blots shown (n=3). C) The levels of

35

S-methionine/cysteine-labeled BACE1

were quantified and the percentage changes, relative to 0h time point, are plotted. No significant
differences in BACE1 half-life were observed between control and ritonavir-treated neurons (n=3,
linear regression analysis).
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Figure 7. PERK regulates basal BACE1 expression in neurons.

A)

DIV 14 pure neuronal

cultures were transfected via magnetotransfection with one of three plasmids: pLENTI CMV/TO
Puro destination vector (backbone), wild-type mouse PERK, or kinase-dead, K618A mutant
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PERK (dnPERK) and complexed with Neuromag transfection reagent. 72 h after transfection,
cultures were harvested and lysates prepared for immunoblotting. Representative blots shown.
B) Densitometric analysis of PERK immunosignals indicate significant overexpression of wild-type
and kinase-dead PERK in pure neuronal cultures compared to empty vector controls (n=3,
*p<0.05, ***p<0.001, one-way ANOVA plus Newman-Keuls post hoc testing).

C, D)

Quantification of p-eIF2α and BACE1 blots show a significant decrease in expression of these
respective proteins in neuronal cultures overexpressing dnPERK compared to neurons
overexpressing wild-type PERK when transfected with 2 μg of plasmid DNA (n=3, Student’s t
test).
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Figure 8.

HIV protease inhibitor-mediated BACE1 upregulation is PERK-dependent.

A-C)

Floxed PERK mouse cortical neuroglial cultures were generated by isolating neurons from brains
of tamoxifen-inducible cre recombinase conditional PERK knockout embryonic mice at E16.517.5. At DIV 10, neuroglial cultures were treated with 0.1 μM or 1 μM 4-hydroxtamoxifen (4-
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OHT), for 96 h to excise the PERK gene (note that estimated PERK half-life is 13 h). Efficiency of
PERK excision was estimated to be approximately 50 to 60% via densitometric analysis (A) (n=4,
*p<0.05, **p<0.01, one-way ANOVA plus Newman-Keuls post hoc testing). Wild-type and PERKexcised neuroglial cultures were treated with 10 μM ritonavir (B) or 1 μM saquinavir (C) for 16 h
and lysates prepared for immunoblotting. Representative images shown (n=4). Compared to
wild-type cultures treated with ritonavir or saquinavir, PERK-excised neuroglial cultures treated
with ARVs showed reduced expression of p-eIF2α and BACE1.
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“Neuronal BACE1 inhibition is protective against antiretroviral-mediated neurotoxicity”
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4.1: ABSTRACT
Despite advances in antiretroviral therapy (ART), HIV remains the leading cause of dementia
among young adults in the United States. Approximately 50% of HIV+ individuals develop some
form of cognitive/motor dysfunction, which can range from asymptomatic neurocognitive
impairment (ANI) to frank dementia. Collectively, the spectrum of neurological dysfunctions
caused by HIV infection is known as HIV-associated neurocognitive disorders (HAND).

A

growing body of evidence suggests that HAND in the post-ART era has evolved from a subacute
dementia to a more insidious, neurodegenerative disease with pathological hallmarks similar to
Alzheimer disease (AD).

Common features among HAND and AD include the presence of

chronic oxidative stress and inflammation, as well as misfolded proteins in the CNS. Additionally,
we recently demonstrated that beta-site APP cleaving enzyme 1 (BACE1), which is the ratelimiting enzyme in the production of beta amyloid (Aβ) from the amyloid precursor protein (APP),
is upregulated in brains of ART-medicated, HIV+ individuals and that ART drugs increase BACE1
expression and Aβ peptide production in primary neurons via chronic activation of the unfolded
protein response (UPR). Therefore, we hypothesized that ART-mediated BACE1 upregulation in
neurons may be contributing to neurological dysfunction in patients with HIV via aberrant
production of Aβ peptides.

In this report, we demonstrate that pharmacological inhibition of

BACE1 is neuroprotective against ART-mediated toxicity and that inhibition of the unfolded
protein response can mitigate ART-mediated upregulation of BACE1 in neurons.

Together,

these results suggest that inhibiting neuronal BACE1 function, either directly or upstream, may be
a viable adjunctive neuroprotective therapy in the treatment of HAND.

136

4.2: INTRODUCTION
Beta-site APP cleaving enzyme 1 (BACE1) is a transmembrane aspartyl protease that was
initially identified as the primary beta-secretase enzyme responsible for cleaving the amyloid
precursor protein (APP) to generate beta amyloid (Aβ), the primary component of senile plaques
in AD (1, 2). Post-mortem analyses have revealed that BACE1 expression and enzymatic activity
are significantly upregulated in AD brains compared to age-matched controls and BACE1 colocalizes with amyloid plaques (3-6). BACE1 expression is controlled at the transcriptional and
translational level by a host of stress factors including inflammation, ischemia, oxidative stress,
and energy deprivation (7-9).

Oxidative stress, which is a common feature among many

neurodegenerative diseases, is particularly important in the pathogenesis of AD as it has been
shown to increase expression of β- and γ-secretase leading to overproduction of Aβ, which itself
induces oxidative stress, yielding a positive feedback loop (10).
Recent studies have shown that oxidative stress and BACE1 upregulation are salient
features of many CNS inflammatory and neurodegenerative diseases. In particular, HIV infection
is associated with a spectrum of neurocognitive impairments, termed HIV-associated
neurocognitive disorders (HAND), characterized by chronic neuroinflammation, oxidative stress,
and neurodegeneration (11-13).

Despite the successes of antiretroviral therapy (ART) in

suppressing HIV viral loads to undetectable levels and decreasing HIV-related morbidity and
mortality, the prevalence of HAND continues to escalate.

Furthermore, increasing evidence

suggests that HAND pathology has evolved in the post-ART era from a subcortical encephalitis to
a more cortical and hippocampal, neurodegenerative condition with Alzheimer disease (AD)-like
pathological hallmarks, including neurofibrillary tangles and intracellular Aβ accumulation (14-19).
We recently showed that ART-medicated, HIV+ individuals also display increased expression of
intraneuronal Aβ oligomers and beta-site APP cleaving enzyme (BACE1) compared to ART-naïve
and uninfected controls, suggesting that antiretrovirals may be contributing to enhanced Aβ
production in the CNS of HAND patients through a BACE1-dependent mechanism (20).
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Although it remains unclear what specific role ART has on the persistence and
progression of HAND, many classes of ART drugs induce a wide range of systemic metabolic
and neural disturbances that could themselves influence the neurocognitive status of HIV+
individuals. Nucleoside reverse transcriptase inhibitors (NRTIs) have been linked to oxidative
stress and mitochondrial dysfunction, manifested clinically as peripheral neuropathy and
myopathy, while HIV protease inhibitors (PIs) are associated with atherosclerosis, lipodystrophy,
and diabetes (21-31). Recently, several groups have shown that PIs can also induce oxidative
stress via production of reactive oxygen species (ROS) leading to neuronal damage and death in
vitro (12, 32).

Through these and numerous other cellular mechanisms, including 26S

proteasome inhibition, ART drugs, and PIs in particular, induce ER stress and activate the
unfolded protein response (UPR) in a wide variety of cell types (25, 26, 28, 33-36).

In

eukaryotes, the UPR is tightly regulated by the ER-resident chaperone, Binding Protein
(BiP)/GRP78, which binds to and keeps inactive, three sensor proteins, pancreatic ER kinase
(PERK), activating transcription factor 6 (ATF6), and inositol-requiring enzyme 1α (IRE1α), under
basal cellular conditions (37-39). Following induction of ER stress, BiP is recruited to aid in
protein refolding allowing for the subsequent activation of PERK, ATF6, and IRE1α. Transient
activation of the UPR initially results in PERK-mediated phosphorylation of the translation
initiation factor, eIF2α, and global suppression of protein translation. Paradoxically, this event is
accompanied by selective translational upregulation of a subset of mRNAs, characterized by the
presence of multiple uORFs in the 5’ UTR, that typically encode for molecular chaperones and
transcription factors involved in cellular adaptation to stress, such as ATF4 (40). Despite having
no known chaperone function, BACE1 mRNA, which contains three uORFs and 4 uAUGs in the
5’ leader sequence, is also translationally upregulated in response to ER stress and has been
shown to increase via a translational mechanism in neurons treated with ART drugs (7, 41, 42).
Altogether, these results indicate that ART drugs activate the unfolded protein response
in neurons, likely through a pro-oxidative mechanism, leading to translational upregulation of
BACE1, aberrant production of Aβ, and cellular toxicity. Therefore, we hypothesized that
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pharmacological inhibition of UPR signaling and/or BACE1 activity in ART-treated neurons would
mitigate cellular damage and death. Using an acute, in vitro model of ART exposure, we show
that inhibition of two eIF2α kinases, PERK and PKR, suppresses ART-mediated BACE1
upregulation in neurons while direct BACE1 inhibition is protective against ART-mediated
neuronal damage, suggesting that BACE1 may be a potential therapeutic target in the treatment
of HAND.

4.3: EXPERIMENTAL METHODS
Preparation of Primary Neuronal Cultures: All primary rat cortical neuroglial cultures were
isolated from frontal cortices of embryonic day 16.5-17.5 Sprague-Dawley rat pups, with
modifications of previously described protocols (43).

Briefly, cortical cell suspensions were

isolated from rat pups and plated in poly-L-lysine (Peptide International) coated tissue culture
o

dishes and maintained in neurobasal media containing B27 supplement at 37 C with 5% CO2, as
described previously (44, 45). Unless otherwise indicated, all experiments were performed at 1421 days in vitro (DIV) on neuronal cultures containing approximately 90% neurons and 10%
astrocytes/glia. 50% of neurobasal media volume was replaced with fresh media 10 days after
plating cells.
Drug Treatments: To model mild oxidative stress or ER stress in neurons, 10 DIV rat cortical
cultures were treated for 12 hours with 10 and 20 µM hydrogen peroxide diluted in water from a
30% w/w stock solution (Sigma, St. Louis, MO) or 10 µM ritonavir, respectively. All antiretroviral
drugs were obtained from the AIDS research and Reference and Reagent Program (Division of
AIDS, NIAID, NIH) and prepared in DMSO at 25 mM stock concentrations.

To assess the

neuroprotective properties of BACE1 inhibition, neuronal cultures were pre-treated with 1 µM
Beta-Secretase Inhibitor IV (Calbiochem, Billerica, MA) for 30 minutes followed by treatment with
hydrogen peroxide or ritonavir, as indicated. eIF2α kinase inhibition assays were performed
using the 7DG PKR inhibitor (Sigma; IC50 = 5 µM) and GSK2606414 PERK inhibitor (EMD
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Millipore; IC50 = 0.4 nM) and were prepared in DMSO stocks and added to cultures by dilution at
the indicated final concentrations.
Immunofluorescence Staining of Neuronal Cultures: To assess neuronal damage and death,
15 µM propidium iodide was added to neuronal cultures grown on coverslips 15 minutes prior to
the end of drug treatments. Cultures were washed twice with PBS and fixed for 30 minutes in 4%
paraformaldehyde/4% sucrose in PBS, followed by permeablization in 0.2% BSA + 0.1% Triton
X-100/PBS for 1 hour at room temperature. Coverslips were then washed twice with PBS and
o

incubated with anti-MAP2 antibody (1:1000) in normal antibody diluent overnight at 4 C. After
washing in PBS-T, coverslips were incubated in a fluorescein isothiocyanate-conjuagated goat
anti-mouse IgG secondary antibody (1:200 for 30 min at room temperature, Jackson
ImmunoResearch Lab, West Grove, PA). Coverslips were mounted on slides and the number of
MAP2+ cells determined through blind counting of all fields (15 at 200x) in three adjacent vertical
columns through the center of each coverslip. Images were captured using a Nikon Eclipse E400
fluorescent microscope (Nikon Corp, Tokyo, Japan) equipped with an Olympus DP70 digital
camera (Olympus Corp, Tokyo, Japan). Propidium iodide puncta were counted by hand using
the NIH ImageJ software program (Image J v1.44, NIH) and plotted as fold change compared to
untreated controls. Averages are expressed as mean ± SEM.
To determine the effect of oxidative and ER stress on synaptic integrity, neuronal cultures were
treated with H202 or ritonavir as described above, fixed, and incubated in anti-synapsin antibody
o

(1:300) overnight at 4 C.

Coverslips were then incubated in a fluorescein isothiocyanate-

conjugated goat anti-rabbit IgG secondary antibody (1:200) for 30 minutes at room temperature.
For each treatment group, 15 images were captured on three coverslips from three independent
experiments using fluorescence microscopy.

Post-acquisition analysis was performed using

Metamorph 6.0 (Universal Imaging, Downingtown, PA). Briefly, intensity of synapsin staining was
determined by the measurement of integrated pixel intensity (defined as total pixel intensity times
the area of pixels with positive synapsin signal). This value was divided by the total MAP2 area
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(also quantified using Metamorph) to account for global changes in neuronal density. For all
imaging quantification, three coverslips were counted from three independent experiments.
Averages are expressed as mean ± SEM.
Immunoblotting: Whole cell extracts of primary rat cortical cultures were prepared using icecold whole-cell lysis buffer (50 mM Tris pH 7.5, 120 mM NaCl, 0.5% NP-40, 0.4 mM Na3VO4, 100
o

mM DTT, and 1:100 protease inhibitor cocktail. Lysates were centrifuged at 14,000 g at 4 C for
10 minutes and protein concentrations determined using the Bradford method and equal amounts
of protein (20 µg) loaded into each well of a 4-12% Bis-Tris Gradient gels followed by transfer to
PVDF membranes at 25 volts at room temperature for 1 hour. Membranes were then blocked in
tris buffered saline (TBS) with 0.1% tween (TBS-T) plus 5% bovine serum albumin (BSA) for 3060 minutes at room temperature. Blocked membranes were incubated in BACE1 primary
o

antibody (Cell Signaling) overnight at 4 C, washed with TBS-T, and incubated with HRPconjugated goat-anti rabbit secondary antibody for 30 minutes at room temperature. Membranes
were developed using SuperSignal West Dura extended duration substrate and pixel intensities
of ROIs quantified via densitometric analysis using the NIH ImageJ software program. BACE1
band intensity was normalized to actin loading controls. Immunoblots shown are representative
of three independent biological replicates.
Statistical Analysis: All data were analyzed by Prism 5.0 software (Graphpad Software, San
Diego, CA). All quantifications are expressed as mean ± SEM. Data with multiple categories
were analyzed by one-way analysis of variance (ANOVA) plus Newman-Keuls post hoc test, as
indicated. Values of p <0.05 were considered significant.

4.4: RESULTS
BACE1 inhibition mitigates MAP2 and synapsin loss in primary neurons treated with hydrogen
peroxide. Numerous studies have shown that neurons exposed to mild oxidative stress display
increased expression of BACE1 at the transcriptional and translational levels leading to enhanced
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production of Aβ species (8, 46, 47). To investigate the role of BACE1 in neurons undergoing
oxidative stress we first treated primary rat neuroglial cultures with 10 and 20 µM hydrogen
peroxide (H202) for 24 hours in the presence or absence of a cell-permeable beta secretase
inhibitor (BSI) and assessed cellular damage and death via MAP2 (blue), synapsin (green), and
propidium iodide staining. We observed that BACE1 inhibition alone had no apparent effect on
cellular or synaptic density, nor did it have any effect on propidium iodide uptake compared to
vehicle controls (Figure 1). Neuronal cultures treated with 10 µM H202 showed decreased MAP2
expression and increased uptake of propidium iodide, but no evident changes in synapsin, while
cultures pre-treated with 1 µM BSI showed reduced uptake of propidium iodide but no apparent
rescue of MAP2 expression (Figure 1). At 20 µM H202, neuronal MAP2 and synapsin levels
were reduced, while propidium iodide uptake was increased compared to vehicle controls but
decreased compared to 10 µM H202-treated neurons. Pre-treatment with 1 µM BSI partially
rescued MAP2 loss and completely rescued loss of synapsin. The number of propidium iodide
puncta was increased in BSI pre-treated 20 µM H202 neuronal cells, suggesting BACE1 inhibition
may result in a delayed death response (Figure 1).
BACE1 inhibition prevents MAP2 loss in ritonavir-treated neurons. Our previous studies have
shown that ritonavir, and other PI class drugs, induce toxic oxidative stress in primary neurons
followed by translational upregulation of BACE1 (12, 20). Therefore, we sought to determine
whether BACE1 has a protective or deleterious effect on neuronal survival following chronic
exposure to ritonavir. Primary rat cortical cultures were pre-treated with DMSO vehicle or 1 µM
BSI for 30 minutes then 10 µM ritonavir for 48 hours. Cultures were stained with propidium iodide
to assess cellular viability and immunostained for MAP2 and synapsin, as described above.
Similar to our previous observations, BACE1 inhibition had no effect on MAP2+ cell count,
synapsin intensity, or propidium iodide uptake compared to untreated and vehicle controls (Figure
2A). 48 hour ritonavir treatment resulted in a three-fold decrease in MAP2+ cell count and nearly
a three-fold increase in propidium iodide uptake, but no change in synaptic integrity relative to
MAP2 area in 10 DIV neuronal cultures (Figure 2A-D). Pre-treatment with BSI rescued MAP2+
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cell loss in ritonavir-treated neurons and decreased propidium iodide uptake (Figure 2F).
Together, these results suggest BACE1 may contribute to neuronal damage and death in the
context of oxidative stressors, such as hydrogen peroxide and PI-class antiretroviral drugs.
Small molecule inhibitors of PKR and PERK block HIV protease inhibitor-mediated
phosphorylation of eIF2α in neurons. ART drugs have been shown to increase expression of
neuronal BACE1 through an eIF2α-dependent translational mechanism in vitro (20). Thus, we
hypothesized that pharmacological inhibition of eIF2α phosphorylation would block ritonavirmediated BACE1 upregulation in neurons. Among the four known eIF2α kinases, we first tested
an inhibitor (7DG) of double-stranded RNA-dependent protein kinase (PKR), which has been
shown to respond to various stressors including viral infection, calcium dysregulation, and
oxidative/ER stress and has been implicated in translational BACE1 regulation (47-49). We
observed that neurons pre-treated with 7DG and exposed to 16 hour ritonavir or saquinavir
treatment showed significantly reduced levels of phospho- eIF2α compared to ART-only treated
cultures (Figure 3A and 3B). Notably, 7DG also reduced levels of phospho- eIF2α to half the
level of untreated and vehicle controls, indicating PKR may play a role in maintaining basal levels
of phospho- eIF2α in neurons. We also observed that PKR inhibition in the presence of ritonavir
or saquinavir reduced BACE1 expression levels compared to ART-only controls, however, this
change was not statistically significant (Figure 3C).
Based on our previous observations that PERK is involved in ART-mediated BACE1
upregulation in neurons, we tested the effects of a PERK inhibitor (GSK2606414, abbreviated
GSK) on phospho- eIF2α and BACE1 levels in ritonavir and saquinavir-treated neurons. We
found that 0.5 µM GSK significantly reduced phospho- eIF2α levels in ritonavir and saquinavirtreated neurons compared to ART-only controls (Figures 3D-E and G-H).

Similar to 7DG,

administration of GSK reduced BACE1 levels in the presence of ART, but the change was not
statistically significant (Figures 3F and 3I). These results suggest that PKR and PERK both
contribute to BACE1 upregulation in ART-treated neurons through phosphorylation of eIF2α.
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However, inhibition of only one eIF2α kinase may not be sufficient to fully suppress BACE1
upregulation mediated by ART.
PERK inhibitor compound, GSK2606414, does not alleviate ritonavir-mediated neurotoxicity in
primary neuroglial cultures. Genetic and pharmacologic knockdown of PERK activity has been
shown to have protective effects in the CNS of animals infected with prions as well as in
Alzheimer disease mouse models (7, 50-52). Therefore, we tested whether PERK inhibition
abrogates ritonavir-mediated neurotoxicity. Unexpectedly, we found that use of the GSK PERK
inhibitor augmented ritonavir-mediated losses in MAP2 and increased propidium iodide uptake
(Figure 4). Notably, administration of GSK alone appeared to have toxic effects on neuronal
cultures, as indicated by reduced MAP2 expression and a robust increase in propidium iodide
uptake compared to untreated and vehicle controls, suggesting that this compound may have
toxic side-effects unrelated to PERK inhibition or that PERK itself may play an important role in
cellular maintenance and homeostasis in neurons, thus limiting its therapeutic potential.

4.5: DISCUSSION
The persistence of less severe manifestations of HAND, including ANI and mild neurocognitive
disorder (MND), despite the widespread implementation of combination ART in 1996 highlights
the need for new therapeutic targets and adjunctive therapies in the management of HAND.
Previous attempts to mitigate neurocognitive decline in HIV+ individuals focused on the use of
ART regimens with high CNS penetrance, as estimated by the CNS-penetrance effectiveness
(CPE) scoring system. While many clinical studies found that higher CPE scores were initially
successful at improving patients’ neuropsychological performance, others found an inverse
relationship between CPE scores and neurocognitive/motor performance despite decreased CSF
HIV RNA levels (53-57). To date, promising adjunctive therapies with anti-oxidant and antiinflammatory properties such as selegiline, minocycline, and memantine, have been largely
unsuccessful at reversing long-term cognitive decline in HAND patients. Here, we build on our
previous observations that ART drugs increase BACE1 expression in vitro and in vivo to show
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that BACE1 inhibition is protective against ART-mediated neurotoxicity, thus identifying BACE1
as a potential therapeutic target in HAND and other CNS inflammatory diseases in which
oxidative and ER stress are prevalent.
We first sought to understand the role of BACE1 in neuronal survival under conditions of
oxidative stress. Previous studies have demonstrated that oxidative stress can induce cellular
redistribution of BACE1 to endosomal compartments co-localizing with APP and/or lead to
transcriptional and translational upregulation of BACE1 expression in neurons (8, 47). Given that
BACE1 is translationally repressed under normal conditions, but selectively upregulated during
ER and oxidative stress, we initially hypothesized that BACE1 may play a role in cellular stress
adaptation and/or survival. Consistent with this idea, Kamenetz et. al. reported that Aβ produced
by BACE1 cleavage of APP was protective against neuronal hyperactivity and excitotoxicity in
vitro (58). However, our observations in H202-treated neurons suggest that BACE1 contributes
to neuronal damage and death in the presence of mild to severe oxidative stress over 24 hours.
These findings were corroborated with our 48-hour ART treatment studies in which BACE1
inhibition partially rescued ritonavir-mediated losses in MAP2+ cell count and propidium iodide
uptake. While informative, these observations raise questions regarding the basic physiological
functions of BACE1 in neurons, which remain largely elusive.

Among its few known roles,

BACE1 appears to be involved in peripheral, and potentially CNS, myelination via cleavage of
neuregulin-1, and is thought to be important for maintenance of synaptic functioning (2, 59).
Additionally, BACE1 is upregulated in neurons in response to a host of inflammatory mediators,
including interferon-γ, tumor necrosis factor α, interleukin-1β, and Aβ, and contains transcription
factor binding sites for Sp1, CREB, NF-κB, STAT1, and PPARγ among others.
Based on our studies and previous reports, neuronal upregulation of BACE1 appears to
be deleterious to cell survival during stress conditions.

However, the cellular context of the

specific stressor may be critical in determining whether the upregulated protein in question is prosurvival or pro-death. Recently, Baleriola et. al. demonstrated that Aβ42, when applied to distal
axons of rat hippocampal neurons, induces phosphorylation of eIF2α and local translation of a
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subset of mRNAs, including ATF4 (60). ATF4, typically considered to be a neuroprotective gene
involved in cellular adaption to ER stress, was then shown to propagate a neurodegenerative
signaling cascade in Aβ42 –treated neurons, leading to cell death. Therefore, it is likely that
stress-induced genes, such as ATF4 and BACE1, that are translationally upregulated in response
to phospho- eIF2α, which is elevated in brains of AD and HAND patients, play both protective as
well as deleterious roles in neuronal survival depending on the chronicity and localization of the
stressor. Careful time course experiments will be necessary to determine if BACE1 has an initial
protective role in neurons undergoing oxidative and ER stress that becomes toxic over time,
similar to what has been reported with ATF4.
The unfolded protein response has recently become an area of therapeutic interest in the
treatment of neurodegenerative diseases and is of particular interest in HAND given our previous
observations of elevated UPR markers in the CNS of HAND patients and ART drug-mediated
BACE1 upregulation via phospho-eIF2α-dependent translational control in neurons (61, 62).
Here, we used a pharmacological approach to assess the contribution of two eIF2α kinases,
PERK and PKR, to ART-mediated BACE1 upregulation. In agreement with our previous work,
we found that inhibition of PERK blocked ART-mediated phosphorylation of eIF2α; however,
BACE1 was not significantly reduced compared to ART-only controls, emphasizing the redundant
nature of the four eIF2α kinases. Furthermore, use of the GSK PERK inhibitor did not alleviate
ritonavir-mediated loses in MAP2, indicating that this inhibitor, although protective in an AD
mouse model, may be neurotoxic in vitro. Alternatively, PERK may be critical for neuronal health
and survival during normal and/or acute stress conditions, limiting its therapeutic potential.
Indeed, disruption of PERK signaling in CNS neurons has been shown to induce cognitive and
behavioral deficits in mice (63). Unexpectedly, we found that PKR played a major role in
maintaining basal levels of neuronal phospho-eIF2α and PKR inhibition completely abrogated
ritonavir and saquinavir-mediated phosphorylation of eIF2α, but only partially reduced BACE1
levels. Future studies with 7DG will be utilized to determine if PKR inhibition is protective against
ART-mediated neurotoxicity in vitro and in vivo.

146

In the present study, we did not test the effect of GCN2 and HRI inhibitors, however, work
by Vassar and colleagues suggests that GCN2 does not contribute significantly to ER-stress
mediated upregulation of BACE1 in neurons (7).

Nonetheless, GCN2 remains an intriguing

therapeutic target for HAND, as it has been shown to have inhibitory effects on HIV replication
and is directly cleaved by the HIV protease to overcome this antiviral effect (64). Ultimately,
successful adjunctive therapies for HAND will likely have to include pharmacologics that alleviate
ER and oxidative stress, thereby slowing or preventing the

toxic

accumulation of

neurodegenerative proteins, such as Aβ, that have become increasingly prevalent in the
pathology associated with HIV infection in the CNS.
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Figure 1. BACE1 inhibition mitigates MAP2 and synapsin loss in primary neurons treated with
hydrogen peroxide. Rat cortical neuroglial cultures grown on coverslips for 10 DIV were treated
with DMSO vehicle or pretreated with 1 µM cell-permeable beta secretase inhibitor (BSI) for 30
minutes then treated with 10 or 20 µM hydrogen peroxide (H202) for 24 hours. Cultures were
stained with propidium iodide (red) and immunostained for MAP2 (blue) and synapsin (green).
Neurons pre-treated with 1 µM BSI displayed decreased propidium iodide staining, increased
expression of synapsin and increased MAP2+ cells compared to untreated cultures in the
presence of 10 and 20 µM H202. Images were captured using epifluorescent microscopy at 40x
magnification. Representative images shown.
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Figure 2. BACE1 inhibition prevents MAP2 loss in ritonavir-treated neurons. A) Rat cortical
cultures were grown on coverslips for 10 DIV and treated with DMSO vehicle or 1 µM cellpermeable beta-secretase inhibitor (BSI) for 30 minutes followed by 48 hour treatment with 10 µM
ritonavir. To assess cellular damage and death, cultures were stained with propidium iodide (red)
and immunostained for MAP2 (blue) and synapsin (green). B-D) In the presence of ritonavir,
neurons pre-treated with 1 µM BSI showed a significant increase in the number of MAP2+ cells
and a small decrease in propidium iodide staining. No changes in synapsin were observed
between treatment groups (n=4, *p<0.05, **p<0.01, ns: not significant, one-way ANOVA plus
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Newman-Keuls post hoc testing).

Images were captured at 40x magnification using

epifluorescent microscopy. Representative images shown.
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Figure 3. Small molecule inhibitors of PKR and PERK block HIV protease inhibitor-mediated
phosphorylation of eIF2α in neurons.

Primary rat neuroglial cultures aged 21 DIV were

pretreated with DMSO vehicle or an inhibitor of PKR (7DG) or PERK (GSK2606414) for 1 hour
followed by treatment with 10 µM ritonavir or 1 µM saquinavir for 16 hours. Neuronal lysates
were immunoblotted for phospho- and total eIF2α and BACE1. Actin was used a loading control
for BACE1 while phospho-eIF2α was normalized to total eIF2α. A-C) PKR inhibition with 10 µM
7DG in neurons significantly reduced basal levels of phospho-eIF2α and prevented ritonavir and
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saquinavir-mediated phosphorylation of eIF2α. 7DG also reduced neuronal BACE1 expression in
ART-treated neurons, however the change was not significant (n=3 **p<0.01, ***p<0.001, oneway ANOVA plus Newman-Keuls post hoc testing).

D-I) Inhibition of PERK with 0.5 µM

GSK2606414 did not affect basal levels of phospho-eIF2α, but resulted in a significant decrease
in phospho-eIF2α expression in ritonavir and saquinavir-treated neurons compared to vehicle
pre-treated controls (n=3, *p<0.05, one-way ANOVA plus Newman-Keuls post hoc testing).
BACE1 levels were not significantly altered in neurons treated with GSK2606414, although we
observed a trend towards decreased BACE1 expression in PERK-inhibited, ART-treated neurons.
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Figure 4. Pharmacological inhibition of PERK does not alleviate ritonavir-mediated neurotoxicity
in primary neuroglial cultures. Rat cortical neuroglial cultures were grown on coverslips for 10
DIV and pre-treated with DMSO vehicle or 0.5 µM PERK inhibitor, GSK2606414 (GSK) for 30
minutes followed by treatment with 10 µM ritonavir for 48 hours.

Cells were stained with

propidium iodide (red) and immunostained for MAP2 (blue) and synapsin (green) to assess
neuronal damage and death. Neuronal cultures pre-treated with GSK did not appear significantly
different compared to controls in the presence of ritonavir. MAP2 and synapsin levels appeared
similar while propidium iodide puncta were increased in GSK pre-treated neurons.
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CHAPTER 5
CONCLUSIONS AND FUTURE DIRECTIONS
5.1: OVERVIEW
The advent of combination antiretroviral therapy in 1996 represented a revolutionary
breakthrough in the treatment of HIV and validation of rational drug design via structural biology
as an essential methodology in the treatment of human disease.

When on ART, patients

experience suppressed viral replication, reconstitution of the immune system, and improved longterm survival. However, with aging of the HIV-infected population, the prevalence of HAND has
continued to escalate. Furthermore, the life expectancy of ART-medicated, HIV-positive patients
remains 10-30 years less than that of uninfected individuals, highlighting the need for
advancements in the understanding of HIV comorbidities including HAND neuropathogenesis (1).
Since the implementation of ART, HAND has evolved from a rapidly progressing, subcortical
encephalitic condition to a prolonged, cortical, neurodegenerative disease. While contributions of
HIV replication, immune activation, and drugs of abuse are known to drive neuronal damage, it is
less clear what effect antiretroviral drugs have in the onset and progression of HAND, however, a
plethora of data suggests that ART toxicity is likely to play a key role in CNS toxicity, as it does in
the peripheral nervous system. The aim of our work has been to determine the contributions of
ART, on a cellular and molecular level, to the evolution and persistence of HAND pathology with
the long-term goal of uncovering novel therapeutic strategies to combat cognitive deficits in aging,
HIV-infected populations. To that end, we employed in vitro models of ART exposure to show
that HIV protease inhibitors, and NRTIs to a lesser extent, induce UPR activation in primary rat
and human fetal neurons (Chapter 3). Consistent with previous studies, activation of the UPR
resulted in translational de-repression of BACE1 and enhanced production of Aβ peptides.
These effects were mitigated by knockdown of neuronal PERK or overexpression of a kinasedead PERK mutant.

Importantly, we found evidence of UPR activation and upregulation of
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BACE1 protein levels in ART-treated humans and macaques infected with HIV and SIV,
respectively. In Chapter 4, we sought to elucidate the role of BACE1 in neuronal survival and
stress response by challenging neurons with oxidative and ER stressors in the presence of a
pharmacological inhibitor of BACE1. We found that BACE1 inhibition partially protected cells
against hydrogen peroxide and ART-mediated neuronal damage and death as indicated by
decreased uptake of propidium iodide and rescue of MAP2 and synapsin protein expression.
Additionally, we observed that inhibition of PKR, one of the four eIF2α kinases, blocked ARTmediated phosphorylation of eIF2α and upregulation of BACE1.

Ultimately, a detailed

understanding of the molecular mechanisms by which antiretrovirals induce toxicity in neurons is
vital to the development of safer drug regimens and the discovery of novel therapeutics sorely
needed in HAND.

5.2: ANTIRETROVIRALS AND THE UNFOLDED PROTEIN RESPONSE
In Chapter 3, we built upon previous observations of ART toxicity in neurons to determine
which specific molecular pathways were affected in cells upon exposure to commonly prescribed
antiretroviral drugs. Consistent with findings in hepatocytes, adipocytes, and macrophages, PI
and NRTI-class ART drugs were found to activate ER stress in rat and human fetal neurons in a
dose-dependent manner, as indicated by elevated expression of BiP, p-eIF2α, and splicing of
XBP1 mRNA by IRE1α. We did not test the ability of other ART drug classes to induce ER stress
in neurons; however, we are currently conducting an extensive analysis on a panel of NRTIs,
nNRTIs, and PIs to determine if our findings with ritonavir, saquinavir, and AZT are representative
of their drug class. Current efforts are also underway to determine the precise mechanism by
which PIs and NRTIs induce ER stress, although the answer is likely to be multifactorial (Figure
1).

A 2005 study by Parker et. al. suggested that PIs activate ER stress in adipocytes via

inhibition of 26S proteasome activity and blockade of glucose transporter 4 (GLUT4) (2).
Intriguingly, Vassar and colleagues found that inhibition of glucose utilization resulted in PERKdependent phosphorylation of eIF2α in vivo and in vitro (3). Furthermore, mutation of the Ser51
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eIF2α phosphorylation site in mice results in fatal hypoglycemia and defective gluconeogenesis,
indicating that the primary physiological function of p-eIF2α in mammals is nutrient-sensing and
regulation of glucose homeostasis (4). Given that PIs induce insulin resistance in patients, it
stands to reason that inhibition of glucose transport and utilization may be a key mechanism of
cellular stress in the periphery as well as in the CNS, where GLUT4 is known to be expressed in
the hippocampus. We will first assess glucose uptake in insulin-stimulated hippocampal neurons
3

treated with increasing doses of ritonavir using a [ H]2-Deoxyglucose uptake assay. Based on
previous work with PIs in other cell types, we predict that ritonavir will dose-dependently block
glucose uptake in neurons. Using immunofluorescence analysis, we will then assess whether
any of the major glucose transporters in neurons, including GLUT1, GLUT3, or GLUT4 fail to
translocate to the plasma membrane after insulin-stimulation in the presence of ritonavir.

A

previous study in 3T3-L1 adipocytes demonstrated that GLUT3 and GLUT1 properly translocate
to the plasma membrane in the presence of indinavir, but that indinavir inhibits the intrinsic
transport activity of GLUT4 after its translocation (5). As glucose uptake by GLUT4 in muscle
cells is dependent upon PI3-kinase activation (6), we will determine if ritonavir inhibits PI3-kinase
in neurons as a mechanism of GLUT4-specific glucose transport inhibition.

Ultimately, a

comprehensive analysis of the effects of PIs on neuronal insulin sensitivity and signaling will be
critical for advancing our understanding of the potential metabolic side-effects of ART in the CNS
of drug-treated, HIV-positive individuals.
Inhibition of 26S proteasome activity by PIs has been confirmed in various cell types and
cell-free systems and is likely to be important as an ER-activating mechanism in neurons as
indicated by a recent report showing that pharmacological inhibition of proteasome activity with
MG115 or MG132 directly activates PERK in neural cells (7). Future studies are necessary to
determine if PIs can inhibit proteasome function in primary neuroglial cultures prior to
phosphorylation of eIF2α. This can be assessed with the use of a fluorometric assay wherein a
peptide substrate of the proteasome (LLVY) is linked to a fluorophore (7-amino-4methylcoumarin) which fluoresces after cleavage of the LLVY-AMC bond. In this manner it will be
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possible to determine if proteasome inhibition is an early event in PI-mediated cell toxicity and if
rescue of proteasome activity abrogates PI-mediated activation of ER stress.
We have previously shown that antiretrovirals induce production of reactive oxygen
species (ROS) in primary neurons as early as 6 hours after treatment, hypothesized to be the
result of disrupted mitochondrial DNA synthesis and depletion of enzymes necessary for the
electron transport chain (8-11). ROS, in turn, can activate ER stress via disruption of cellular
calcium homeostasis or widespread oxidation of proteins leading to impaired protein degradation
(12).

To assess whether ART-induced oxidative stress is sufficient and/or necessary for

downstream activation of the UPR, we would inhibit ROS production with the use of a fumaric
acid ester, monomethyl fumarate (MMF). MMF, the hydrolyzed, active metabolite of dimethyl
fumarate (DMF), is an anti-inflammatory that activates the Nrf2-dependent antioxidant response
pathway leading to upregulation of detoxification enzymes, such as NQO-1 and heme oxygenase
1 (HO-1), and has been shown to protect neurons from ART-induced damage and death (8, 13,
14). DMF is currently used for the treatment of psoriasis in Europe and ongoing clinical trials
indicate DMF shows promise as a disease-modifying agent in multiple sclerosis, highlighting its
favorable in vivo efficacy and safety profile (13, 15-18). Thus, DMF represents an intriguing
candidate for adjunctive therapy in the treatment of HAND, as reviewed by Gill and Kolson (19).

5.3: MECHANISMS OF BACE1 REGULATION IN NEURONS
Our work also confirms a 2008 report by O’ Connor et. al. that UPR activation in neurons
results in translational upregulation of BACE1. Importantly, we used a 5’UTR deletion construct
to confirm that translational control of BACE1 during ER stress is dependent upon the presence
of the 5’UTR. Whereas 16 hour ritonavir treatment in neurons overexpressing wild-type BACE1
resulted in increased BACE1 expression compared to vehicle controls, neurons overexpressing
the -5’UTR construct did not show any changes in BACE1 protein when treated with ritonavir.
Importantly, we observed a much larger increase in BACE1 protein due to deletion of the 5’ UTR
as compared to induction of ER stress with ritonavir. These results suggest that ritonavir partially
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de-represses BACE1, likely through the use of p-eIF2α-mediated scan through of uORFs after reinitiation. However, secondary structures in the 5’UTR likely remain intact and therefore could
contribute to partial repression of translation. Elevated BACE1 in neurons containing the 5’UTR
deletion-construct thus reflects a coincident loss of all uORFs and secondary structures leading to
translational initiation of all associated ribosomes at the true start codon, compared to neurons
transfected with the BACE1 cDNA containing the full length 5’ UTR where initiation at the bone
fide start codon remains sub-maximal due to secondary structures or incomplete scan-through of
all three uORFs. Based on previous studies of BACE1 translational control, we predict that
mutation or deletion of uAUG #2 and/or #4 would further enhance BACE1 expression during ER
stress by limiting translation re-initiation at these start codons. A thorough analysis of BACE1
5’UTR uAUG mutants will be necessary to confirm if these uAUGs are critical to BACE1
translational control during ER stress or if secondary structures play a more prominent role in
repression.
Although not supported by our data, there is also evidence that BACE1 transcript and
protein stability can be influenced by microRNAs and non-coding antisense mRNAs (20). In
particular, four microRNAs (miR-107, miR-9, miR-29a, miR-29b) are known to bind BACE1
mRNA and regulate translational efficiency while increasing the stability of the transcript (21, 22).
Interestingly, several of these microRNAs were shown to be downregulated in AD brains and
were inversely correlated with BACE1 mRNA levels in the CNS (21).

Alternatively, BACE1

stability can be affected by proteasome activity, as shown in a 2004 report where inhibition of
proteasome activity with lactacystin, but not other protease inhibitors, led to accumulation of
ubiquitinated BACE1 and increased amyloidogenic processing of APP (23).

We found that

ritonavir had no effect on BACE1 protein stability in vitro, however, a parallel post-mortem
analysis of BACE1 protein and mRNA levels in the CNS of HAND patients will be necessary to
determine if BACE1 is increased only at the translational level as in AD.
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In addition to increasing the expression of BACE1, we also observed that ritonavir and
combinations of antiretrovirals increased production of Aβ peptides by two-fold in CHO cells
stably expressing human APP and in primary rat neuroglial cultures. Unexpectedly, we found
that CHO cells treated with ritonavir showed an increase in Aβ42 secretion but not Aβ40,
conflicting with a report by Vassar et. al. which showed that overexpression of BACE1 in cells
stably transfected with wild-type human APP increased production of Aβ40 and Aβ42 peptides
equally (24). Our results in CHO cells appear to be a cell-specific artifact, as we observed
comparable increases in Aβ40 and Aβ42 in primary rat neuronal cultures treated with
combinations of antiretrovirals. Alternatively, our observations in rat neurons may be a result of
combination ART treatment compared to the ritonavir-only treatments in CHO cells. Rigorous in
vivo validation of ART effects on Aβ production are needed to determine the long-term effects of
these drugs on amyloidogenesis in the brain. Although several groups have reported elevated
Aβ accumulation and deposition in ART-treated, HIV-positive individuals compared to ART-naïve
controls, there are several technical concerns with these studies regarding the antibody (4G8)
used to detect amyloid. Specifically, 4G8 can detect full-length APP in addition to sAPPβ, and Aβ
peptides, therefore, it is unclear which Aβ domain-containing species these groups were
observing in HAND patients. Given the limitations associated with post-mortem human analyses,
the use of transgenic mouse models of AD will be critical to ascertain a clear understanding of the
interplay between antiretrovirals and amyloid pathology in the CNS.

Previously, Ikezu and

colleagues found that 30-day oral administration of nelfinavir (PI) or lopinavir/ritonavir had no
effect on Aβ accumulation in two-month-old APP SCID mice (generated by crossing CRND8
transgenic mice with BALB/cBy-Prkdc

scid

mice) despite achieving CSF/IC50 ratios of 4.3 and 3.3,

respectively (25). However, previous studies using CRND8 transgenics indicated that ThioflavinS-positive amyloid deposits were not prevalent until 3 months of age and dense-core neuritic
plaques were not observed until 5 months of age (26). Importantly, none of the animals included
in the Ikezu study displayed evidence of amyloid pathology; therefore, inclusion of age-matched,
CRND8 transgenic controls will be necessary to ensure pathology in the APP SCID mouse

164

develops in a similar, age-dependent manner. We propose using the APP/PS1 double knock-in
mouse model of AD, in which FAD-causing mutations were targeted into their endogenous genes,
resulting in age and region-dependent amyloid deposition beginning at 6 months of age (27).
Treatment of these animals with antiretrovirals at 6 and 12 months of age will provide critical
insights into the effects of ART on the initiation of amyloidogenesis, while avoiding the caveats of
a transgenic AD model that utilizes exogenous overexpression of APP.

5.4: eIF2α KINASES AS THERAPEUTIC TARGETS IN HAND
PERK is the primary kinase responsible for eIF2α phosphorylation during conditions of
oxidative and ER stress. Our results suggest that PERK is also involved in maintenance of basal
p-eIF2α in neurons and ART-mediated increases in p-eIF2α and BACE1 (Chapters 3 and 4).
Notably, while overexpression of kinase-dead PERK resulted in a significant decrease in p-eIF2α
and BACE1 expression in neurons, overexpression of wild-type PERK increased p-eIF2α but did
not change BACE1 levels, suggesting that in the absence of an oxidative or ER stressor,
phosphorylation of eIF2α does not necessarily lead to translational upregulation of BACE1. To
confirm this hypothesis, future experiments will be conducted in which wild-type and kinase-dead
PERK constructs are overexpressed in neurons in the presence and absence of ritonavir. While
overexpression of wild-type PERK is predicted to augment the effects of ritonavir through
enhanced and/or sustained phosphorylation of eIF2α, overexpression of kinase-dead PERK
should partially block ritonavir-mediated upregulation of BACE1, as observed in our PERK
conditional knockout cells (Chapter 3) and PERK inhibitor studies with the novel compound
GSK2606414 (Chapter 4).
Accumulating evidence suggests that aberrant UPR signaling through PERK is a key
mechanism underlying amyloidogenesis and cognitive decline in neurodegenerative diseases,
such as AD (3, 28-32).

We and others have shown that ART contributes to enhanced

amyloidogenic processing of APP in primary neurons via ER stress activation (33-35). Therefore,
to determine if PERK is directly involved in antiretroviral-mediated Aβ production in vivo, we will
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cross APP/PS1 double knock-in mice (described previously) with conditional PERK knockouts
and treat the resulting APP PERK-/- mice with ART for up to 30 days and assess changes in Aβ
production and amyloid pathology beginning at 6 months of age. As PERK haploinsufficiency is
sufficient to prevent BACE1 elevation, reduce Aβ and plaque burden, and rescue memory deficits
in a 5XFAD mouse model, we predict that conditional knockout of PERK in adult mice will
abrogate ART-mediated phosphorylation of eIF2α and upregulation of BACE1, while preventing
or slowing any accumulation of intraneuronal or extracellular Aβ that might occur.

These

experiments will also reveal whether PERK inhibition represents a promising therapeutic avenue
in the treatment of HAND.
Phosphorylation of eIF2α is mediated by three kinases in addition to PERK, including
HRI, GCN2, and PKR. While HRI is not expressed in neurons, GCN2 is expressed at high levels
in the brain compared to other organs and responds to a variety of stress conditions, similar to
PERK. Additionally GCN2 has been shown to play a role in learning and memory via regulation
of early and late-phase long-term potentiation (LTP) (36).

Paradoxically, genetic deletion of

GCN2 in APP/PS1 mice was shown to rescue impairments in synaptic plasticity and spatial
memory, suggesting this kinase becomes dysregulated or maladaptive in neurodegenerative
disease (31).

Additionally, GCN2 has been shown to inhibit HIV replication and is directly

cleaved by the HIV-1 protease (37). Therefore, future experiments involving in vivo and in vitro
knockdown of GCN2 will be informative in understanding the contribution of this kinase to CNS
health in the presence of HIV and/or antiretroviral drugs.
PKR also appears to have a role in AD pathogenesis via stress-mediated upregulation of
BACE1 (38-40). Our results in Chapter 4 indicate that PKR is partially responsible for ARTmediated increases in p-eIF2α and BACE1 and may play a role in maintaining basal levels of peIF2α in neurons. Although PKR knockout in APP/PS1 mice did not prevent amyloid pathology
or rescue cognitive deficits (31), it is likely that PKR, GCN2, and PERK all contribute to eIF2α
phosphorylation in chronic, neurodegenerative diseases given the widespread inflammation,
energy deprivation, and accumulation of misfolded proteins that routinely accompany these
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diseases. Additionally, inhibition of any one of the eIF2α kinases via targeted therapeutics in vivo
is likely to be compensated by the overlapping functions of the other kinases, suggesting that
direct targeting of eIF2α itself may be more efficient at ameliorating aberrant UPR signaling in
chronic CNS disease. However, it remains unclear whether sustained eIF2α phosphorylation is
an early, driving force behind the neurodegenerative process or a downstream cellular adaptation
to the accumulation of misfolded proteins and gradual deterioration of protein folding and clearing
mechanisms associated with normal aging. Whether stress-induced eIF2α phosphorylation is
ultimately protective or deleterious to neuronal survival in the brain is incompletely understood
and likely depends on the chronicity and severity of the stressor.

Canonical activation and

regulation of the UPR in general, and the PERK pathway in particular, is designed to be rapid and
transient, exemplified by the fact that many of the translational targets of p-eIF2α are themselves
transcription factors. A 2007 report by DeGracia and Hu concluded that neuronal survival during
transient cerebral ischemia was dependent upon recovery from translational inhibition by p-eIF2α
(41). However, long-term translational arrest via chronic UPR activation in neurons is associated
with enhanced production of neurodegenerative proteins, impaired LTP, and in the case of
ischemia/reperfusion, cell death. These conflicting roles for the UPR suggest that its activation is
biphasic: adaptive and protective during transient stress but apoptotic during chronic/severe
stress (42). Extensive animal studies with modulators of eIF2α, such as growth arrest and DNA
damage inducible protein 34 (GADD34), a specific eIF2α phosphatase, will be critical to
determine the safety of this therapeutic approach in the context of HIV infection and long-term
exposure to antiretroviral drugs.

5.5: CONSIDERATIONS FOR IN VIVO ANALYSIS OF ART-ASSOCIATED CNS DAMAGE
We confirmed the biological significance of our in vitro findings with a well-characterized,
SIV/pigtail macaque model of HIV CNS disease in which 90% of infected animals treated with
placebo develop neurologic disease within 12 weeks post-inoculation, while animals treated with
ART do not develop SIV encephalitis nor do they develop neurological dysfunction (43).
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Strikingly, SIV-infected macaques treated with combination ART showed significantly elevated
expression of BACE1 and APP, a sensitive marker of neuronal damage, in the hippocampus
compared to SIV-infected, placebo-treated controls (Chapter 3).

Together with our previous

reports of ART-associated synaptic injury in this same macaque model (8), these results
demonstrate that oral administration of successful ART to primates negatively impacts neuronal
and synaptic viability in the CNS either through direct or peripheral toxicities. Furthermore, these
data strongly suggest that antiretroviral agents themselves, not viral infection, are responsible for
increased CNS expression of BACE1. Treatment of uninfected pigtails macaques with ART is
currently ongoing and will be necessary to confirm this hypothesis. Notably, we did not observe
statistically significant changes in BiP or p-eIF2α in ART-treated macaques compared to
uninfected or placebo-treated controls, however, changes in ER stress markers are likely to be
region- and cell-specific, thus, immunofluorescent analysis will be necessary to properly assess
the level of UPR activation in the macaque brain. Furthermore, successful detection of phosphoproteins in post-mortem tissue is highly dependent upon post-mortem interval (44), therefore, we
will measure changes in alternative UPR markers, such as sXBP1, ATF6α/β, ATF4, and CCAATenhancer-binding protein homologous protein (CHOP) via immunofluorescent and western
blotting analysis.
Our initial post-mortem analysis of brain tissue from a small cohort of 13 patient samples
from the NNTC revealed two important findings: BACE1 levels are significantly upregulated in the
hippocampus of HAND patients compared to HIV-negative controls and intraneuronal Aβ
oligomers are elevated in the hippocampus of HAND patients despite the absence of overt plaque
pathology or changes in total APP (Chapter 3). Interestingly, we did not find an association
between the severity of HAND and Aβ oligomer burden in the hippocampus, indicating
dysregulated APP processing may be an early event in pathogenesis. Notably, the patients
tested in this cohort ranged from 31 to 53 years of age, therefore, advanced amyloid pathology
would not be expected even in the presence of FAD-causing mutations. Similar to our findings in
macaques, HAND patients did not display statistically significant changes in BiP or p-eIF2α
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compared to uninfected or HIV-positive, neurocognitively normal controls by western blotting
analysis. These results conflict with our previous reports in which immunofluorescent analysis
revealed elevated markers of UPR activation, including BiP and p-eIF2α, in HAND patients (45,
46), emphasizing the importance of this approach to examine changes in protein levels that can
vary across subcellular compartments, cell types, and brain regions.

Our analysis of HAND

patients is also limited by low statistical power owing to small sample size and lack of data on
antiretroviral regimens. To address these concerns, we have begun extended analysis of a large
cohort (n=60) of patients from the NNTC grouped into three categories: 20 HIV(-), 20
HIV(+)/ART-naïve, 20 HIV(+)/ART-treated for at least 12 months (Table 5.1). Importantly, the
ART regimens of our drug-treated patient samples were carefully documented which will allow us
determine for the first time if long-term use of specific ART regimens/antiretroviral drug classes
correlate with changes in UPR activation, BACE1 expression, and aberrant APP processing in
the CNS. The importance of these studies are highlighted by the conflicting neuropsychological
data obtained in cross-sectional and longitudinal clinical studies of HIV-positive patients
beginning ART or switching to ART regimens with higher predicted CNS penetrance. While these
studies have largely assessed the initial effects of ART on neurocognitive function in drug-naïve
patients, our studies will provide critical information on the cumulative, long-term effects of ART
on neuropathology in HIV-positive individuals.

5.6: BACE1 FUNCTIONS IN NEURONS: IMPLICATIONS FOR A NOVEL THERAPEUTIC
TARGET IN HAND
A growing body of literature suggests that BACE1 is induced by a variety of stress
conditions including oxidative stress, cerebral ischemia, traumatic brain injury, and impaired
energy metabolism associated with neurodegeneration (3, 47-54). In Chapter 4, we investigated
the role of BACE1 in cell survival and adaptation to oxidative and ER stress. Although the
regulation and timing of BACE1 expression in neurons suggest it may be involved in an acute
neuronal stress response, we found that inhibition of BACE1 activity protected cells from
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hydrogen peroxide-induced damage and death. At acute doses of hydrogen peroxide, BACE1
inhibition mitigated loss of MAP2 and synapsin, but did not change the number of propidium
iodide puncta, suggesting that loss of BACE1 activity either slowed the death response in
neurons or restricted cell loss to glia. Recent preliminary work in our lab has demonstrated that
toxic doses of hydrogen peroxide induce acute loss of astrocytes prior to the loss of neurons,
suggesting that astrocytes buffer and protect neurons from changes in redox potential and that
BACE1 may be involved in a delayed death response in neurons. In support of this conclusion,
previous reports have shown that during apoptosis BACE1 protein degradation in lysosomes is
inhibited by caspase-3-mediated cleavage of Golgi-localized γ-ear-containing ARF-binding
protein 3 (GGA3), an adaptor protein required for BACE1 lysosomal trafficking and degradation,
leading to enhanced Aβ production and cell death (55).

Thus, BACE1 may be involved in

programmed cell death as a means to prevent spread of cytotoxic ROS in the brain. However,
what role BACE1 might play in sub-toxic oxidative stress conditions remains unclear.

An

additional consideration is the possibility that the beta-secretase inhibitor utilized in our study is
protecting neurons via off-target effects on other proteases, such as caspases, however, this is
unlikely given the high-specificity of the compound, which has an IC50 of 15nM for BACE1, 230nM
for BACE2, 7.6uM for cathepsin D, and greater than 50uM for the related aspartic protease renin.
However, off-target effects of the BACE1 inhibitor on initiator and effector caspases will be
verified by western blotting for active caspase-3 and caspase-9 in neurons following treatment
with hydrogen peroxide, an important next step for our studies.
Alternatively, BACE1 might exert a specific neuroprotective role against excitotoxic
insults based on its ability to cleave voltage-gated sodium channels (VGSCs). Excitotoxins, such
as N-methyl-D-aspartate (NMDA), which bind to glutamate receptors, induce acute excitotoxicity
in neurons via influx of calcium and sodium (56). We propose to examine the role of BACE1
during excitotoxicity by treating primary neurons with NMDA in the presence or absence of a
BACE1 inhibitor.

Neuronal viability will be assessed by changes in MAP2, synapsin, and

propidium iodide inclusion. Additionally, we will correlate cell damage and death with levels of
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calcium and sodium influx after NMDA treatment in BACE1 inhibited neurons with the use of
fluorescent dye assays. Although BACE1 inhibition is not predicted to mitigate NMDA-mediated
influx of calcium, this assay will allow us to determine if BACE1 mediates neuroprotective effects
by regulating sodium influx via VGSC activity and function, which would have larger implications
in diseases such as epilepsy where neuronal hyperactivity is prevalent. Hypothetically, BACE1
cleavage of VGSCs could also counteract the enhanced, region-specific expression of cortical
VGSCs found in a rodent model of absence epilepsy, which was thought to correlate with the
determined regions of seizure onset (57).
Finally, we found that BACE1 inhibition also partially protected neurons from ritonavirmediated toxicity over 48 hours. Although we have data to suggest that ritonavir and other PIclass drugs exert their neurotoxic effects through production of ROS, there is an abundance of
data indicating ART drugs have a plethora of other toxic effects mediated through calcium
dysregulation, inhibition of proteasome function, and mitochondrial toxicity, suggesting BACE1
might play a role in balancing cell survival and death in response to a wide variety of insults. As
such, BACE1 is an appealing target for therapeutic intervention in HAND, wherein patients are
chronically exposed to toxic effects of antiretroviral drugs, low levels of insidious HIV replication,
neuroinflammation, and accelerated aging. One major advantage of targeting BACE1 in HAND
versus sporadic neurodegenerative diseases, such as AD, is the ability to identify HIV as a
causative agent, and not merely a risk factor, for HAND, lending certainty to physicians for
recognizing the at-risk patient population. Presumably, BACE1 inhibition in HAND would exert
neuroprotective effects primarily through inhibition of Aβ production, however, the failure of
previous amyloid-directed therapeutic agents in AD, where amyloid pathology is abundant,
warrants significant skepticism with this approach in HAND. In particular, plaque disruptors, antiAβ immunotherapy, and γ-secretase inhibitors and modulators all failed to demonstrate
substantial reductions in CSF Aβ in clinical trials and many of these agents displayed significant,
dose-limiting side-effects, which in turn restricted their Aβ-lowering capabilities (58).
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Early BACE1 inhibitors also failed to exhibit sufficient in vivo potency due to their poor
pharmacokinetic profiles. Notably, first generation BACE1 inhibitors were structurally similar to
the peptidomimetic HIV protease inhibitors, highlighting the structural homology between BACE1
and the HIV protease. Yet, despite their similarities to BACE1 inhibitors, HIV protease inhibitors
have not displayed any apparent anti-BACE1 activity in vitro or in vivo. Current efforts in BACE1
inhibitor design have shifted towards the use of small molecule inhibitors, several of which have
progressed into phase 3 clinical trials. The new generation inhibitors, including MK-8931 (Merck
and Co.) and LY-2886721 display high affinity for BACE1, potently reduce CNS levels of Aβ in
non-human primates and avoid the off-target effects on cathepsin D and renin that plagued earlier
compounds. Additionally, these compounds avoid the insurmountable mechanism-based side
effects that accounted for the failure of γ-secretase modulators and inhibitors. Although complete
loss of BACE1 activity is known to cause a multitude of phenotypes, including peripheral
hypomyelination, the use of potent pharmacological agents against BACE1 avoids these effects
by only partially inhibiting BACE1 activity, which appears to be sufficient to achieve a desirable
neuroprotective outcome. Genetic studies in AD mouse models showed that 50% knockdown of
CNS BACE1 in PDAPP/BACE1

+/-

transgenic mice resulted in only a 12-20% reduction in Aβ

levels, but which translated to 75% less amyloid plaque burden compared to PDAPP/BACE1

+/+

mice (58, 59). Importantly, BACE1 heterozygous knockout mice display none of the phenotypes
of homozygous BACE1 knockouts, suggesting that complete loss of BACE1 function is necessary
for phenotypic abnormalities (58). In patients with HAND, amyloid plaque burden has not been
definitively established as a common pathological feature, however aberrant intraneuronal Aβ
accumulation has been observed in addition to reduced CSF Aβ42 levels, which is a biomarker of
AD and is thought to be the result of accumulation of insoluble Aβ within the brain parenchyma
(60). Taken together with our studies, these observations suggest that patients suffering from
HAND would stand to benefit from BACE1-directed therapeutics as a means to normalize Aβ
levels within the CNS and improve cognitive functioning.
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In summary, the body of work presented in this thesis advances our understanding of the
cellular and molecular effects of antiretroviral drugs on CNS neurons in vitro and in vivo while
further delineating the basic biological functions of BACE1 as a stress response protein.
Additionally, we present novel features of HAND pathogenesis in the post-ART era, including
intraneuronal accumulation of oligomeric Aβ, that have not previously been described pre-ART.
Importantly, our work provides the first mechanistic link between the persistence and evolution of
HAND as a chronic, neurodegenerative condition with the widespread use of antiretroviral drugs,
taking into account the known toxicities of ART in the peripheral nervous system. Our data
demonstrate that PI-class antiretroviral drugs potently activate the UPR in neurons leading to peIF2α-mediated translational upregulation of BACE1 and enhanced amyloidogenic processing of
APP. Furthermore, toxic effects of chronic ART treatment in neurons were reversible with the use
of a cell-permeable beta-secretase inhibitor, thus providing preliminary evidence for BACE1
inhibition as an adjunctive neuroprotective therapy in the treatment of HAND. These results
highlight the role of antiretroviral drugs as mediators of neuronal damage and death in HAND and
underscore the importance of novel therapeutic strategies in the treatment of HIV CNS disease.
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Table 1

Summary of human samples from NNTC for post-mortem analysis
HIV -

HIV +
No ART

HIV +
w/ ART

20

20

20

Age at death, mean ± SD

42.8 ± 5.6

39.7 ± 7.3

45.3 ± 6.7

Hours postmortem, mean ± SD

9.9 ± 5.7

10.0 ± 6.4

12.4 ± 7.9

Male (%)

80%

90%

80%

Female (%)

20%

10%

20%

White (%)

11 (55%)

12 (60%)

15 (75%)

Black (%)

7 (35%)

8 (40%)

5 (25%)

Other/Unknown (%)

2 (10%)

0 (0%)

1 (5%)

Hispanic (%)

5 (25%)

3 (15%)

3 (15%)

Not-Hispanic (%)

15 (75%)

17 (85%)

17 (85%)

HIVE (%)

-

6 (30%)

1 (5%)

Log plasma HIV c/mL, mean ± SD

-

4.1 ± 1.4

4.7 ± 1.1

Log Brain HIV c/g, mean ± SD

-

3.4 ± 1.9

4.1 ± 0.9

Characteristic
Number of Subjects

Sex

Race

Ethnicity

Disease Parameters
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Log CSF HIV c/mL, mean ± SD

-

3.4 ± 1.8

2.8 ± 1.1

CD4+ lymphocytes/mm3, mean ± SD

-

108 ± 118

85 ± 118

-

6 (30%)

14 (70%)

Subsyndromic (%)

-

1 (5%)

1 (5%)

MCMD (%)

-

2 (10%)

9 (45%)

HAD (%)

-

3 (15%)

4 (20%)

-

5 (25%)

4 (20%)

Neurocognitively Normal (%)

-

1 (5%)

2 (10%)

No Neurocognitive Data

-

8 (40%)

0 (0%)

PI-experienced (%)

-

-

17 (85%)

PI-naïve (%)

-

-

3 (15%)

NRTI-experienced (%)

-

-

20 (100%)

NRTI-naïve (%)

-

-

0 (0%)

Neurocognitive Impairment Status
HAND (%)

Neuropsych Impairment Other Origin
(%)

ART Treatment Status
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Figure 1. Proposed mechanisms of antiretroviral drug-induced ER stress in neurons. ART drugs
induce ER stress in a wide variety of cell types via multiple, distinct mechanisms including
inhibition of GLUT4 transport activity, generation of reactive oxygen species, inhibition of 26S
proteasome activity, and dysregulation of intracellular calcium stores. These insults can induce
chronic activation of ER stress in neurons leading to suppressed global protein synthesis and
impaired LTP, accompanied by translational de-repression of BACE1 and ATF4, both of which
have been implicated in apoptosis and neurodegeneration.
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